glaxosmithkline glaxosmithkline plc annual report year end st december content report director financial summary joint statement chairman chief executive officer description business corporate governance remuneration report operate financial review prospect financial statement director statement responsibility report auditor consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement group company principal financial statement financial record investor information shareholder return taxation information shareholder shareholder information share capital cross reference form f glossary term annual report approve board index director nd march publish th april contact detail glaxosmithkline financial summary increase business performance cer sale trading profit profit taxation earningsnet income earning ordinary share p p total result profit taxation earningsnet income earning ordinary share p p business performance result exclude merger item restructure cost sale trading profit exclude healthcare service business disposed cer represent growth constant exchange rate represent growth actual exchange rate financial highlight pharmaceutical sale cent sale growth key therapeutic area central nervous system cent respiratory cent antiviral cent new product contribute nearly billion growth cent avandiaachieve sale million seretideachieve sale million launch plan april business performance pretax profit cent business performance earning share cent shareholder return dividend glaxosmithkline share glaxo wellcome shareholder p p smithkline beecham shareholder p p share price london stock exchange glaxosmithkline share st december glaxo wellcome share th december st december smithkline beecham share th december st december glaxo wellcome share equivalent glaxosmithkline share smithkline beecham share equivalent glaxosmithkline share cautionary statement forwardlooke statement safe harbor provision private security litigation reform act company caution investor forwardlooke statement projection company include document subject risk uncertainty cause actual result differ materially project factor affect company operation discuss risk factor annual reportglaxosmithkline joint statement chairman chief executive officer financial outlook pharmaceutical sale growth key driver glaxosmithkline current strong business performance company benefit delivery billion cost saving result merger manufacturing restructuring plan place benefit performance business lead company forecast earning share growth exclude merger restructuring cost effect currency ofaround cent despite impact product divestment require regulatory body order complete themerg effect reduce company earning share expectation year cent company expect earning share growth accelerate mid teen reflect strong business performance boost cost saving past year momentous industry leader glaxosmithkline big event millennium year start life new company rapid pace theannouncement th january intention implement plan work year mergeglaxo wellcome smithkline beecham create ofthe world lead researchbase healthcare company mission improve quality human life enable people feel well live long follow regulatory shareholder approval company mission give purpose size give opportunity th december year spirit company passion innovation achievement employee work hard achieve objective maintain couple unmatched sense urgency believe momentum exist business plan merger enable attain success world class leader twostrong company rich heritage pharmaceutical discovery development prove record success bring company complex challenge marketplace succeed complete integration quickly realise benefit merger proper respect employee deliver result bedone integration priority improve rd productivity achieve excellence product commercialisation despite uncertainty integration planning process bethepartner choice inlicense work partnership wewere able turn strong set result year government agency charity expand access sale combine group reach billion growth toourmedicine ofnine cent constant exchange rate exclude healthcare service pharmaceutical great year particularly good build new product portfolio result united states large market report sale billion cent new product invest billion rd previous launch major market year investment key technology fully integrate contribute billion sale represent cent business yield formidable early stage pipeline totalpharmaceutical sale grow cent promise compound offer great hope well medicine disease cancer obesity diabete heart disease business climate europe remain demand growth cent broadly line market radically redesign rd organisation achieve inthe rest world sale grow cent reflect benefit scale sacrifice advantage small doubledigit growth asia pacific middle east africa flexible working environment strong link research andcanada zeffixand paxilwere launch japan late andcommercial operation build new structure product strong start enable maximise value medicine excellence product commercialisation key driver ourbusiness consumer healthcare business performance affect current market leader therapeutic competition smoking cessation area confident area central nervous system cns respiratory metabolicgastro business performance improve intestinal gi antiinfective strong position realise benefit acquisition block drug complete achieve goal january block drug sale country add approximately million glaxosmithkline consumer cns large product sale category lead seroxatpaxilwhich healthcare business wellknown brand number selective serotonin reuptake inhibitor sensodyne market new retail prescription expect expand value approval market product treat general vaccine business continue doubledigit anxiety disorder post traumatic stress disorder growth cent result new product combination vaccine infanrix grow cent respiratory flixotidefloventremain world lead asthma continue strength near term expect drive medicine seretideha enjoy strong launches europe new vaccine include launch new vaccine launch usa advairin april high hope success glaxosmithklinejoint statement chairman chief executive officer industry leader medicine treat hivaid world leader discovery development medicine combivirand ziagenboth grow december effectively treat hivaids glaxosmithkline determine launch triple combination medicine fight play deal desperate humanitarian crisis hivaid trizivir usa launch blight destroy life million europe people disappoint employee stakeholder public comment far fail convey metabolicgi business suffer blow immense complexity issue credit withdrawal recently launch medicine lotronex substantial contribution company make effective treatment irritable bowel syndrome result theus food drug administration concern effect real progress increase number patient treat therapeutic category avandia new onlycome concert action company diabete treatment exceptional year single glaxosmithkline work actively partnership government big contributor company growth market political develop real solution donor funder great growth potential expand help buy medicine organisation ground working treatmentoption avandiain order provide benefit provide medical facility establish reliable drug distribution toevenmorepatient system provide patient proper care treatment wewill shareholder update progress strong product grow marketplace manypromising compound come early stage rd acknowledgement add new compound portfolio throughintelligent inlicense announce despite merger activity company honour unprecedented licensing agreement month withaward recognise excellence wide range activity recently e merck partial agonist depression award glaxosmithkline come merger sepsicure endotoxin binder sepsis phase ii complete vote britain admire clinicaltrial company annual management today award accolade determined live meeting societys challenge deeply indebted employee commitment leadership size bring visibility accountability recognise proud achieve year success responsibility society operate listen lay strong foundation building address legitimate concern affect business glaxosmithkline shareholder aware creation glaxosmithkline wish thank director glaxo wellcome coincide upsurge public comment concern smithkline beecham leave company consequence issue particular use animal discovery testing merger executive director andrew bonfield james medicines access medicine develop world cochrane jeremy strachan extremely valuable glaxosmithkline require governmental regulatory agency contribution success business help tosubmit data safety efficacy new medicine derive bring merger arthur li baroness hooper depart animal model effort reduce number give valuable service nonexecutive director derek ofanimal research computer modelling bonham decide seek election nonexecutive technique method replicate director forthcome agm thank thecomplex physiological process live creature service glaxo wellcome glaxosmithkline influence drug substance safe toxic different behalf board corporate executive team organ continue use animal discover thank shareholder support creation anddevelop new medicine ensure care glaxosmithkline commit achieve good return forbeyond high standard set regulator unreservedly forall shareholder stakeholder vibrant new company condemn use threat intimidation individual engage legitimate lawful activity case employee engage discovery development medicine potential save prolong human life devastating impact hivaid epidemic population economy develop country particularly subsaharan africa throw role responsibility pharmaceutical industry provider medicine effective treatment disease sharp relief glaxosmithkline move quickly build leadership exhibit sir richard syke j p garnier previous company include groundbreake chairman chief executive officer pledge supply hivaids medicine develop country government price reduction cent february extend commitment offer supply deep discount nongovernmental organisation un agency employer africa direct access topatient clinic hospitalsglaxosmithkline description business description business discuss activity resourcesandthe operating environment business identifie development achievement follow heading business history development company product operating environment competition regulation operating activity market distribution manufacture supply research development operating resource intellectual property information technology glaxosmithkline people property plant equipment business community environment health safety global community partnership access medicine discussion group management structure corporate governance procedure set corporate governance pagesto discussion group operate financial performance financial resource give operate financial review andprospect page report glaxosmithkline group mean glaxosmithkline plc subsidiary associated undertaking thecompany mean glaxosmithkline plcglaxosmithkline share mean ordinary share ofglaxosmithkline plc p report figure quote market size market share market growth rate relate year end th september orlater available glaxosmithkline estimate base onthe recent datum independent external source value sterle relevant exchange rate figure quote product market share reflect sale glaxosmithkline licensee brand name appear italic report trade marks glaxosmithkline plc subsidiary associate company theexception nicoderm trade mark hoechst marion roussel inc bexxar trade mark corixa corporation inc coreg trade mark licence roche laboratories inc factive trade mark oflgchemical ltd navelbine trade mark pierre fabr mdicament panorex trade mark centocor inc licence group glaxosmithkline description business business history development company glaxosmithkline plc subsidiary associated undertaking constitute major global healthcare group engage creation discovery development manufacture marketing pharmaceutical product vaccine overthecounter otc medicine healthrelate consumer product glaxosmithkline corporate head office london area glaxo wellcome house berkeley avenue greenford middlesex ub nn england tel glaxosmithkline operational headquarters philadelphia usa operating company country product sell country principal research development rd facility uk usa japan italy belgium product currently manufacture country major market group products usa japan theuk france germany italy glaxosmithkline plc public limited company incorporate thdecember english law th december company acquire glaxo wellcome plc smithkline beecham plc english public limited company way scheme arrangement merger company glaxo wellcome smithkline beecham major global healthcare business business segment glaxosmithkline operate principally industry segment pharmaceutical prescription pharmaceutical vaccine consumer healthcare overthecounter medicine oral care nutritional healthcare business healthcare service segment primarily clinical laboratory diversify pharmaceutical service dispose description businessglaxosmithkline product pharmaceutical therapeutic area trade mark compound mechanism indication vary country cns disorder seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety inhibitor wellbutrin bupropion noradrenaline reuptake inhibitor depression imigranimitrex sumatriptan ht agonist migraine cluster headache naramigamerge naratriptan ht agonist migraine lamictal lamotrigine sodium channel modulator epilepsy requip ropinirole dopamine agonist parkinson disease zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction respiratory flixotideflovent fluticasone propionate inhale antiinflammatory asthma bronchial condition serevent salmeterol xinafoate bronchodilator bronchial asthma bronchitis seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma propionate flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis ventolin salbutamolalbuterol bronchodilator bronchial asthma bronchitis becotidebeclovent beclomethasone dipropionate inhale antiinflammatory bronchial asthma bronchitis beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis antibacterial augmentin amoxycillin broad spectrum antibiotic common infection clavulanate potassium zinnatceftin cefuroxime axetil oral antibiotic common infection fortumfortaz ceftazidime injectable antibiotic severe life threatening infection amoxil amoxycillin broad spectrum antibiotic common infection zinacef cefuroxime injectable antibiotic surgical infection antiviral trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaid abacavir combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaid epivirtc lamivudine reverse transcriptase inhibitor hivaid retrovirazt zidovudine reverse transcriptase inhibitor hivaid ziagen abacavir reverse transcriptase inhibitor hivaid agenerase amprenavir protease inhibitor hivaid valtrexzelitrex valaciclovir dna polymerase inhibitor shingle genital herpe zovirax aciclovir dna polymerase inhibitor herpe infection shingle chicken pox cold sore zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection heptodinepivir hbv relenza zanamavir neuraminidase inhibitor influenza treatment malarone atovaquone electron transport system malaria treatmentprophylaxis inhibitor metabolic avandia rosiglitazone ppargamma agonist type diabete gastrointestinal zantac ranitidine hydrochloride antisecretory duodenal ulcer stomach ulcer reflux dyspepsia pyloridtritec ranitidine bismuth citrate antisecretory plus antibiotic eradication h pylori vaccine havrix hepatitis engerixb hepatitis b twinrix hepatitis b infanrix diphtheria tetanus acellular pertussis oncology zofran ondansetron ht receptor antagonist nausea vomit cancer emesis therapy hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast cancer panorex maba monoclonal antibody colorectal cancer adjuvant therapy cardiovascular coreg carvedilol alphabetablocker congestive heart failure lanoxin digoxin cardiac antiarrhythmic congestive heart failure cardiac arrhythmia flolan epoprostenol inhibitor blood clot primary pulmonary hypertension lacipil lacidipine calcium channel blocker hypertension pritor telmisartan angiotensin ii antagonist hypertension glaxosmithkline description business product pharmaceutical antibacterial group market range antibiotic glaxosmithkline principal pharmaceutical product presently direct major therapeutic area analysis salesby augmentinis broadspectrum antibiotic suitable treatment therapeutic area description principal product wide range common bacterial infection particularly setout effective respiratory tract infection zinnatis oral antibiotic primarily communityacquire sale therapeutic area infection low respiratory tract fortumand zinacefare central nervous system disorder hospitalbase injectable antibiotic market respiratory antibacterial antiviral antiviral combivir combination retrovirand epivir consolidated metabolic gastrointestinal position reverse transcriptase inhibitor vaccine cornerstone multiple antihiv product regimen physician oncology emesis acceptance clearly demonstrate value place cardiovascular minimising pill burden face patient dermatological arthritis ziagenis group new reverse transcriptase inhibitor product potency ease use resistance profile allow divested product play significant role variety highly active tolerate andsimplified hiv treatment regimen triziviris combination combivirand ziagen combine central nervous system cns disorder antihiv therapie tablet twice daily administration seroxatpaxilis selective serotonin reuptake inhibitor ssri ageneraseis new protease inhibitor treatment hiv approve depression panic obsessive compulsive disorder medicine class bring market social anxiety disorder approval obtain generalise glaxosmithkline ageneraseha twice daily dose regime anxiety disorder post traumatic stress disorder significant food drink restriction wellbutrini antidepressant available usa normal zeffixhas approve marketing usa europe china orsustaine release tablet formulation market treatment chronic hepatitis b imigranimitrexis ht receptor agonist treatment zoviraxis treatment herpe infection ofsevere frequent migraine cluster headache chicken pox genital herpe shingle cold sore new reference product sector naramigamergeis antiherpes compound valtrex reinforce group presence group new migraine product inthis market treatment zoster episodic lamictalis treatment epilepsy combination longterm suppression genital herpe product achieve penetration mature relenza group novel treatment influenza market successful treatment severe case new class drug know neuraminidase inhibitor target requipi specific dopamine dlike receptor treatment primary site viral replication direct delivery ofparkinson disease airway inhaler zybanis novel nicotinefree prescription medicine available metabolic gastrointestinal asasustainedrelease tablet treating problem avandiais potent novel class oral antidiabetic smokingaddiction agent call thiazolidinedione ppargamma agonist treatment type diabete respiratory sereventis longacting bronchodilator ventolina selective zantac treatment peptic ulcer disease range shortacte bronchodilator treatment asthma ofgastric acid relate disorder continue play major role treatment number market patent protection flixotidefloventand becotidebecloventare inhale steroid lose pyloridtritecis combination antibiotic treatment inflammation associate bronchial asthma eradication helicobacter pylori causative agent chronic bronchitis inulcer seretideadvair combination sereventand flixotide offer lotronex novel treatment multiple symptom irritable alongacte bronchodilator antiinflammatory single bowel syndrome approve use usa follow inhaler priority review launch subsequently flixonaseflonaseand beconaseare intranasal preparation withdraw follow discussion food treatment perennial seasonal rhinitis drugadministration interpretation datum relate togastrointestinal effect group respiratory product available wide choice delivery system include diskusaccuhaler dry powder multidose inhalerdescription businessglaxosmithkline vaccine category product glaxosmithkline market range hepatitis vaccine havrix overthecounter medicine protect hepatitis engerixbagainst hepatitis b analgesic panadol twinrixis combine hepatitis b vaccine protect dermatological oxy disease vaccine available adult gastrointestinal tum paediatric strength tagamet hb infanrixis range paediatric vaccine combination infanrix zantac relief provide protection diphtheria tetanus pertussis respiratory tract contac whooping cough infanrix penta provide additional protection beecham hepatitis b polio andinfanrix hexafurther add beconase hayfever protection haemophilus influenzae type b smoking control nicorette causesmeningitis nicoderm cq niquitin cq additionally glaxosmithkline market priorixa measles nicabate mumps rubella vaccine typherix vaccine protection vitamin natural abtei typhoid fever lymerix vaccine protection oral care aquafresh lyme disease maclean odol oncology emesis drb zofrani prevent nausea vomiting associate chemotherapy radiotherapy cancer available nutritional healthcare lucozade bothoral injectable form approve use ribena prevention treatment postoperative nausea vomit horlick hycamtinis second line treatment ovarian cancer overthecounter medicine forsmall cell lung cancer significant product panadol widely available panorexis monoclonal antibody license nonaspirin analgesic smoking cessation product nicorette cancertherapy nicodermcq niquitincqand nicabate tum calciumbase antacid tagamethbfor prevention relief heartburn cardiovascular contacand beechamsrange treatment cold coregis block agent prove effective influenza variety vitamin tonic product lead abtei intreate mild moderate congestive heart failure ingermany consumer healthcare market additionally otc version zantacand beconase dermatological group principal dermatological product betnovate oral care thehigher potency dermovateand new cutivateare lead oral care product aquafresh macleansand antiinflammatory steroid product treat skin disease odoltoothpaste toothbrush sell aquafreshand suchas eczema psoriasis drbesttrademark divest product nutritional healthcare accordance agreement regulatory approval category principal product lucozade glucose merger glaxo wellcome smithkline beecham energy drink ribena line juice drink rich vitamin c product kytril treatment chemotherapy horlick range milkbase malt food chocolate drink radiotherapy induce nausea vomit famvir antiviral treatment shingle herpe divest block drug indecember january glaxosmithkline complete acquisition block drug add product range sensodynetoothpaste product consumer healthcare poligripdenture adhesive polidentdenture clean glaxosmithkline principal consumer product presently directedto major area analysis sale area isset overthecounter medicine oral care nutritional healthcare divest product glaxosmithkline description business operating environment competition pharmaceutical antibacterial major product compete glaxosmithkline semisynthetic pharmaceutical industry highly competitive glaxosmithkline penicillin antiinfective include limited principal competitor large international pharmaceutical generic brand cephalosporin increase degree company substantial resource company particularly japan quinolones augmentinhas experience major product mention increase competition usa particularly pfizer medicine subject competition different therapy zithromax bayer cipro abbotts biaxin lose patent period patent protection patent protection country europe amoxilha generic version manufacturer generic product typically patent protection number year subject donot bear research development cost consequently competition generic brand areable offer product considerably low price thebrande competitor research developmentbase antiviral pharmaceutical company normally seek achieve sufficiently glaxosmithkline drive create sustainable leadership select high profit margin sale volume period patent therapy area underline pioneer role hiv market protection repay original investment fund research retrovirand epiviracte cornerstone combination forthe future therapy available combivirin single tablet launch ziagenand ageneraseand recently trizivirfurther broaden competition generic product generally occur thegroup portfolio hiv product zoviraxface competition glaxosmithkline patent major market expire response generic acyclovir valtrexha help strengthen glaxosmithkline undertake range activity include company position antiherpe area introduce innovative product market possible accelerate process new product bring metabolic gastrointestinal tomarket major competitor avandiaare takeda chemical acto increase brand share customer copromote eli lilly usa gastrointestinal market zantacface significant competition omeprazole ultimately glaxosmithkline believe competitive position proton pump inhibitor generic ranitidine hydrochloride dependent discovery development new product effective marketing exist product vaccine pharmaceutical industry introduction new product glaxosmithkline major competitor vaccine market include process competitor affect pricing level result aventis pasteur merck american home product engerixband product replacement assurance havrixcompete vaccine produce merck comvax glaxosmithkline product outmoded recombivax hb hepatitis b vaqta hepatitis infanrixs notwithstanding patent trademark protection addition major competitor aventis pasteur tripedia trihibit increase government pressure physician wyeth ayerst acelimune tetramune patient use generic pharmaceutical brandname medicine increase competition product competition consumer healthcare go patent major competitor consumer healthcare market cns disorder procter gamble colgatepalmolive american home product major competitor paxilin selective serotonin reuptake unilever johnson johnson companies major inhibitor ssri market prozac eli lilly zoloft pfizer international company continue extremely active forest laboratory celexa success seroxatpaxilha highly competitive market addition target generic manufacturer large small company compete glaxosmithkline continue respond appropriately note glaxosmithkline select market financial statement legal proceeding usa major competitor product otc medicine imigranhas grow glaxosmithkline lead product tylenol cold cold remedy clearasil acne treatment pepcid address previously unmet need migraine indigestion private label smoking cessation uk sufferer company launch compete major competitor product lemsip cold remedy nurofen product new formulation imigransuch nasal spray anadin analgesic nicotinell smoking cessation remedy introduction naramighave helped glaxosmithkline nutritional healthcare major competitor horlicksare retain lead competitor migraine market ovaltine milo malt food chocolate drink competitor ribenaare primarily local fruit juice company lucozade respiratory compete energy drink growth glaxosmithkline new respiratory product flixotide sereventand recently launch seretide continue consumer healthcare business rely development drive growth market establish product highquality brand product good consumer acceptance ventolinand becotidehave face generic competition support advertising brand promotion line extension year maintain significant sale major competitor newformulation package innovation glaxosmithkline glaxosmithkline respiratory product singulair merck ability compete effectively dependent skill develop new scientifically support product line extension performance superior competitor back compelling advertisingdescription businessglaxosmithkline regulation pharmaceuticals usa debate reform healthcare system result increase focus pricing international pharmaceutical industry highly regulate currently government price control private sector purchase national regulatory authority administer panoply law usa federal legislation require pharmaceutical manufacturer andregulation govern testing approval manufacturing pay prescribe rebate certain drug enable label marketing drug review safety eligible reimbursement medicaid healthcare programme andeffectiveness pharmaceutical product regulatory requirement major factor determine substance pharmaceutical market worldwide continue develop marketable product experience increase pressure pricing reimbursement time expense associate development government healthcare provider nonprice factor new product high volume principally drive particular importance requirement country growth pharmaceutical expenditure product authorise register prior marketing authorisation registration maintain subsequently europe historically affect government regulation pricing reimbursement pharmaceutical industry continue national regulatory authority jurisdiction include experience pressure price range measure usa european union japan australia high include acrosstheboard price cut link price lowcost standard technical appraisal consequently introduction country price referencing delay agree reimbursement new pharmaceutical product generally entail lengthy increase pressure generic substitution approvalprocess demonstration add value new medicine european union procedure obtain country crossborder import fromlowprice market exert marketing authorisation medicinal product commercial pressure incountryprice centralised procedure application direct japan government measure curb growth theeuropean medicine evaluation agency lead healthcare expenditure include biennial price cut authorisation valid member state compulsory product derive biotechnology optional new value money activesubstance innovative medicinal product increasingly necessary demonstrate value mutual recognition procedure applicable formoney new product particular overall effect majority conventional medicinal product operate mutual healthcare cost market need satisfy healthcare recognition national marketing authorisation purchaser value money hurdle interm possible matter resolve bind arbitration product acceptance additional regulatory test ofsafety national authorisation available medicinal product efficacy quality market member state market difficult obtain premium price new grant marketing authorisation afford company datum chemical entity represent significant improvement protection period competitor rely exist therapy usa new product confidential datum regulatory file basis able command price reflect clear recognition marketing authorisation datum protection period begin value thedate authorisation grant european union andexpire year authorisation grant future development centralise procedure year authorisation possible predict extent grantedvia mutual recognition procedure depend groupsbusiness affect future legislative regulatory onthecountry concern development relate specific pharmaceutical product pricing product glaxosmithkline anticipate introduction new product continue require substantial effort time expense regulation consumer healthcare comply regulatory requirement consumer healthcare industry subject national regulation price control test approval manufacturing labelling addition form regulation refer marketing product country high standard technical manycountrie price pharmaceutical product control appraisal entail lengthy approval process new product law launch government influence price pharmaceutical national regulatory authorisation require approve product control national healthcare organisation switch product prescription otc requirement bear large cost supply product include longterm experience quality safety efficacy consumer oftheproduct wide patient population datum confirm country france japan prices individual thatthe relevant condition selflimite easily product regulate uk price control reference diagnose bythe consumer limit overall profitability measure rate return capital employ sale product supply national healthservice glaxosmithkline description business operating activity market distribution promotion glaxosmithkline product supplement scientific seminar advertising medical journal glaxosmithkline sell product worldwide television advertising provision sample direct mailing extensivenetwork subsidiary licensee distributor ofprinte material information contain company gross profit margin earn sale pharmaceutical site world wide web product generally higher earn sale directtoconsumer dtc advertise major component consumer product reflect risk uncertaintie product marketing usa dtc advertisement inherent develop marketing pharmaceutical risk primary source information patient request specific brand include high level research development expenditure product physicians usa required discover test obtain patent protection new product competition new generic product outside usa dtc prohibit limited rolein inform patient european union canada glaxosmithkline worldwide business subject number dtc currently prohibit australia government allow dtc risk inherent conduct business certain country include advertise pharmacyonly product subject certain safeguard possible nationalisation expropriation restrictive new zealand dtc allow self regulated industry government action capital regulation addition currency collaboration advertising standard agency fluctuation change economic condition occur market allow dtc date impact limit time time favourable unfavourable effect trading income glaxosmithkline regard addition direct marketing product subsidiary factor deterrent expansion international associate glaxosmithkline enter agreement operation company closely review method withother pharmaceutical company comarkete operation particularly develop country develop copromotion product market strategy respond change economic political condition market distribution consumer healthcare marketing distribution pharmaceutical principal market consumer healthcare otc medicine analysis pharmaceutical sale geographic region set arethe uk germany australia argentina italy mexico japan south africa france nutritional drink business particularly strong uk ireland india range sale geographic region ofproduct available market principal market oral care product germany uk usa europe otc product distribute retail outlet directly rest world wholesaler asia pacific distribution oral care nutritional healthcare product japan wide selection outlet directly latin america wholesalers organisation sell team dependent middle east africa onthe outlet pattern individual country canada glaxosmithkline sell prescription medicine primarily wholesale drug distributor independent chain retail pharmacy physician hospital clinic government entity institution product ordinarily dispense public pharmacy prescription write physicians usa worlds large pharmaceutical market pressureto contain healthcare cost encourage growth manage care organisation pharmacy benefit manager intermediary use range method low cost include substitution generic product cheap therapy brand product prescribe doctor glaxosmithkline contract manage care sector increase importance supplier healthcare community market glaxosmithkline deploy sale force representative support medical staff promote prescription product medical prescriber healthcare purchaser personal visitsdescription businessglaxosmithkline manufacture supply consumer healthcare supply consumer healthcare manufacturing site spread country employ glaxosmithkline portfolio different product staff consumer healthcare supply chain diverse range tablet toothpaste inhaler complex include manufacture supply otc medicine oral care capsule different pack size presentation nutritional healthcare smoking cessation product manufacture medicine begin development therapeutic active ingredient select formulation global strategic master plan manufacture supply gms develop manufacturing process strategic master plan smp longterm programme forfull scale volume production active compound primary integrate change enhance competitiveness productivity manufacturing site convert active compound finish glaxo wellcome manufacturing site announce october dosage formulation responsibility secondary base interdependent initiative manufacturing site manufacture excellence network rationalisation procurement excellence apply network follow merger glaxo wellcome smithkline ofmanufacturing supply location beecham december gms operate single global network site country employ people programme include leansigma tool technique year gms produce tonne bulk active challenge current way work forecast billion pack package deliver sale financial benefit lead improvement area country manage approximately new product reduce cycle time increase productivity improve delivery launch year performance smp implementation proceeding plan completion gms focus deliver secure source supply high quality product global supply initiative compliance regulatory requirement customer global supply initiative gsi year programme announce expectation february restructure smithkline beecham supply good class cost network align manufacturing strategy business need lead edge practice performance site network rationalisation purchasing initiative inprocurement global function implementation advanced stage cent benefit deliver site plelan france camacari brazil organisation toledo spain baranzate italy sell gms operation structure supply chain region glaxosmithkline integration active supplythe active ingredient nonantibiotic product merger glaxo wellcome smithkline beecham produce site network locate australia manufacture supply organisation present synergy india ireland singapore uk usa approximately opportunitie addition significant saving forecast staff employ manufacturing supply active glaxo wellcome smp smithkline beecham gsi ingredient secondary pharmaceutical site programme smp gsi implementation programme antibiotic supply global organisation site align integration relate change deliver synergy spread country total staff maintain security supply employ site broad range antibiotic product manufacture package vaccine vaccine production locate principally rixensart belgium european region site european region spread dresden germany country employ people total european site manufacture nearly external supplier major pharmaceutical product market glaxosmithkline procurement global function support function inawide variety finish dosage form areasof glaxosmithkline business manufacture north america region pharmaceutical site thelargest area billion spend external supplier north america region locate puerto rico canada usa year include purchase active ingredient chemical site employ staff intermediate finish finish product gms take appropriate step protect supply chain disruption international region international region comprise result interrupted external supply appropriate stock manufacturing site country spread distinct hold contracting alternative register supplier area employ people site inmiddle eastafrica site spread asia pacific area block drug site china japan latin america acquisition block drug company inc january areseven site add seven site employee gms consumer healthcare supply chain glaxosmithkline description business research development pharmaceutical number significant regulatory submission usa include global biological pharmaceutical research development rd function glaxosmithkline responsible submission gi alpha reductase inhibitor generation information acquisition knowledge treatment benign prostatic hyperplasia submit require discover develop register commercialise effectively fda late december market innovative prescription medicine vaccine delivery submission noncfc meter dose inhaler formulation system treatment prevention human disease advairfor asthma submission use avandiain combination insulin fundamental goal thorough understand treatment type diabete disease investigation increasingly original work revise submission extra strength formulation ingenetic predictive medicine research addition antibiotic augmentin use child work create new medicine vaccine extensive effort submission sustain release formulation antibiotic gain clear understanding unmet need augmentinfor use adult europe usa patientsand healthcare provider contribution overall submission adolescent use intranasal imitrexfor direction rd treatment migraine glaxo wellcome smithkline beecham invest submission seroxatpaxilfor treatment generalise billion pharmaceutical rd anxiety disorder posttraumatic stress disorder submission infanrix penta combine diptheria tetanus approximately staff involve biological pertussis polio hepatitis b paediatric prophylactic vaccine pharmaceutical rd activity site worldwide submission twinrix combine hepatitis b site include prophylactic vaccine uk beckenham cambridge dartford greenford addition bla bexxar novel treatment non harlow stevenage tonbridge ware welwyn hodgkin lymphoma resubmitte fda september garden city priority review usa research triangle park north carolina philadelphia europe significant regulatory submission include upper merion upper providence pennsylvania oncedaily dose regiman epivirfor hiv infections santa clara palo alto california fluoroquinolone antibiotic factive belgium rixensart malaria prophylaxis indication malarone canada mississauga france les ulis renne product development pipeline set page show italy verona milan considerable breadth depth japan tsukuba science city takasaki discovery project progress spain madrid nonclinical safety testing early phase clinical switzerlandgeneva development list table opposite significant work rd go compound undergo rigorous nonclinical clinical prepare plan procedure optimal integration key commercial assessment lead proof concept decision glaxo wellcome smithkline beecham rd process month glaxosmithkline able operate effectively efficiently day merger despite resource devote addition compound identify table opposite activity significant new medicine deliver follow compound inlicense schedule market gw mixed monoamine reuptake inhibitor phase ii development inlicense neurosearch january product approval submission sb selective rna polymerase inhibitor phase ii approval receive number new medicine development treatment solid tumour inlicense vaccine significant new indication taiho july formulation exist product summarise repifermin keratinocyte growth factor phase ii development tableopposite wound care mucositis treatment inflammatory bowel number approval receive disease inlicense human genome science october notable approval malarone sb dual alpha integrin antagonist enter phase ii combination atovaquone proguanil treat prevent development treatment range inflammatory disease malarial infection paediatric use relenzato treat include asthma rheumatoid arthritis inflammatory bowel disease influenza european approval receive multiple sclerosis inlicense tanabe december amgchewabledispersible tablet formulation lamictalfor february glaxosmithkline complete treatment paediatric epilepsy inlicense agreement e merck sb ssri hta receptor partial agonist phase ii development treatment depression mood disorder second sepsicure gr phospholipid antiendotoxin emulsion enter phase ii development treatment sepsisdescription businessglaxosmithkline product deliver market approval date product countryregion description advair august usa dry powder combination formulation longacte bronchodilator salmeterol glucocorticoid antiinflammatory agent fluticasone diskusdelivery system treatment asthma agenerase october europe potent protease inhibitor treatment hiv infections avandia july europe selective ppar agonist oral combination treatment type diabete specific subgroup patient combination metformin sulphonylurea flovent september usa dry powder formulation fluticasone multidose diskusdelivery system diskus treatment asthma infanrix hexa october europe conjugate recombinant paediatric vaccine diphtheria tetanus pertussis hepatitis b inactivated polio prophylaxis h influenzaetype b prophylaxis infanrix penta october europe recombinant paediatric vaccine diphtheria tetanus pertussis hepatitis b inactivated polio prophylaxis seretide june uk viani noncfc meter dose inhaler formulation longacte bronchodilator salmeterol december europe glucocorticoid antiinflammatory agent fluticasone treatment asthma seroxat september europe selective serotonin reuptake inhibitor treatment posttraumatic stress disorder seroxat november europe selective serotonin reuptake inhibitor treatment generalise anxiety disorder trizivir november usa combination reverse transcriptase inhibitor single tablet january europe significantly reduce pill burden improve compliance patient hiv infection compound progress phase clinical development compound mechanism indication gw thrombin inhibitor atrial fibrillation venous thrombosis gw peroxisome proliferatoractivator receptor agonist dyslipidaemia gw acenep inhibitor hypertension inlicense zambon october sb lppla inhibitor atherosclerosis sb ht receptor antagonist atrial fibrillation sb osteoclast vitronectin receptor antagonist osteoporosis rheumatoid arthritis sb beta adrenergic receptor agonist type diabete obesity inlicense asahi february gw second generation cox inhibitor inflammatory pain gw glycine receptor antagonist migraine prophylaxis smoking cessation sb reversible proton pump inhibitor gastroesopahgeal reflux disease inlicense yuhan october gw erbb egrf dual kinase inhibitor solid tumour gw cckb receptor antagonist anxiety disorder gw nk receptor antagonist depression vaccine conjugate vaccine prophylaxis pneumoniae infection elderly population recombinant vaccine prophylaxis hepatitis e subunit vaccine prophylaxis influenza new delivery method discontinuation follow request fda lotronex treatment irritable bowel syndrome voluntarily withdraw market november step take indepth discussion fda interpretation datum relate gastrointestinal sideeffect occur patient treat product include rare report fatality causalrelationship lotronexha establish regulatory submission rest world withdraw final analysis datum second phase iii clinical trial gv glycine antagonist acute treatment stroke demonstrate difference clinical outcome see placebo work product stop addition development lotrafiban oral platelet aggregation inhibitor stop concern safety ofthecompound glaxosmithkline description business product development pipeline publish february key maa marketing authorisation application eu phase evaluation clinical pharmacology usually conduct volunteer nda new drug application usa phase ii determination dose initial evaluation efficacy conduct new indication line extension market product inasmall number patient v vaccine phase iii large comparative study compound versus placebo andor establish p pharmaccine treatment patient establish clinical benefit safety date submission regulatory agency date regulatory approval maa euapproval date al approvable letter label update estimate filing date compound type indication phase maa nda antimicrobial host defence sb bacterial protein synthesis inhibitor bpsi prevention recurrent sinusitis sb antifactor ix monoclonal antibody severe sepsis septic shock stroke factive broad spectrum fluoroquinolone antibiotic respiratory tract infection iv formulation iii factive broad spectrum fluoroquinolone antibiotic respiratory urinary tract infection submit sfeb sdec oral formulation bactroban nasopharyngeal bpsi prevention recurrent sinusitis ii tafenoquinesb aminoquinoline malaria prophylaxis adult iii augmentin sr beta lactam antibiotic respiratory tract infection submit sdec sdec incl penicillinresistant pneumoniae modify release formulation augmentin es beta lactam antibiotic acute otitis medium incl penicillinresistant submit na soct pneumoniae paediatric highdose suspension malarone electron transport system inhibitor malaria treatment prophylaxis approve ssep ajul antiviral gr phospholipid antiendotoxin emulsion sepsis ii ziagen reverse transcriptase inhibitor hiv infection combination epivir ii gw protease inhibitor agenerase prodrug hiv infection iii epivir reverse transcriptase inhibitor hiv infection daily dosing submit ssep trizivir epivirretrovirziagen combination tablet hiv infection approve ajan anov zeffix reverse transcriptase inhibitor paediatric hepatitis b iii valtrexzelitrex nucleoside analogue cold sore iii na valtrexzelitrex nucleoside analogue hsv suppression immunocompromise patient iii na valtrexzelitrex nucleoside analogue prevention hsv transmission iii relenza neuraminidase inhibitor influenza prophylaxis iii relenza neuraminidase inhibitor influenza treatment patient asthmacopd iii cardiovascular urogenital gw ppar alphagamma dual agonist dyslipidaemia gw thrombin inhibitor atrial fibrillation venous thrombosis gw ppar agonist dyslipidaemia gw acenep inhibitor hypertension sb tachykinin nk receptor antagonist urinary incontinence copd sb antifactor ix monoclonal antibody stroke severe sepsis septic shock sb indirect thrombin inhibitor atrial fibrillation stroke prevention sb lppla inhibitor atherosclerosis sb ht receptor antagonist atrial fibrillation ii sb potassiumcalcium channel blocker cardiac arrhythmia ii enrasentan sb endothelial cell receptor antagonist congestive heart failure ii telmisartan angiotensin ii antagonist hypertension combination iii na hydrochlorothiazide gi alpha reductase inhibitor benign prostatic hyperplasia alopecia submit sdec gi alpha reductase inhibitor alopecia bph ii tranilast endothelial cell proliferationmigration inhibitor restenosis iii coreg beta blocker severe heart failure iii na description businessglaxosmithkline estimate filing date compound type indication phase maa nda metabolic musculoskeletal repifermin keratinocyte growth factor wound care ibd ii gi ccka receptor agonist obesity gallstone prophylaxis gw beta adrenergic receptor agonist type diabete obesity sb beta adrenergic receptor agonist type diabete obesity gi ppar gamma agonist type diabetes iii avandia insulin action enhancer type diabete combination insulin submit sfeb sb osteoclast vitronectin receptor antagonist osteoporosis rheumatoid arthritis neurology gastrointestinal gw sodium channel inhibitor epilepsy bipolar disorder ii gw cox inhibitor second generation pain include inflammatory pain gw glycine receptor antagonist migraine prophylaxis smoke cessation sb anticonvulsant epilepsy sb ht receptor antagonist cognitive impairment sb yh reversible proton pump antagonist gastroesophageal reflux disease requip nonergot dopamine agonist parkinson disease control release formulation ii nabumetone q nonsteroidal antiinflammatory osteoarthritis pain iii imigranimitrex ht agonist migraine needlefree injection formulation ii imigranimitrex ht agonist adolescent migraine nasal formulation submit sfeb sdec naramigamerge ht agonist menstrual migraine prophylaxis iii oncology gw erbb egfr dual kinase inhibitor solid tumour sb cxc chemokine prevention chemotherapyinduce cytopaenias stem cell mobilisation sb tumour activate prodrug colorectal cancer second line therapy maytansineantibody conjugate sb selective rna polymerase inhibitor solid tumours ii hycamtin topoisomerase inhibitor colorectal cancer second line therapy ii hycamtin topoisomerase inhibitor small cell nonsmall cell lung cancer ii line therapy hycamtin topoisomerase inhibitor myelodysplastic syndrome iii hycamtin topoisomerase inhibitor small cell lung cancer oral second line therapy iii hycamtin topoisomerase inhibitor ovarian cancer line therapy iii bexxar iradiolabelle antib monoclonal antibody nonhodgkin lymphoma submit na ssep psychiatry gw glycine receptor antagonist smoking cessation migraine gw cckb receptor antagonist anxiety disorder gw nk receptor antagonist depression sb ht receptor antagonist depression c sba emd ssri ht receptor partial agonist depression gw u noradrenaline reuptake inhibitor attention deficit hyperactivity disorder ii gw mix monoamine reuptake inhibitor depression ii seroxatpaxil selective serotonin reuptake inhibitor depression dispersible tablet iii tbd seroxatpaxil cr selective serotonin reuptake inhibitor premenstrual dysphoric disorder control iii tbd release formulation seroxatpaxil selective serotonin reuptake inhibitor generalise anxiety disorder approve anov sapr seroxatpaxil selective serotonin reuptake inhibitor posttraumatic stress disorder approve asep sjul glaxosmithkline description business estimate filing date compound type indication phase maa nda respiratory inflammation gw adenosine agonist asthma copd fluticasonesalmeterol beta agonistinhale corticosteroid rhinitis intranasal combination product sb tachykinin nk receptor antagonist copd urinary incontinence sb tr dual alpha integrin antagonist vla asthma rheumatoid arthritis ii sb osteoclast vitronectin receptor antagonist rheumatoid arthritis osteoporosis ariflo pde lv inhibitor asthma ii ariflo pde lv inhibitor copd iii tbd mepolizumab sb antiil monoclonal antibody asthma steroid sparing ii flovent inhale corticosteroid asthma daily dose iii na flixotideflovent inhale corticosteroid copd approve asep noncfc meter dose inhaler propellant gr serevent beta agonist asthma copd iii flixotideflovent inhale corticosteroid asthma copd approve aapr ventolin beta agonist asthma copd approve ajun aljan seretideadvair beta agonistinhale corticosteroid asthma approve ajun sdec diskusaccuhaler dry powder inhaler seretideadvair beta agonistinhale corticosteroid copd iii seretideadvair beta agonistinhale corticosteroid paediatric asthma approve asep seretideadvair beta agonistinhale corticosteroid asthma line therapy iii serevent beta agonist copd iii ventolin beta agonist asthma copd approve adec aljul hepatitis vaccine childadol twinrix dose recombinant combine hepatitis b prophylaxis childadol iii twinrix dose recombinant combine hepatitis b prophylaxis adult submit na submit extra strength hepatitis b recombinant extra strength hepatitis b prophylaxis iii tbd poornonresponder hepatitis e recombinant hepatitis e prophylaxis paediatric vaccine infanrix pentahepbipv recombinant diphtheria tetanus pertussis hepatitis b approve approve submit inactivated polio prophylaxis infanrix hexahep bipvhib conjugatedrecombinant diphtheria tetanus pertussis hepatitis b approve approve tbd inactivated polio prophylaxis haemophilus influenzae type b prophylaxis pneumoniae paediatric conjugate pneumoniae disease prophylaxis child iii mmr varicella live attenuate measle mump rubella varicella prophylaxis iii tbd rotarix live attenuate oral rotavirus prophylaxis ii n meningitidis ac conjugate meningitis prophylaxis ii meningitis b cuba subunit meningitis b prophylaxis tbd vaccines boostrix subunit adolescentadult booster diphtheria tetanus approve approve pertussis epsteinbarr virus recombinant ebv prophylaxis ii malaria recombinant malaria prophylaxis ii human papillomavirus recombinant prophylaxis hpv infection ii simplirix recombinant genital herpe prophylaxis ii new influenza subunit influenza prophylaxis new delivery hiv recombinant hiv prophylaxis pneumoniae elderly conjugate pneumoniae disease prophylaxis pharmaccine treatment chronic infectious disease cancer sb recombinant treatment chronic hepatitis b ii sb recombinant treatment lung cancermelanoma ii gw disc treatment genital herpes ii gwpowderject recombinant hepatitis b treatment idescription businessglaxosmithkline summary pipeline phase phase ii phase iii file sb bactroban factive factive sb ziagen tafenoquine sb augmentin gw sb gw malarone gw sb zeffix epivir gw enrasentan sb valtrexzelitrex trizivir gw gi relenza gi sb requip telmisartan imigranimitrex sb imigranimitrex tranilast bexxar sb hycamtin gi seroxatpaxil gi gw u nabumetone q flixotideflovent gw gw naramigamerge ventolin sb mepolizumab sb hycamtin seretideadvair sb gr seroxatpaxil avandia gw gw ariflo twinrix dose v gw sb flovent infanrix penta hep bipv v sb sb tr serevent infanrix hexa hep bipvhib v sb yh ariflo seretideadvair boostrixv gw repifermin coreg sb sb twinrix dosesv sb gw extra strength hepatitis b v gw sb emd pneumoniae v sb n meningitidis ac v mmrvaricella v gw rotarixv fluticasonesalmeterol epsteinbarr virus v sb malaria v hepatitis e v human papilloma virus v new influenza v simplirixv hiv v meningitis b cuba v pneumoniae v sbm p gwpowderject technology p sb p gw p content drug development portfolio change time new compound progress discovery development development market owe nature drug development process unusual compound especially early stage investigation terminate progress development competitive reason new project preclinical development disclose project type identify glaxosmithkline description business rd process complementary new technology work process redesign work conduct glaxo wellcome carry glaxo wellcome past year develop smithkline beecham early year fully way associate disease patient genetic implement rd organisation focus glaxosmithkline aim identify gene relevant consolidation new process common disease large unmet medical need asthma unified glaxosmithkline organisation considerable effort go noninsulin dependent diabetes migraine osteoarthritis metabolic align quantitative performance measure new syndrome depression chronic obstructive pulmonary disease early process productivity rd effectively onset heart disease alzheimer disease monitor term value add overall business initiative large international collaborative study benefit initiative high initiate disease network bring quality new molecule early clinical assessment clinician expert diagnosis disease isalso good evidence independent benchmarking centre skilled analyse genetic clinical datum glaxo wellcome smithkline beecham fast application genetic science healthcare product development time industry bedriven single nucleotide polymorphism snp highdensity learning previous redesign work bring mapping new technology liken road map effect glaxosmithkline traditional functional snps acting signpost tell scientist barrier research development commercial genome glaxo wellcome smithkline beecham manufacturing long exist organisation member snp consortium launch april keymultidisciplinary matrix organisation create consortium comprise pharmaceutical technology ensure continuity discovery launch process company academic centre wellcome trust include produce order highdensity snp map human genome work progress ahead schedule datum centre excellence drug discovery effectively integrate place public domain latestage research earlystage development new product development integrate clinical regulatory centre excellence drug discovery commercial activity glaxo wellcome smithkline beecham experiment new product supply align scaleup subsequent number way manage drug discovery order manufacture physical product optimise progression new medicine describe detail agree glaxosmithkline novel approach integration latestage discovery earlystage development clear focus unify approach generation critical drug discovery phase adopt demonstration commercial product value customer approachis base sound understand creative customer include patient healthcare professional budget entrepreneurial environment need enhance scientific holder regulator population need knowledge expertise require discover new drug term assess value new product rd provenvalue position ensure develop right product generate right information product centre excellence drug discovery cedd increasingly mean safety efficacy quality create glaxosmithkline focus specific disease area information evidence product value measure summarise overall reduction healthcare utilisation increase length antibacterial host defence centre upper providence quality life increase workplace productivity usa cardiovascular cancer urogenital centre upper early drug discovery new technologies merion usa past year glaxo wellcome smithkline metabolic musculoskeletal viral disease centre beecham invest heavily establish integrate new research triangle park usa technologies harness therapeutic potential offer neurology centre harlow uk elucidation human genome highthroughput ht psychiatry centre verona italy technologies ht gene sequence ht chemistry ht respiratory inflammation respiratory pathogen screen fully establish mean glaxosmithkline centre stevenage uk substantial resource identify significant number novel molecular target structurally diverse compound cedd autonomy select new compound efficiently screen compound target addition internal external source cedd responsible select ht biology technology help determine relevant optimal candidate series similar chemical compound therapeutic application new drug modulate pathological ensure candidate safe animal model mechanism underpin different disease bedevelope technical perspective achieve technology cornerstone activity genetic cedd responsible conduct preclinical discovery research design provide asteady stream earlyclinical work require prove compound safe validate drug target suitable series leadcompound andefficacious patient proofofconcept provisionof newlycreate centres excellence fordrug discovery confidence decision point follow thorough senior review information generate decision progress compound late stage drug development necessary largescale clinical trial conducted successfully register commercialise productdescription businessglaxosmithkline new product development animal research provide focus development commercialisation ethical scientific legal reason animal experimentation process proceed unison major functional remain essential discovery subsequent safety evaluation component medical regulatory product strategy new medicine glaxosmithkline policy replace animal integrate management organisation latestage product experiment possible use alternative development glaxo wellcome smithkline beecham invitrocell culture computer modelling technique animal organise therapeutic area area experiment unavoidable approach seek reduce identify glaxosmithkline thenumber animal improve technique methodology example approach include antimicrobial host defence antiviral use transgenic animal breed genetic change cardiovascular urogenital well model human disease metabolic musculoskeletal work use noninvasive imaging understand pathological neurology gastrointestinal process effect experimental drug far few oncology animal require traditional vivopharmacological psychiatry method respiratory inflammation development sensitive assay methodology reduce number animal require assess effect worldwide vaccine rd conduct biological division novel drug candidate locate principally rixensart belgium manage independently pharmaceutical development additionally effort minimise discomfort essentially similar approach development adopt animal study bothvaccine prescription medicine research development consumer healthcare pharmaceutical therapy area vaccines development manage crossfunctional matrix team responsible principal centre consumer healthcare research maximise worldwide development opportunity development uk usa consumer healthcare product team work ensure alignment liaise closely pharmaceutical ensure commercial betweenregional marketing need clinical commercial opportunity otc field identify quickly possible information generate new product develop glaxosmithkline pursue possible opportunity team collaborate early stage integrate technical switch prescription product otc product development manufacturing function ensure rapid effective launch delivery product increasingly incorporate genetic research clinical trial ofnew innovative medicine glaxosmithkline enable healthcare provider prescribe medicine accurately base patient predict response profile term drug safety efficacy addition genetic research enable well understanding cause common disease disease arise complex interaction number gene variant environmental factor identify gene predispose patient particular disease understand role disease progression lead identification new way intervene disease understanding provide great confidence exist drug target relevant tothe disease new product supply efficient delivery rapid worldwide uptake new product closely link ease manufacture issue scaleup manufacturing technology consider early stage product development process move smallscale production experimental material early clinical study largescale industrial manufacturing product supply fast efficient responsibility new product supply partnership rd preclinical staff global manufacturing supply partnership ensure development organisation deliver product optimise term largescale commercial manufacturing glaxosmithkline description business operating resource intellectual property pharmaceutical table set patent expiry date active ingredient significant glaxosmithkline product therapeutic area product active ingredient patent expiry date active ingredient major country cns disorder seroxatpaxil paroxetine wellbutrin bupropion basic compound patent expire formulation patent expire imigranimitrex sumatriptan usa naramigamerge naratriptan lamictal lamotrigine requip ropinirole zyban bupropion basic compound patent expire formulation patent expire respiratory flixotideflovent fluticasone propionate serevent salmeterol xinafoate usa seretideadvair fluticasone propionate patent cover combination expire salmeterol xinafoate flixonaseflonase fluticasone propionate antibacterial augmentin coamoxiclav basic compound patent expire exception usa france italy zinnatceftin cefuroxime axetil patents cefuroxime axetil se generally expire spc exist europe patent amorphous form cefuroxime axetil expire fortumfortaz ceftazidime basic compound patent expire amoxil amoxycillin basic compound patent expire antiviral combivir lamivudine zidovudine patent combination active ingredient expire epivir lamivudine retrovir zidovudine basic compound patent expire patent use hiv infection expire ziagen abacavir agenerase amprenavir valtrex valaciclovir zovirax aciclovir basic compound patent expire zeffixepivirhbv lamivudine relenza zanamivir metabolic avandia rosiglitazone gastrointestinal zantac ranitidine basic compound patent expire oncology zofran ondansetron patent use emesis emesis patent position hepatitis vaccine engerixand havrix infanrixand lymerixis highly complex glaxosmithkline license patent pertain engerix late expire recently grant patent pertain havrixexpire infanrixus patent expire glaxosmithkline license patent covering lymerixthat provide protection description businessglaxosmithkline glaxosmithkline highly value intellectual property believe support merger process worldwide portfolio patent trade mark information technology play key provide plan particular value information merger derive exist system glaxo wellcome smithkline beecham intellectual property include patent trade mark register ofmajor importance ensure new company design copyright system place function effectively soon merger complete day glaxosmithkline patent employee country email account able glaxosmithkline obtain patent country contact colleague electronically employee use significant product discover develop rd short code dial site search online phone activity patent protection available united states directory access company intranet site crosssite europejapan significant market new active link key business application provide ingredient pharmaceutical formulation manufacturing process medical use global communication glaxosmithkline continue patent protection past year see major growth number internal form key pharmaceutical product major website allow information share company market addition obtain patent anticipate ona global basis support internal search engine patent protection grant new drug analogous externally internet ability arein development absence effective patent toprovide share access information enable grow protection pharmaceutical develop country use virtual team work collaboratively span multiple continue adverse effect pharmaceutical company geographie time zone subject stringent time constraint include glaxosmithkline information exchange electronically broad array glaxosmithkline routinely engage dispute patent ofsupplier customer partner protection product process protect intellectual property right unauthorise access key system grow risk pose seenote financial statement legal proceeding computer viruse major issue intruder detection software add company firewall virus scan trade mark implement gateway server desktop level separate glaxosmithkline pharmaceutical product protect approach adopt glaxo wellcome smithkline beecham register trade mark major market glaxosmithkline integrate common standard approach pursue policy enforce trade mark right vigorously forglaxosmithkline infringement unauthorised use trade mark country local variation enhance business performance example united states trade mark paxili virtually glaxosmithkline major business process rely instead seroxatand advairis instead seretide heavilyon use information technology rd smithkline beecham glaxo wellcome major trade mark protection continue country long programme capture key information source electronic asatrade mark renew appropriate time form available require result glaxosmithkline trade mark respect pharmaceutical effort possible number regulatory drug product generally assume increase importance patent submission past year solely electronic form new drug product expire particular country submission page size ability avoid generate paper submission gives rise significant intellectual property consumer healthcare saving time cost glaxosmithkline consumer healthcare business brand project implement standard system orient company consider trademark manufacture resource planning glaxo wellcome site product particular value consumer brand protect seven uk jurong singapore support trademark majority market brand past year single system supply sell glaxosmithkline vigorously protect trademark chain smithkline beecham introduce standard enterprise financial infringement commercial software location ability toconsolidate mission critical operation way reflect information technology grow availability reliability global datum network information technology play strategic role ensure common process standard implement glaxosmithkline site addition provide low operating cost facilitate communication access information glaxo wellcome smithkline beecham instal major global basis system usa analyse commercially available prescribing support key business process local regional datum well understand locally glaxosmithkline functional global level product marketplace possible target enable transformation extension key business promotional detail activity measure market activity response information system transmit electronically field sale force response upload system grow availability require technology infrastructure sale force automation system deploy major commercial market glaxosmithkline description business transforming extend business activity train development insight gain genomic proteomic transform comprehensive training development opportunity way disease target identify validate information available employee level include access selfhelp generate variety external source need integrate computerbase training module development planning key internally generate information rapid flexible manner element overall performance planning year rely heavily information technology support analysis executive leadership development programme database require significant amount process design identify prepare key talent necessary power take advantage advance computer technology grow business worldwide particular programme develop skill identify critical future business success ebusiness asentrepreneurship partner crossfunctional collaboration glaxo wellcome smithkline beecham recognise global problem solve grow importance ebusiness small dedicated team place web base interface major customer property plant equipment implement usa current project span broad range key audience include opinion leader healthcare glaxosmithkline operating establishment country professional patient public geographical spread group activity headquarters location country indicate list glaxosmithkline people group company glaxosmithkline conduct research development site manufacture product skill intellect glaxosmithkline employee site country refer research fundamental current future success business development pharmaceutical manufacture itisglaxosmithkline human capital maximise potential supply group scientific commercial financial asset objective human resource policy maintain reputation glaxosmithkline invest nearly billion property ofglaxosmithkline employer choice role human acarrying value financial statement billion resource provide alignment business strategy billion carrying value invest plant equipment people strategy glaxosmithkline invest billion new andrenewal property plant equipment property mainly heldfreehold performance reward new investment finance exist group liquid resource importance people operate resource translate group st december contractual commitment employment practice recognise value future expenditure million operating lease individual compensation benefit package design commitment approximately million beenlightene competitive attuned local market glaxosmithkline business sciencebase technologyintensive compensation include skill performancebase pay highly regulate governmental authority glaxosmithkline contribute retention key skill consistent recognition allocate significant financial resource renewal andreward superior performance accomplishment maintenance property plant minimise risk business target interruption production achieve compliance regulatory standard research development alternative work schedule flextime teleworke adjust manufacture active pharmaceutical ingredient require use work week recognise employee work good environment ofchemical hazardous material glaxosmithkline observe integrate family personal life stringent procedure use specialist skill manage environmental risk activity environmental issue communication involvement date operation modify discontinue extensive range communication programme stimulate reference environment health safety involvement glaxosmithkline goal progress include note financial statement presentation business result groupwide magazine site newspaper video record voice mail message senior glaxosmithkline believe facility adequate executive officer access glaxosmithkline intranet current need integration glaxo wellcome smithkline beecham operation subsequently likely share ownership scheme encourage participation owner involvethe rationalisation disposal number ofthebusiness increase awareness short longterm sitesandpropertie business objective diversity diversity central effective deployment skill need compete modern global economy group value diversity opinion perspective background glaxosmithkline remain committed employment policy whichdo discriminate potential exist staff ground colour race ethnic national origin gender marital status religious belief disability uk employee disabled whilst employment result unable perform normal duty effort offer suitable alternative employment assistance retrainingdescription businessglaxosmithkline business community environment health safety chlorofluorocarbon cfcs world lead provider metereddoseinhaler mdi keep glaxosmithkline global quest improve treatment respiratory tract disease glaxosmithkline quality human life environment health safety ehs issue currently change propellant mdi cfc nonozone important new company glaxosmithkline vision deplete hfc ventolinmdis new propellant environment health safety adopt work launch country flixotidemdi hfca proceed agree ehs policy corporate ehs function launch country aim transition form responsible recommend policy smooth possible doctor nurse pharmacist strategy provide direction support significant issue importantly patient feel comfortable continue use develop standard appropriate business need reformulate product addition sale diskus dry main task integrate programme powder inhaler continue grow demonstrate commitment company new glaxosmithkline ehs programme provide choice healthcare provider patient good company view similaritie commitment manager staff high standard ehs contract manufacturing practice expect merger result continue increase use external contract manufacturer improvement ehs performance glaxosmithkline monitor supplier supply active ingredient fine chemical progress report set goal target intermediate finish product glaxosmithkline continue develop integrate ehs contract audit contract manufacturer key supplier glaxosmithkline ehs standard measure information ehs glaxosmithkline find ehs performance manage potential threat supply theehs review available secretariat company chainsecurity head office contaminate land eh management system uk statutory provision deal historically successful management environment health safety contaminate land introduce virtue iia beena high priority glaxo wellcome smithkline environmental protection act insertion section beecham company global standard guideline environment act review carry environment health safety issue set key requirement available datum operational facility uk determine implementation policy programme base designate contaminate land new management system model international standard regime review indicate facility unlikely organisation iso glaxosmithkline ehs department designate contaminate land additional datum evaluate possibility groupwide iso certification need facility study site newehs management system place arrange collect data usa group glaxo wellcome smithkline beecham perform audits remain actively involve resolution remedial site toassess report implementation corporate policy mid late stage remediation performance establish global standard recent contaminate land issue include site uk company perform audits country include forwhich agreement reach local planner contract manufacturing key supplier audits demolition remediation negotiation currently underway agree cleanup standard north carolina state ehs awards regulatory agency remediate soil groundwater contamination glaxo wellcome smithkline beecham internal site awardschemes design reward innovation outstanding achievement eh management information provision financial statement estimate find ehs review cost remediation goal target regulatory compliance broad goal ehs new company integrate well effort ensure effective legal company combine ehs programme compliance occasional event result permit regulatory recognise leader industry year group breach occur take seriously step expect develop ehs standard management system take prevent future occurrence andstart process companywide iso certification thedata company collect analyse major environmental improvement project evaluate develop baseline combine company ulverston antibiotic site uk currently engage annual improvement target million project upgrade treatment site wastewater irvine scotland antibiotics facility million intend explore impact implementation approve construction high temperature compost sustainable development principle glaxosmithkline unit waste sludge generate onsite wastewater treatmentplant glaxosmithkline description business global community partnership malaria glaxosmithkline work partnership roll malaria glaxosmithkline recognise corporate social responsibility international national stakeholder develop today business environment require innovative programme implement innovative sustainable plan reduce suffering help build healthy successful community world anddeath malaria create blend traditional philanthropy major company undertake pilot programme kenya commitment new partnership public health uganda assess feasibility donation product develop world glaxosmithkline work hard malarone order preserve efficacy malaroneand far creatively enable people feel well possible prevent emergence resistance important andlive long product reserve use secondline anti remit glaxosmithkline global community partnership malarial ineffective pilot site successfully follow encompass great challenge face society protocol determine patient require treatment include ambitious corporate citizenship project malaroneand patient treat standard therapy embark tuberculosis effort tackle parasitic disease malaria lymphatic action tb launch july glaxosmithkline filariasis develop world combat scourge commit million year fund research human immunodeficiency virus hiv acquire immune university uk south africa canada world tb day deficiency syndrome aid country safety net glaxosmithkline announce million fund statefunde healthcare system action tb year challenge empower community affect goal programme deliver drug early stage social environment traditional philanthropic ofdevelopment backup alternative candidate mean innovative programme design avaccine early stage development include identification strengthen expert particular field ofcandidate antigens identification surrogate marker management active programme science education use drug vaccine trial child age live community major glaxosmithkline location community programme united kingdom companys partnership department health hiv aids thecharity barnardo establish right fit programme glaxosmithkline provide support exist year right fit major initiative help young people unle programme reduce mothertochild transmission hiv teacher youth worker tackle smoke diet fitness develop country glaxosmithkline donation million spread threeyear life project large single contribution positive action longterm international programme company uk objective programme hiveducation community care launch new initiative positive impact health young people uk increase involvement people live hiv support result far encourage project theun international partnership aids africa support benefit young people july glaxosmithkline principal sponsor glaxosmithkline provide medical research thworld aids conference durban south africa reinforce annual scheme million award medical company commitment fight hivaid research project year charity invite apply year project select fund lymphatic filariasis approximately charity fund year global humanitarian programme help programme diabete uk cystic fibrosis trust eliminate lymphatic filariasis lf disable tropical disease digestive disorder foundation meningitis research foundation know elephantiasis glaxosmithkline donate million motor neurone disease association treatment antiparasitic drug albendazole develop world country glaxosmithkline annual impact award programme recognise excellent work small charity work healthcare estimate glaxosmithkline provide billion sector winner receive award unrestricted treatment albendazole year fight win charity range support break transmission lf parasitic disease spread health need male female sex worker community care mosquito prevent disease world health organisation service carer support isolate area scottish highlands advise albendazole coadministere diethylcarbamazine dec ivermectin single annual joint venture vso royal college paediatric treatmentfor year entire endemic community child health receive donation fund trainee consultant paediatrician spend glaxosmithkline actively participate lf global alliance ayear high specialist training develop country coalition glaxosmithkline world health organisation avso volunteer focus provide share paediatric public private academic institution ministry skill area need benefit poor health endemic country disadvantage childrendescription businessglaxosmithkline donation enable charity beat bowel cancer provide equipment centre assist early diagnosis disease bowel cancer second big cancer killer uk cause cent death breast cancer community programme europe programmes europe focus children health support provide reach young europe run befriender international umbrella organisation samaritan movement worldwide help child develop skill cope stress funding provide programme run aid organisation project hope russia combat substance abuse bosnia apaediatric rehabilitation programme barretstown gang camp ireland support seriously ill child europe receive community programme north america community partnership focus well access well healthcare grant million award northamerica community partnership team million threeyear initiative glaxosmithkline university pennsylvanias institute ageing threeyear children health fund grant million support refer initiative programme ensure child medical insurance receive healthcare service impact award programme grant healthcare organisation recognition exceptional work delivery community healthcare community programme rest world outside europe usa focus health education glaxosmithkline phase personal hygiene sanitation education health education programme target primary school child aged year goal reduce diarrhoearelate disease associate poor hygiene school initiative extend pilot country kenya cte divoire include uganda peru nicaragua glaxosmithkline indigenous community healthcare initiative innorthern queensland australia design implement communityled programme improve health indigenous community develop replicable communityled model charitable support charitable donation glaxosmithkline company world total approximately million uk glaxosmithkline charitable donation million project uk develop world particular emphasis area uk international healthcare medical scientific education environment art additionally glaxosmithkline uk operating company contribute million way community investment inthe community local factory site glaxosmithkline description business access medicine price available aai represent discount ofsome cent world price offer glaxosmithkline determine play improve glaxosmithkline notforprofit organisation able access medicine world poor people million deliver antiretroviral patient develop country include people develop country ready access basic selling directly aid organisation un agency use healthcare service include safe effective medicine programme company involve initiative improve health additionally company work employer africa develop world include tackle major killer hivaid offer hivaids care treatment directly staff malaria tb glaxo wellcome smithkline beecham workplace clinic history address develop world disease term rd undertake effort improve access work partnership exist medicine glaxosmithkline commit maximise affordable access medicine develop world explore framework rd disease develop world company offer low price medicine glaxosmithkline make significant investment research need develop country new product prevent treat develop world disease thecompany extensive research programme addition acknowledgement improve access prevention treatment disease focus medicine share responsibility framework need embrace international effort hivaid malaria tb glaxosmithkline core principle partnership protection product company work develop vaccine diversion parallel trade agreement develop country disease dedicate specialist team company price benchmark price develop work treatment tropical disease program country framework currently exist todevelop antimalarial deworme agent antidiarrhoeal company work hard stakeholder product available discount price framework develop development drug vaccine involve external research collaboration example company agreement real progress tackle hivaids pandemic malaria vaccine initiative nonprofit organisation test particularly subsaharan africa increase donor funding theonly malaria vaccine candidate effectiveness develop world need enhance healthcare capacity prevent malaria speed development vaccine facilitate purchase antiretroviral medicine potential save live million child significantly reduce price cost antiretroviral therapy associate health care infrastructure collaborative project include commission necessary deliver patient way mean medicine malaria venture action tb programme ofmany develop country government harness academic expertise order develop new tb treatment pharmaceutical industry role play improve effort develop incentive joint funding access significant barrier exist notably poverty inadequate essential stimulate research addition research public spending weak healthcare infrastructure effort glaxosmithkline continue work donor agency problem address shared responsibility sector identify additional research development funding society include government develop develop country disease effectively tackle develop world international agency nongovernmental agency pharmaceutical company commitment low price glaxo wellcome smithkline beecham offer low price range medicine use develop country significantly cover vaccine antiretroviral therapy hivaid company lead provider vaccine develop world offer substantial discount government charity agency public health programme nearly year glaxosmithkline company offer low price anti retroviral accelerate access initiative aai aim accelerate sustain access appropriate intervention prevention care treatment people live hivaids aai partnership pharmaceutical industry un agency work government ensure appropriate treatment patient term overall health care use drugsglaxosmithkline corporate governance section discuss glaxosmithkline management structure governance procedure board corporate executive team merger glaxo wellcome smithkline beecham board executive dialogue shareholder annual general meeting accountability control combine code memorandum articles association glaxosmithkline glaxosmithkline corporate governance bd board sir christopher hogg aged nonexecutive director sir christopher non c sir richard syke aged executive director smithkline beecham plc nonexecutive nonexecutive chairman sir richard chairman glaxo chairman reuters group plc allied domecq plc wellcome plc completion merger nonexecutive director air liquide sa chairman formglaxosmithkline plc rector imperial college royal national theatre board science technology medicine doctorate microbial b peter job age biochemistry bristol university doctor science degree nonexecutive director mr job nonexecutive university london fellow royal society sit director glaxo wellcome plc chief executive number government scientific committee receive reuters group plc nonexecutive director knighthood services pharmaceutical industry schroders plc nonexecutive director rio tinto plc f df john mcarthur age sir roger hurn age nonexecutive director mr mcarthur nonexecutive nonexecutive deputy chairman sir roger appoint director glaxo wellcome plc dean harvard nonexecutive director glaxo wellcome plc deputy business school nonexecutive director bce inc cabot chairman nonexecutive chairman marconi plc corporation rohm haas company springs industries inc prudential public limited company nonexecutive director aes corporation ici plc chairman court governor f henley management centre donald mchenry aged bd nonexecutive director mr mchenry nonexecutive sir peter walters age director smithkline beecham plc distinguish nonexecutive deputy chairman sir peter nonexecutive professor practice diplomacy school foreign director smithkline beecham plc chairman service georgetown university president irc group completion merger appointment llc nonexecutive directorship include cocacola include nonexecutive deputy chairman hsbc holdings company fleetboston financial corporation att plc chairman institute economic affairs corporation previously serve ambassador nonexecutive director saatchi saatchi plc permanent representative united nations dr jeanpierre garnier age b sir ian prosser aged chief executive officer dr garni appoint executive nonexecutive director sir ian nonexecutive director smithkline beecham plc serve chairman director smithkline beecham plc chairman bass plc pharmaceutical appointment chief operating nonexecutive deputy chairman bp amoco plc officer chief executive officer april member world travel tourism council cbi nonexecutive director united technologies corporation president committee member board trustee eisenhower exchange b fellowship hold phd pharmacology university dr ronaldo schmitz aged louis pasteur france mba stanford university nonexecutive director dr schmitz nonexecutive usa director glaxo wellcome plc nonexecutive director legal general group plc member board john coombe aged director rohm haas company cabot corporation chief financial officer mr coombe executive member board executive director director glaxo wellcome plc responsible deutsche bank ag finance investor relation member uk accounting standard board chairman group dr lucy shapiro age f nonexecutive director dr shapiro nonexecutive paul allaire aged director smithkline beecham plc professor nonexecutive director mr allaire nonexecutive department developmental biology director director smithkline beecham plc chairman xerox beckman centre stanford university school medicine corporation nonexecutive director j p morgan co inc hold phd molecular biology albert einstein college lucent technologies inc sara lee corporation pricelinecom inc medicine f dr michle barzach age e john young age nonexecutive director dr barzach nonexecutive nonexecutive director chairman glaxosmithkline director glaxo wellcome plc chairman external remuneration nomination committee mr young advisory panel health nutrition population world formerlynonexecutive vice chairman smithkline beecham plc bank director board international aids vaccine nonexecutive appointment include directorship initiative consultant health strategy french chevron corporation lucent technologies inc affymetrix inc minister health family perlegen sciences inc vicechairmanship novell inc derek bonham age nonexecutive director chairman glaxosmithkline audit membership board committee indicate follow committee mr bonham nonexecutive director symbol glaxo wellcome plc nonexecutive chairman cadbury schweppes plc imperial tobacco group plc fieldens plc chairman member nonexecutive director txu corporation audit b finance c mr bonham seek election board annual remuneration nomination e f general meeting corporate governanceglaxosmithkline corporate executive team howard pien president pharmaceutical international jp garni mr pien president pharmaceuticals smithkline beecham chief executive officer responsibility commercial operation dr garni chief executive officer smithkline beecham worldwide pharmaceutical business hold key position join smithkline beecham president usa uk north asia join smithkline beecham pharmaceutical business north america serve chairman work abbott laboratories merck pharmaceuticals appointment chief operating officer elect smithkline beecham david stout board director president pharmaceutical mr stout appoint president pharmaceutical north america jim beery smithkline beecham join smithkline beecham senior vice president general counsel senior vice president director sale marketing mr beery senior vice president general counsel president schering laboratory corporate secretary smithkline beecham join responsibility include pharmaceutical operation worldwide thecompany responsible legal matter manufacture thegroup retire glaxosmithkline june tim tyson john coombe president global manufacturing supply chief financial officer mr tyson appoint senior vice president director mr coombe group finance director glaxo wellcome plc worldwide manufacture supply glaxo wellcome join glaxo group financial controller hewa previously vice president general manager business appoint board executive director operation glaxo wellcome inc join company responsible finance subsequently add responsibility member glaxo wellcome commercial operation investor relations committee bob ingram chris viehbacher chief operating officer president pharmaceutical operation president pharmaceuticals europe mr ingram chief executive glaxo wellcome plc mr viehbacher appoint glaxo wellcome commercial chairman subsidiary glaxo wellcome inc join operation committee regional director europe glaxo inc merck appoint board director continental europe january addition glaxo wellcome chief executive role chairman chief executive president directeur glaxo wellcome responsible global business operation general glaxo wellcome france join glaxo wellcome jim niedel chief science technology officer tachi yamada dr niedel glaxo wellcome executive director responsible chairman research development science technology appoint glaxo wellcome previously president smithkline beecham healthcare services board responsibility group research dr yamada appoint chairman research development development join glaxo wellcome pharmaceutical director smithkline professor medicine chief division clinical beecham chairman department pharmacology duke university medical center internal medicine university michigan medical school physicianinchief university michigan medical center james palmer senior vice president clinical development pharmaceutical rd jack ziegler dr palmer responsible glaxo wellcome medical president consumer healthcare regulatory product strategy activity worldwide physician appoint president consumer healthcare smithkline bytraining join glaxo member glaxo beecham mr ziegler responsible company wellcome commercial operation committee global consumer healthcare operation join smithkline beecham head north american consumer dan phelan healthcare division president north america division senior vice president human resource appoint executive vice president mr phelan appoint senior vice president director human resource smithkline beecham hewa senior vice president director operations administration research development appoint vice president director personnel pharmaceutical join smithkline beecham manager oflabour relations glaxosmithkline corporate governance merger glaxo wellcome smithkline beecham board executive glaxosmithkline plc acquire glaxowellcome plc smithkline board beecham plc way scheme arrangement merger board glaxosmithkline plcis responsible group company effective th december system corporate governance ultimately accountable date glaxo wellcome smithkline beecham operate group activity strategy financial performance separate company management respective board comprise executive nonexecutive director board director role nonexecutive director bring independent judgement board deliberation decision director glaxo wellcome smithkline beecham year sir richard syke nonexecutive chairman dr jeanpierre garni chief executive glaxo wellcome plc sir roger hurn sir peter walters nonexecutive deputy sir richard syke chairman chairmen sir roger hurn nonexecutive deputy chairman robert ingram chief executive sir richard syke employ glaxo wellcome plc executive dr michle barzach nonexecutive chairman nonexecutive director consider derek bonham nonexecutive independent give nonexecutive deputy chairmen james cochrane appoint independent company john coombe consider necessary appoint senior independent peter job nonexecutive director professor arthur li nonexecutive board meet regularly year formal john mcarthur nonexecutive schedule matter reserve decision dr james niedel delegates specific responsibility board committee dr ronaldo schmitz nonexecutive describedbelow board work agree agenda jeremy strachan review key activity business receive paper presentation enable effectively minute board smithkline beecham plc committee remuneration nomination committee sir peter walters nonexecutive chairman place agenda board company secretary jan leschly chief executive retire th april responsible board available individual director jeanpierre garni chief executive th april inrespect board procedure paul allaire nonexecutive andrew bonfield company secretary simon bicknell sir christopher hogg nonexecutive baroness hooper nonexecutive board committee donald mchenry nonexecutive audit committeereview financial internal reporting sir ian prosser nonexecutive process system internal control management risk dr lucy shapiro nonexecutive external internal audit process committee consist dr tadataka yamada entirely nonexecutive director itmeet time year john young nonexecutive chief executive officer chief financial officer head internal audit corporate compliance external auditor incorporation glaxosmithkline inattendance company incorporate limited company finance committeereview approve major financial thdecember subsequently change security transaction company dividend glaxosmithkline plc convert public limited company result announcement business annual general onnd company trade meeting incorporation th december acquire glaxo wellcome smithkline beecham report financial remuneration nomination committeedetermine statement company cover period incorporation term service remuneration executive director st december include result separate glaxo corporate officer consider appointment director wellcome smithkline beecham business year corporate officer committee consist entirely non executive director chief executive officer attend meeting director glaxosmithkline remuneration consider period incorporation rd follow serve director company corporate executive team executive management group responsibility drusilla rowe th december th january chief executive officer senior manager form eleanor zuercher th december th january corporate executive team member corporate antonia ree th january th january executive team responsibility list corporate hackwood director limit th january th executive team robert stern th january th rupert bondy th rd remuneration director stephen cowden th rd information remuneration director give director list board appoint remuneration report rd serve datecorporate governanceglaxosmithkline dialogue shareholder accountability control company report formally shareholder twice year glaxo wellcome smithkline beecham itshalfyear fullyear result announce report glaxo wellcome smithkline beecham operate separate andor summary review issue shareholder company management respective board time chief executive officer chief financial officer director completion merger th december presentation result institutional investor analyst company operate broadly similar process internal medium london new york control base assessment risk framework company announce financial result quarterly control procedure manage risk monitor compliance procedure case company process accord annual general meeting company take place london guidance internal control issue turnbull formal notification send shareholder month committee inadvance meeting business presentation shareholder director available formally glaxo wellcome coordination internal control reporting meeting informally question detail responsibility company secretary receive report annual general meeting set follow section functional operational compliance group upwards annual general meeting report executive committee audit committee smithkline beecham establish risk oversight compliance chief executive officer chief financial officer maintain council support corporate compliance department adialogue institutional shareholder company plan coordinate internal control risk management activity objectives programme regular meeting assist audit committee perform responsibility speak regularly external conference presentation respect internal control company investor relation department office glaxosmithkline bring adopt procedure london philadelphia act focal point contact previously operate glaxo wellcome smithkline beecham institutional investor year discussion follow set procedure companys internet site give access current financial accountability control operate glaxosmithkline business information thegroup consistent follow glaxo wellcome smithkline beecham annual general meeting glaxosmithkline control framework company annual general meeting hold pm glaxosmithkline operate attaches importance clear onst queen elizabeth ii conference centre principle procedure design achieve accountability broad sanctuary westminster london swp ee control appropriate sciencebase business operate multinationally highly regulate business sector central director direction resource allocation risk management key director require retire article functional activity commercial strategy research company article association exception development manufacture information system human resource mr bonham directors present financial practice commercial financial responsibility election annual general meeting biographical detail clearly delegate local operating unit support regional director give board page management structure auditor principle design provide environment central resolution propose appoint pricewaterhousecooper leadership local operating autonomy framework auditor authorise director determine exercise accountability control group key remuneration functional activity management sector represent corporate executive team special business ongoing process identify evaluate company seek manage significant risk affect business authorise donation eu political organisation incur policy procedure risk manage eu political expenditure theprocess accord guidance internal control issue authorise director allot share maximum turnbull committee assessment group risk current issue share capital review update annually operate level director authority disapply preemption right business unit require process risk mapping allot new share certain circumstance assessment independent specialist team review report maximum cent current issue share capital compliance obtain authority purchase ordinary share company identify number key area ofrisk maximum cent current issue subject regular reporting share capital environment safety risk management address comprehensive architecture set target provide guidance theycan achieve glaxosmithkline corporate governance manufacturing audit committee board glaxosmithkline policy manufacturing carry audit committee board responsibility review tocorporate standard meet exceed applicable effectiveness system internal control management requirement regulatory body food risk process monitor compliance law drugadministration regular audits manufacture facility regulation ethical code practice standard carry independent internal board receive regular report area significant risk specialist team thecompany relate internal control addition consideration report board review annually clinical trial overall framework effectiveness control trial carry accordance strict good clinical practice guideline regulation aim ensure integrity control mitigate eliminate risk cover result datum safety human subject addition number area risk inherent trial procedure subject audit anindependent company business necessary risk order internal specialist team achieve satisfactory return shareholder example development potential product clinical trial involve preclinical study risk product willfail demonstrate efficacy safety trial undertake support safety new compound necessary obtain marketing approval regulatory body require conduct good laboratory practice glp case company objective apply expertise glp dictate strict worldwide regulation prudent management risk elimination risk element study subject audit independent internal specialist team monitor compliance associate company company cent interest quest diagnostic inc financial reporting account associate company activitie comprehensive budgeting system annual plan ofqu company core business approve director result operating unit competencie interest quest hold report monthly compare plan forecast prepare investment company review quest regularly year company announce result system internal control quarterly basis combine code investment appraisal company seek uphold report compliance clearly define framework control capital good practice corporate governance combine code expenditure include use appropriate authorisation level principle good governance code good practice capital expenditure application consistent format combine code issue uk list authority include review commercial strategic rationale guidance list company forthe investment combine code comprise recommendation good treasury operation practice term control reporting function treasury operation govern policy approve board board company combine code set principle subject internal external audits heading director operate unit control director remuneration financial control procedure include information system relation shareholder control detailed policy procedure manual write accountability audit confirmation compliance internal control policy obtain finance director general manager operating prescribe detail provision respect unit annually operate unit complete selfassessment principle specifically provision require director report questionnaire business risk internal control annual account review company internal external auditor director remuneration director responsibility account risk oversight compliance council rocc going concern rocc responsible coordinate internal control internal control risk management activity company ensure assignment designate manager manage significant risk compliance membership comprise head department internal director report compliance combine code control risk management audit andor compliance responsibility report accordance provision term reference include ensure regular gap combine code set director statement analysis carry identify gap internal control responsibility provide report audit committee addition report provide separate internal control audit compliance department company rocc support corporate compliance departmentcorporate governanceglaxosmithkline memorandum articles association glaxosmithkline registration transfer suspend time period exceed day year director annual report glaxosmithkline plc time time determine file follow summary provide principal provision registrar company generally respect company memorandum association articles association class share copy file registrar company provision article apply uncertified share memorandum contain fundamental provision extent inconsistent company constitution article contain rule hold share uncertified form internal management control company iithe transfer title share mean system crest memorandum association iiiany provision regulation memorandum association glaxosmithkline provide principal object thing hold c dividend distribution asset liquidation company glaxo wellcome smithkline beecham carry profit glaxosmithkline available distribution business general commercial company carry permit law distribute glaxosmithkline trade business activity nature time time determine recommendation director capable conveniently advantageously thedirector distribute way dividend respect carry accounting reference period shall distribute way dividend holder ordinary share article association voting opinion glaxosmithkline profit justify payment resolution vote general meeting decide director far applicable legislation allow pay poll poll member present person interim dividend share class amount proxy shall vote ordinary share respect period think fit holder director decide voting right director withhold payment exercise member pay company dividend monie payable respect ordinary share allcall sum payable respect share person hold cent exist company director decide voting right share class serve person direction notice exercise member fail period failure provide glaxosmithkline information day provide glaxosmithkline information concern interest share require provide concerninginterest share require provide underthe company act thecompanie act far right attach term issue b transfer ordinary share ofany share provide dividend declare member transfer ordinary share apportion pay pro rata accord amount pay certificated form instrument transfer usual uponthe share portion period respect formorin form director approve dividend pay suchinstrument properly stamp lodge glaxosmithkline class ordinary share glaxosmithkline accompany relevant share certificate holder share general law entitle evidence director reasonably require participate surplus asset windingup proportion right transferor transfer transfer shareholding liquidator sanction ordinary share uncertificated form carry extraordinary resolution divide member kind mean relevant system define regulation asset glaxosmithkline shall consist director absolute discretion give property kind liquidator deem fair reason decline register transfer share nota fully pay share article contain restriction variation right change capital transfer fully pay share provide transfer favour subject provision company act term transferee ii transfer respect ofissue share concern right attach class class share iii holder share ofshare vary write consent holder default term notice serve glaxosmithkline threequarter nominal value issue share class pursuant provision section company act orwith sanction extraordinary resolution pass notice refusal register transfer send transferee separate meeting holder share class month instrument transfer lodge separate meeting provision article director decline register transfer ordinary share relate general meeting shall apply necessary person hold cent exist share quorum shall person hold represent class person serve direction notice proxy onethird nominal value issue share failure provide glaxosmithkline information concern class provide adjourn meeting holder interest share require provide share class present person proxy shall quorum company act transfer show director approve transfer define article transferor isnot default meet certain condition set inthe article glaxosmithkline corporate governance glaxosmithkline ordinary resolution increase share director firm partner employee capital consolidate divide share share member act professional capacity glaxosmithkline large nominal cancel share take agree auditor remunerate director take person subject applicable legislation director officer subdivide share share small nominal interested company promote glaxosmithkline glaxosmithkline interested liable glaxosmithkline subject provision company toaccount glaxosmithkline member benefit act special resolution reduce share capital capital receive redemption reserve share premium account undistributable reserve glaxosmithkline subject requirement j director remuneration company act right holder class director pay fee rate share purchase share time time determine director fee satisfied share noncash form director e unclaimed dividend whois appoint executive office act chairman dividend unclaimed period year date vicechairman serve committee director perform resolution pass payment forfeit service director consider extend revert glaxosmithkline ordinary service director shall entitle receive glaxosmithkline stop send dividend warrant post remuneration way salary commission respect share consecutive payment director committee authorise director remain uncashed return undelivered payment maydecide director pay reasonable travel hotel remain uncashed return undelivered expense incur attend return glaxosmithkline establish new address holder meeting director committee director make reasonable enquiry case glaxosmithkline glaxosmithkline incur connection resume send warrant holder person entitle performance duty glaxosmithkline share transmission claim arrear k pension gratuitie director f untraced shareholder director committee authorise director glaxosmithkline sell share glaxosmithkline provide benefit payment gratuity pension insurance advertising intention wait month share allowance benefit director director issue year period relation connect person dependant dividend payable claim far director aware glaxosmithkline l borrowing power receive indication relevant period far legislation allow director exercise whereabouts holder share person entitle glaxosmithkline power borrow money mortgage charge transmission sale glaxosmithkline glaxosmithkline undertake property present indebted holder share person future uncalled capital issue debenture entitle transmission equal net security security outright collateral proceed sale security debt liability obligation glaxosmithkline orofany party g limitation right nonresident foreign shareholder retirement removal director limitation impose article association annual general meeting glaxosmithkline firstly onthe right nonresident foreign shareholder onethird director retire rotation eligible requirement glaxosmithkline serve notice forreelection onethird number number shareholder outside united kingdom united states director retire number near onethird ifthere director retire h general meeting shareholder directorsto retire office time glaxosmithkline require hold annual general meeting ofthe previous annual general meeting year extraordinary general meeting shareholder call retireby rotation secondly number necessary board call promptly receipt ofdirector retire remain minimum require requisition shareholder retire long office case thosewho appoint reappointe day director vote power willbeunless agree determined lot subject provision company act provide director require retire reason age nature director interest declare director special formality apply appointment reelection adirector disqualify office contracting director age limit glaxosmithkline manner contract isintereste liable avoid director year follow completion merger interested liable account glaxosmithkline termination service contract executive director member benefit realise contract reason require board majority twothird director hold office fiduciary relationship establish director vote resolution relate specifically remunerationglaxosmithkline remuneration report remuneration report set prospectively remuneration policy operate glaxosmithkline plc completion ofthe merger th december historically remuneration earn director glaxo wellcome plc andsmithkline beecham plc accordance remuneration policy programme operate glaxo wellcome smithkline beecham independent company remuneration policy glaxosmithkline describe process policy programme take effect completion merger th december remuneration glaxosmithkline director set remuneration earn director ofglaxowellcome smithkline beecham appoint director glaxosmithkline interest share option share incentive plan remuneration glaxo wellcome smithkline beecham director set remuneration earn director ofglaxowellcome smithkline beecham appoint director glaxosmithkline director senior management glaxosmithkline set interest director glaxosmithkline plc shares glaxosmithkline plc contract information provide aggregate remuneration interest director senior management glaxosmithkline additional disclosure accordance statutory requirement include note financial statement reference glaxosmithkline share adss mean respectively ordinary share glaxosmithkline plc p ads ofglaxosmithkline plc ad represent glaxosmithkline share remuneration report share adss glaxo wellcome plc smithkline beecham plc st december date prior merger th december include option award participation share adss restate regard number price term share adss glaxosmithkline follow glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline share glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss glaxosmithkline remuneration report remuneration policy glaxosmithkline glaxosmithkline remuneration policy performance bonus base annual performance business team lead global healthcare company glaxosmithkline aim demand financial target individual accomplishment remuneration policy programme enable objective bonus subject upper limit target business recruit retain motivate calibre executive talent performance bring total compensation line need compete international market place competitor panel pay rise target performance exceed glaxosmithkline believe remuneration policy executive total compensation fall level programme represent competitive advantage good practice compensation competitor target achieve heavy emphasis pay performance risk option invest bonus glaxosmithkline share compensation executive longterm incentive plan inwhich case bonus enhance cent share design align executive reward shareholder hold minimum year interest particular creation enhance shareholder value longterm incentive remuneration nomination committee comprise share option participation performance share plan link reward shareholder value long glaxosmithkline establish committee board call medium term respectively describe remuneration nomination rn committee develop company policy executive director remuneration approval share option board determine remuneration package share option allow holder buy share future date executive director rn committee consist exclusively price determine reference open market price share independent nonexecutive director current member time grant intend share option grant committee mr john young chairman mr paul allaire manager glaxosmithkline include dr michle barzach sir roger hurn mr john mcarthur executive directors mr donald mchenry vest option grant executive director subject remuneration company nonexecutive director tothe performance condition earning share growth determine glaxosmithkline board receipt exclude currency exceptional item advice external consultant ninepercent increase uk retail price index threeyear measurement period respect future policy remuneration executive director grant rn committee regularly review performance condition market condition rn committee advice lead firm compensation benefit consultant aim provide package performance share plan incentive reward competitive reference participation performance share plan grant global healthcare company multinational approximately executive company include company consider similar glaxosmithkline term size executive director designate target number share geographical spread complexity business eachparticipant vest award plan subject toa performance condition apply year construct review remuneration package measurement period performance condition consist emphasisis link pay performance reward effective twopart apply cent award management individual achievement mix apackage design align personal reward enhance condition compare glaxosmithkline shareholder value short long term totalshareholder return tsr period tsr executive director remuneration consist component ofcompanie uk ftse index period ifglaxosmithkline rank ftse salary inrelation tsr performance cent performance bonus sharessubject performance condition vest longterm incentive iftheranke th position ftse benefit centofthe share vest glaxosmithkline rank thposition share subject salary performance condition vest th th reflect executive director experience responsibility position vest occur slidingscale market value second performance condition require glaxosmithkline earning share growth exclude currency andexceptional item cent theincrease uk retail price index threeyear performance period condition meet share subject performance condition vest condition meet share subject ofthe performance condition vestremuneration reportglaxosmithkline benefit mr coombes contract specifie compensation pay executive director participate glaxo wellcome smithkline event redundancy event notice termination beecham senior executive pension plan define benefit give case redundancy mr coombe require plan uk cash balance plan usa benefits mitigate loss earning result payable age cash balance plan provide pension provision termination employment compensation payable fund contribution tenpercent theevent termination previously approve smithkline earning pay interest accrue base treasury bill rate beecham glaxo wellcome dr garni mr coombe bonus pensionable participate employee respectively change merger plan include executive director effective rn committee glaxosmithkline executive director participate glaxo wellcome smithkline review contractual term executive director glaxosmithkline beecham employee share plan uk usa executive directors service contract contain garden leave enable glaxo wellcome smithkline beecham employee noncompetition nonsolicitation confidentiality clause uk smithkline beecham employees usa contribute cent pay plan company pay rn committee believe year contract maximum cent pay purchase interest bein good interest glaxosmithkline regard offer glaxosmithkline share aglobally competitive overall remuneration package secure maximum protection intellectual property right benefit healthcare provide line practice market executive employ nonexecutive director glaxosmithkline service contract executive director participate basis senior employee new glaxosmithkline benefit plan payment nonexecutive director glaxosmithkline establish share share ownership guideline enhance link director shareholder glaxosmithkline require nonexecutive director receive align executive interest shareholder executive significant fee form share allocate director require hold share company chief share account offer opportunity invest executive officer require hold share value time balance fee share account share pay base pay executive director glaxosmithkline require directors retirement board later date hold share value time base pay onthe basis dividend reinveste interim purpose requirement share adss hold smithkline beecham bonus deferral plan vest defer award longterm incentive plan include yearend dr garniers total shareholding basis adss mr coombe share result director exceed share ownership guideline director service contract executive director employ service contract glaxosmithkline require year notice termination executive director require month notice dr garniers contract specifie compensation pay company termination employment include immediate payment year salary bonus dr garnier entitle continue participate company longterm incentive plan month follow notice termination company agree time dr garnier notice period reduce year year dr garnier receive year pension accrual termination certain circumstance year accrual glaxosmithkline remuneration report remuneration glaxosmithkline director annual compensation salary emolument salary emolument fee benefit bonus total fee benefit bonus total note executive director dr j p garnier mr j coombe b total nonexecutive director sir richard syke c sir roger hurn sir peter walters efg mr p allaire e dr barzach mr c bonham sir christopher hogg e mr p j job mr j h mcarthur mr f mchenry e sir ian prosser eh dr r schmitz dr l shapiro efi mr j young ef total total compensation dr garni executive director smithkline beecham appoint chief executive officer smithkline beecham th april time salary increase salary fee include company match compensation defer b mr coombe executive director glaxo wellcome c sir richard syke executive chairman glaxo wellcome remunerate executive director andreceive annual performance bonus st january remunerate nonexecutive chairman glaxosmithkline receive fee consist cash element share element glaxosmithkline share inaddition company agree procure sirrichard pension age calculate basis salaryas st december remain fulltime employment th birthday nonexecutive director glaxo wellcome e nonexecutive director smithkline beecham december board smithkline beecham approve additional remuneration nonexecutive director pay annually entirely form share comprise smithkline beecham share chairman smithkline beecham shares smithkline beecham adss nonexecutive director allocate share account th march year th march smithkline beecham share price share ad value share adss allocate date include figure salary fee show market value share adss date allocation share include director interest f sir peter walters dr shapiro mr young elect receive respectively fee form share share allocate account include indirector interest g sir peter walters emolument benefit include payment represent difference remuneration arrangement nonexecutive deputy chairman glaxosmithkline apply previous arrangement nonexecutive chairman smithkline beecham balance period april arrangement smithkline beecham sir peter walters receive annual fee benefit total share allocation smithkline beecham share h sir ian prosser director smithkline beecham st august payment month dr shapiro member smithkline beechams scientific advisory board sab completion merger glaxo wellcome receive fee include director fee service smithkline beecham sab dr shapiro elect receive sab fee form adssremuneration reportglaxosmithkline share option lapse grant average option adss grant price exercise number grant price number grant price dr j p garni option grant dr garni lapse grant average option share grant price exercise number grant price number grant price mr j coombe sir richard syke director interest option company share consequence merger option list exercisable exception option grant mrcoombe exercisable february connection merger circular list particular send shareholder july time holder option glaxo wellcome smithkline beecham share adss offer opportunity exchange option option glaxosmithkline share director elect exchange outstanding glaxo wellcome smithkline beecham options applicable new option glaxosmithkline share glaxo wellcome smithkline beecham share option plan participant elect exchange option receive additional benefit cash sum equal cent exercise price original option additional benefit give new option exercise provide exercise second anniversary effective date merger case sir richard syke cessation executive employment early director hold option glaxo wellcome smithkline beecham share option plan refer note financial statement option glaxo wellcome share option plan exercisable august february option smithkline beecham share option plan exercisable november november share price thmarch glaxosmithkline share glaxosmithkline ad high low share price year end st december glaxosmithkline share respectively high low price glaxosmithkline adss year st december respectively market price glaxosmithkline share glaxosmithkline adss st december respectively grant market option exercise adss date number price price dr j p garni grant market option exercise share date number price price sir richard syke gain option exercise director year st december comprise relate drgarnier relate sir richard syke compare gain exercise option year st december comprising relate dr garnier relate mr coombe relate sir richard syke glaxosmithkline remuneration report smithkline beecham incentive plan vest defer unvested participation participation participation unvested participation participation lapse award grant participation midterm incentive plan gsk adss dr j p garni midterm incentive plan mtip participation grant drgarnier final award share receipt award defer director dr garnier defer receipt award deferred award additional adss subsequently receive dividend reinvestment arenot include director interest technically retain mtip pay term mtip number share adss actually award determined follow end relevant measurement period depend smithkline beecham relative performance period measurement period relate participation grant november march end st december award equivalent cent participation grant th march market price glaxosmithkline share glaxosmithkline ad restate reflect merger respectively connection merger performance condition respect grant march waive final award employee resign end relevant measurement period measurement period relate participation grant november end st december final award percent target number share grant confirm th february time market price glaxosmithkline share glaxosmithkline ad respectively average stock appreciation right sar gsk adss grant price exercise grant dr l shapiro dr shapiro member smithkline beechams scientific advisory board sab completion merger glaxowellcome member sab receive annual grant smithkline beecham sars general vest year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision account accrue gain sar date grant connection merger previously grant sar immediately exercisable market price glaxosmithkline ad st december grant market sar exercise date number price price dr l shapiro gain sar exercise dr shapiro amount remuneration reportglaxosmithkline glaxo wellcome incentive plan share exercise average market price gain share exercise exercise share share annual incentive plan gsk share number grant mr j coombe sir richard syke sir richard syke mr coombe exercise option share award annual incentive plan operate glaxo wellcome award release director march respect award completion merger respect award gain exercise table represent difference money value exercise include remuneration year award relate share exercise average money market price value share exercise exercise share share share longterm incentive plan gsk share number vest grant mr j coombe sir richard syke award march vest th march base performance glaxo wellcome threeyear period end date award vest cent mr coombe sir richard syke exercise award year award march march february vest march march february respectively performance condition lapse completion merger share glaxo wellcome longterm incentive plan award atnil cost pension pension benefit accrue follow director define benefit scheme accrue annual benefit individual director retirement set change year net inflation age dr j p garnier mr j coombe sir richard syke dr garni member smithkline beecham allemployee pension plan entitlement spouse children pension surrender pension early retirement pension reduce factor relate age service apply employee dr garnier case receive additional year service retire glaxosmithkline pension increase grant discretionary basis transfer value payable leave theplan mr coombe sir richard syke member glaxo wellcome uk pension plan spouse provide pension twothird executive pension event death event decide retire early pension reduce cent year age retire pension guarantee increase payment rate increase uk retail price index rpi maximum cent year discretionary increase pay addition allowance discretionary increase transfer value leave glaxosmithkline remuneration report remuneration glaxo wellcome smithkline beecham director contractual fee emolument termination total total salary benefit bonus payment glaxo wellcome director mr r ingram mr j cochrane dr j e niedel mr j w strachan executive director professor li nonexecutive total compensation total compensation payment director total executive director exercise option share award annual incentive plan operate glaxo wellcome award release director march respect award completion merger respect award gain exercise represent difference money value exercise include remuneration year award relate mr ingram mrcochrane dr niedel mr strachan awards march longterm incentive plan vest march base performance glaxo wellcome threeyear period end date award vest cent money value exercise mringram mr cochrane dr niedel mr strachan shares longterm incentive plan award nil cost gain option exercise year st december mr ingram dr niedel mrcochrane mr strachan exercise option accordance term termination contract employment mr p lance exercise share award himunder cycle longterm incentive plan vest march award annual incentive plan gain arise change st december year net inflation pension age mr r ingram mr j cochrane dr j e niedel mr j w strachan mr ingram member glaxo wellcome inc pension plan entitle pension benefit twothird high threeyear average earning completion year service tapering reduction entitlement event completion short period service unreduced benefit payable age retirement age benefit reduce cent year retirement benefit guarantee pay year period automatic increase benefit account inflation mr ingram member money purchase scheme pension contribution scheme respect mringram mr cochrane dr niedel mr strachan members glaxo wellcome uk pension plan spouse provide pension third executive pension event death event executive decide retire early pension reduce cent year age retire pension guarantee increase inpayment rate increase uk rpi maximum cent year discretionary increase pay addition noallowance discretionary increase transfer value leavingremuneration reportglaxosmithkline contractual salary emolument termination total total fee benefit bonus payment smithkline beecham directors mr j leschly mr r j bonfield dr yamada executive director baroness hooper nonexecutive total compensation total compensation payment director total gain option exercise year st december mr leschly mr bonfield dryamada exercise option th march award equivalent cent mtip participation grant november march follow director mr leschly share adss mr bonfield shares dr yamada adss market price share ad date respectively mr leschly realise gain exercise sar smithkline beecham adss year st december herealise gain exercise sars smithkline beecham share mr leschly retire chief executive officer director smithkline beecham annual general meeting th april term retirement arrangement continue remunerate term contract contractual retirement date september time employment terminate payment april include payment director figure mr bonfield retired director smithkline beecham effect completion merger th december theterm contract completion merger mr bonfield receive payment year salary benefit bonus include table addition mr bonfield receive option glaxosmithkline share smithkline beecham employee share option plan award glaxosmithkline share smithkline beecham mti plan market price share dr yamadas benefit include accommodation uk august provide company enable carry duty chairman research development payment director include pension payment payment include inpayment mr w r grant defer fee plan relate period mr grant director smithkline beckman prior merger beecham group defer fee payable year follow mr grants retirement fully providedfor change st december year net inflation pension age mr j leschly mr r j bonfield dr yamada executive expect retire age mr leschly cease chief executive officer director smithkline beecham smithkline beecham annual general meeting th april term retirement arrangement continue remunerate contract reach contractual retirement age september time entitle pension rate twothird final year base salary mr leschlys spouse provide pension cent mr leschlys pension event mr leschlys death pension guarantee increase payment rate increase uk rpi maximum cent year discretionary increase pay addition mr bonfield defer member smithkline beecham uk senior executive pension plan mr bonfields spouse provide pension cent mr bonfield pension event mr bonfield death event chooses draw early pension annual benefit reduce cent year age pension guarantee increase inpayment rate increase uk rpi maximum cent year discretionary increase pay addition noallowance discretionary increase transfer value leave dr yamada member smithkline beecham allemployee pension plan entitlement spouse children pension surrender pension early retirement pension reduce factor relate age service apply employee pension increase grant discretionary basis transfer value payable leave plan glaxosmithkline remuneration report director senior management glaxosmithkline director interest director interest st december convert glaxosmithkline share adss relevant merger ratio follow beneficial interest director company show register maintain company accordance company act share adss march december december march december december note dr j p garnier mr j coombe ab sir richard syke ac sir roger hurn sir peter walters mr p allaire dr barzach mr c bonham sir christopher hogg mr p j job mr j h mcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young glaxosmithkline ad represent glaxosmithkline share figure include deposit share glaxo wellcome annual incentive plan b include nonbeneficial interest trust hold share st december share th march c include nonbeneficial interest trust hold share st december th march addition interest show mr mchenry interest defer fee plan relate period mrmchenry director smithkline beckman priorto merger beecham group defer fee index total return glaxosmithkline share payable seven year follow mr mchenrys retirement total accumulate value defer fee st december restate reflect merger equivalent glaxosmithkline adss fully provide interest abovementione director th march reflect change end financial year th march director interest contract describe end financial year director connect person material interest contract significance relation group business group company director senior management report purpose necessary provide information compensation interest director senior management asagroup group purpose disclosure group define director member corporate executive team company secretary th march person respect financial year total compensation pay group aggregate increase accrue pension benefit thmarch group own share adss constitute cent outstanding share capital company group hold date option purchase share adss issue pursuant glaxo wellcome smithkline beecham executive share option plan group award share adss smithkline beechams midterm incentive plan entitlement glaxo wellcome longterm incentive planglaxosmithkline operate financial review prospect operate financial review prospect discuss operate financial performance group financial outlook financial resource group follow heading financial trend ratio year result year st december compare year st december outlook risk factor financial position resource st december additionally accordance requirement year result year st december compare primarily year st december select financial datum ukus gaap result gaap accounting principle result year compare primarily result precede year reference quarterly halfyearly trend result exchange group multinational business operate countriesand earn revenue incur cost currency result group report sterling affect bymovement exchange rate sterling overseascurrencie company use average exchange rate prevail period translate result cash flow overseas group subsidiary joint venture associate undertaking sterling period end rate translate net asset undertaking currency influence translation usdollar euro japanese yen order illustrate underlie business performance exclude theeffect exchange rate movement translation group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate totranslate result overseas company sterling remain unchanged previous period discussion review term cer state glaxosmithkline operate financial review prospect financial trend ratio business peformance total cer total cer total sale pharmaceutical consumer healthcare total cost sale sell general administration research development trading profit retain business trade profit divest business trade profit total profit taxation earning earning share penny p p p business performance result exclude merger item restructure cost sale early year exclude healthcare service total result profit taxation earning earning share penny p p p research development pharmaceutical consumer healthcare total interest net interest payable interest cover time time time interest cover calculate total profit interest divide net interest payable tax rate business performance total result borrowing net debt gearing ratio gearing ratio calculate net debt percentage shareholder fund minority interestsoperate financial review prospect glaxosmithkline year world economy world market pharmaceutical year commence world economy show sign global pharmaceutical sale increase cent economic slowdown turbulent financial billion compare increase cent event early successfully negotiate wholeyear datum show world economic growth recover world market value growth geographic region bn total momentum outlook world economy favourable growth estimate generally revise usa upwards europe germany economy show continue robust growth france twoother favourable feature oecd organisation uk economic cooperation development economy italy continuedlow inflation nearly sign fall japan unemployment europe attention fix firmly oil market latin america concern focus production stability andthe economic asia pacific consequence continue significant strengthening price middle east africa half year pass recurrence severe canada financial shock see midyear total apparent world economy develop favourably global regional level market remain buoyant represent cent adecade nearly oecd country deliver overall growth global prescription pharmaceutical market compare fall unemployment japan major exception cent decade ago significant recovery japan uniformly favourable economic landscape show sign recovery nonoecd country deliver glaxosmithkline hold second position world pharmaceutical forecast economic growth halfyear market market share cent exclude product divest result merger pfizer market projection overall oecd area economic growth reach share cent ranking worldpharmaceutical market level see expectation world trade similarly change significantly thepast year impact high level confidence level appear high rise merger industry notably glaxo wellcome release official figure economic growth smithkline beecham pfizer warnerlambert monsanto datum begin sign slow bring attention pharmacia upjohn key question prospect economy record period economic growth glaxosmithkline product world product seroxatpaxil augmentin flixotide imigran zantac august international monetary fund announce serevent hadrevise upwards forecast world economic growth temper optimism fundamental concern world market value growth oilmarket price oil triple early therapeutic class bn total mid whilst consensus thinking price cardiovascular wouldprobably weaken high energy cost broadly central nervous system feedingthrough high price slow growth alimentary tract metabolic antiinfective bacterial pharmaceutical market show consistent growth viral fungal exclude vaccine year price remain pressure legislator respiratory regulator world large wealthy economy introduce propose legislative measure cut price andor slow rate growth spending medicine note datum base year th september late october department commerce advance estimate gdp growth show significant slow growth quarter global market receive datum long anticipate indicator recordbreake period strong growth reach turning point gdp datum reinforce late november downward revision commerce department estimate confirm slowdown bring overall economic growth rate close european level low rate growth year global market welcome projection federal reserve economy manage soft landing glaxosmithkline operate financial review prospect exchange migraine portfolio imigranimitrexand naramigamerge grow cent reflect return growth usa indicate chart average sterling exchange account threequarter sale dtc marketing rate weak dollar yen strong campaign migraine awareness programme instrumental european currency aggregate currency increase sale europe sale stable strong growth movement net favourable effect sterling result france offset decline market imigranwas launch compare cent respect sale japan april cent respect business performance earning share sale lamictal epilepsy treatment grow strongly worldwide euro jpy jun particularly usa great market penetration achieve expand market requip treatment parkinson disease market country increase sale cent benefit positive outcome fiveyear comparative study publish smoke cessation market zyban growth cent reflect rollout european market follow european union approval april jun dec jun dec jun dec jun dec jun dec initial sale particularly strong uk germany pharmaceutical sale respiratory flixotidefloventcontinue world high sell asthma glaxosmithkline pharmaceutical sale amount medication indicate chronic obstructive pulmonary million compare million increase disease copd sale increase cent notably cent exclude sale divest product product usawhere dtc promotion expand market lead divest fulfil regulatory condition approval cent increase sale europe group new glaxo wellcomesmithkline beecham merger sale growth combination product seretide launch market continue business cent growth substantially sale flixotidewere maintain despite seretide success volume increase minor net increase price sereventgrew cent growth particularly sale new product launch major market strong market seretideha launch thelast year million represent cent seretide new combination flixotideand serevent continue ofsale grow cent sale franchise product successfully roll market world establish product million represent cent generate sale million significant new sale grow cent sale old product market include spain italy australia uk actively promote million represent cent germany seretideha available year sale decline percent continue strong gain market share launch usa fourth quarter pharmaceutical sale growth advairis plan april approval cent exclude divested product cent sale growth receive end market product european usa affect impact wholesaler stocking union meter dose inhaler delivery device quarter anticipation price increase key product whilst impact sale flixotideand sereventfrom paxil augmentinand wellbutrin achieve significantly theintroduction seretide continue lead asthma high growth prescription volume report sale medication individual product combine sale flixotide indicate underlying business performance remain strong sereventand seretideincrease onethird indicate sale growth europe affect generic competition theircollective strength mild flu season demand antibacterial product total antiasthmacopd sale grow cent reflect pharmaceutical sale therapeutic area strong performance flixotide sereventand seretide offset decline sale old asthma product ventolinand central nervous system becotide patient convert new product antidepressant sector sale billion achieve withstrong growth seroxatpaxiland wellbutrincontribute rhinitis sector growth flixonaseflonaseis similarly offset togrowth cent important market paxilwas decline old product beconase overall group support successful directtoconsumer dtc campaign product sector grow cent support dtc promotional effort enable wellbutrinto increase market advertising usa twothird sale share product benefit overall growth antidepressant market new drug application nda dossier paxilas treatment generalise anxiety disorder post traumatic stress disorder file food drug administration fda paxilwas launch november japan onceaday selective serotonin reuptake inhibitor treatment depression panic disorderoperate financial review prospectsglaxosmithkline pharmaceutical sale therapeutic area total usa europe row therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg dermatological arthritis relafen total sale continue business divest product famvir kytril total pharmaceutical sale cer represent sale growth constant exchange rate sterling growth calculate figure give analysis sale quarter give financial record glaxosmithkline operate financial review prospect antibacterial metabolic gastrointestinal sale antibacterial product increase cent avandia glaxosmithkline new treatment type diabete growth augmentinoffset flat sale zinnatceftinand achieve sale approach half billion pound majority amoxiland decrease fortum theusa launch avandiascript account half thiazolidinedione market market sale reach billion augmentincontinue perform grow cent april fda strongly usa sale grow cent market share approve avandiain combination sulphonylurea ofnearly quarter solid growth achieve latin america previously approve monotherapy combination andsouth east asia europe sale affect generic metformin avandiawill roll europe rest competition world market august avandiareceive zinnatceftindecline seven cent large market positive recommendation uk national institute usa offset growth emerge market clinical excellence nice middle east africa latin america asia pacific zantaccontinue decline face competition generic product alternative antiulcerant treatment rate antiviral decline slow cent zantacs large market growth antiviral sale cent reflect strong growth japan sale remain stable hiv franchise group market range reverse transcriptase inhibitor rtis recently launch protease lotronex treatment irritable bowel syndrome launch inhibitor agenerase steady growth sale herpe usa march generate sale million product continue uptake new product withdraw november follow discussion viraldisease fda interpretation datum relate gastrointestinal effect company disagree sale rtis increase cent combiviragain grow fda assessment safety profile lotronex agree strongly reflect conversion patient constituent single withdraw market withdraw product epivirand retrovir aggregate product regulatory submission worldwide achieve real growth cent exclude effect contract brazil repeat vaccine underlie growth nearer cent vaccine sale reach million increase cent new rti ziagen grow cent reflect continue inthe hepatitis franchise engerixbdecline cent uptake usa europe trizivir combine epivir low sale usa havrix hepatitis grow slightly retrovirand ziagen launched usa december twinrix combine hepatitis b vaccine adult european union uk france january paediatric strength grow cent million triple combination tablet simplifie dose regiman infanrix glaxosmithkline range combination vaccine patient take tablet day diphtheria tetanus pertussis whoop cough grow new protease inhibitor agenerase offer cent october european commission approve infanrix improvement dose regimen majority sale penta provide additional protection hepatitis b usa available european polioand infanrix hexawhich add protection union approval receive october product haemophilus influenzae typeb disease launch market include uk france end year oncology emesis zofran emesis wellestablishe product leader group herpe treatment new valtrexand sector benefit market growth usa old zovirax grow combine rate cent valtrex twothird sale generate continue protect group franchise area strong increase region successful launch japan august therapeutic area zeffix chronic hepatitis b achieve sale million cardiovascular sale stable cent growth coreg firstlaunche asia pacific region perform strongly recent launch pritorfor hypertension european markets thechinese south korean market offset decline old product future sale benefit new datum show coregs effectiveness treat severe relenza new influenza treatment double sale heart failure million follow launch japan december available major market disposal anaesthesia franchise usa end contribute fall therapeutic area cent october glaxo wellcome company dispose portfolio dermatological product contribute cent decline sectoroperate financial review prospectsglaxosmithkline pharmaceutical sale geographic area pharmaceutical sale geographic area usa region cer sale market represent half total group major market total growth pharmaceutical sale grow cent usa avandia launch june achieve sale million europe france andis market leader class benefit withdrawal uk competitor product market quarter italy theyear germany spain respiratory sale increase cent reflect particular central increase acceptance inhale steroid treatment asthma eastern europe plan launch seretideadvairin april europe enhance potential group range asthma treatment rest world asia pacific cns sale increase cent grow antidepressant japan market dtc campaign focusse social anxiety disorder help latin america paxilto grow cent migraine portfolio growth middle east africa offive cent reverse decline see previous year canada reflect promotional effort overall expansion market lamictal small product cer represent sale growth constant exchange rate sterling growth calculate contribute significantly growth sale increase figure give analysis sale quarter give financial percent record page antiviral sector hiv sale grow cent reflect continue growth establish product uptake offset strong performance decline sale new product ziagen ageneraseand initial sale trizivir augmentin mild flu season impact generic generate million sale approval market competition uk germany continue decline trizivirwa receive november herpe sector strong zantac avandiawas launch uk germany late sale valtrexbenefite convenience oncedaily expect launch european market dosage form wide usage longterm herpe suppression therapy rest world overall growth cent reflects mix double digit strong growth sale augmentinand amoxiloffset decline growth asia pacific middle east africa canada ceftinand fortum enable sale antibacterial area slow growth japan latin america outperform market growth augmentinbenefite increase prescriber awareness effectiveness bacteria resistant asia pacific market principally contribute sale growth toother antibiotic australia area large market launch seretide august zybanin november china zeffix minor impact sale growth product disposal launch key factor sale growth cent anaesthesia portfolio dermatological range october lotronex irritable bowel syndrome achieve japan group second large market sale grow sale million prior withdrawal market cent sale asthma product grow quarter launch paxilin november relenzain december add europe million sale offset decline sale antibiotic sale europe represent cent group latin america overall sale growth cent affect pharmaceutical sale grow cent difficult condition brazil exclude brazil sale region france glaxosmithkline large market region sale grow cent mexico group large market grow strongly reflect growth hiv portfolio region sale grow cent good performance asthma franchise launch trizivirand seretidein january therapeutic area particularly vaccine brazil sale add sale potential major market italy germany affect government drive promote generic product spain seretidewa key contributor growth uk market bythe impact hiv contract repeat benefit increase sale seretideand successful launch zyban overall sale decline slightly generic middle east africa region grow cent notable competition parallel trade increase hiv product antibiotic success seretidein market canada sale grow cent reflect strong growth launch contribute cent growth asthmacopd paxiland recent launch seretideand avandia rest range growth lamictaland launch zybancontribute asthmacopd range wellbutrinalso contribute growth cent increase total cns sale sale hiv product zybandecline cent increase cent combination solid growth establish product range uptake recently launch ziagen sale infanrix combination vaccine child grow recent approval infanrixpentaand infanrix hexaoffere potential growth cardiovascular area launch pritorle cent increase sale glaxosmithkline operate financial review prospect consumer healthcare sale trading profit business performance cer illustrate glaxosmithkline business performance otc medicine analysis trading profit subsequent discussion oral care exclude merger item restructuring cost cost arise nutritional healthcare fromthe disposal healthcare service business theanalysis discussion focus retain business total sale continue business ofpharmaceutical consumer healthcare performance divest product ofhealthcare service deal separately total consumer healthcare sale growth glaxosmithkline consumer healthcare sale amount cer million compare million increase sale cent cost sale sell general otc medicine administration sale growth vitamin natural dermatological research offset decline category notably smoke control development gastrointestinal sale affect low sale tumsin trading profit thecompetitive market analgesic affect voluntary recall panadolin australia key market follow atampere threat cost sale cost sale increase increase sale smithkline smoking control sale decline cent reflect beecham reflect benefit manufacturing rationalisation competition market follow introduction private change product mix benefit newly launch product label nicotine replacement therapynrt gum patch reduce external royalty glaxo wellcome cost sale introduction new glaxosmithkline smoking control product increase percentage sale reflect low production market clear nicodermpatchand nicorette orange volume follow stockbuild reduce rate gum prevent inroad private label brand exclude increase second half year manufacture usa smoking control sale grow cent rationalisation deliver efficiency benefit exchange oral care sale aquafreshtoothpaste toothbrush increase sell general administration percent notably usa rest world market sell general administration sga increase line offset decline oral care brand western sale growth high selling cost particularly support product europe glaxosmithkline continue hold number oral launch avandia seretideand paxil offset saving care rank administration cost nutritional healthcare research development strong sale growth achieve nutritional healthcare research development rd expenditure increase range sale lucozadebenefite strong growth lucozade increase sale pharmaceutical rd million sportin uk consumer healthcare rd million block drug trading profit january glaxosmithkline acquire block drug trading profit increase cent increase sale manufacturer sensodynetoothpaste oral healthcare reflect management sga line sale growth low consumer product acquisition extend consumer rate increase cost sale rd healthcare product range expect earning enhance healthcare service healthcare service business divest contribute million trading profit date divestment operate financial review prospectsglaxosmithkline profit taxation business performance merger item restructuring cost divest business analysis discussion profit taxation relate key item discuss business performance merger operating incomeexpense cost effecting merger refer transaction cost amount million cost comprise expense royalty income fee prepare implement scheme arrangement operating expense forthe merger include obtain approval shareholder andregulatory authority secure admission income equity investment glaxosmithkline share official list uk list authority cost higher estimate time issue list particular july delay net operating income low few completion merger pende regulatory approval disposal old product income equity investment include cost incur planning arise integration disposal affymetrix share second half year glaxo wellcome smithkline beecham business reduce group hold cent unify glaxosmithkline business refer integration cost amount million cost include disposal interest associate consultancy fee support integration planning severance group reduce investment affymetrix inc half costsrecognise arise initial stage realise gain million account integration appointment process initial asset writeoff cost disposal interest associate subsequently group million recognise smithkline beecham respect cease significant influence affymetrix time theaccelerate vest share option share incentive award cease equity account investment disposal result merger cost recognise glaxo wellcome share affymetrix second half arise lapse performance condition attach share include investment disposal operate income incentive award result merger implementation integration plan respect business operation commence profitslosse associate joint venture substantively significant cost expect share profit associate arise principally smithkline recognise subsequent year beecham hold inquest diagnostic incorporate hold august order obtain regulatory approval merger glaxo wellcome smithkline beecham agree number product net interest payable divestment significant divestment famvir kytril sell december famvirwas sell interest payable novartis kytrilwas sell roche sale kytrilto investment income roche glaxosmithkline purchase exclusive right coregin usa canada net effect profit tax share interest payable associate product divestment income million manufacturing restructure net interest payable include group share net interest cost million incur glaxo wellcome ofthe associate quest diagnostic million smithkline beecham implementation august apart quest diagnostic interest previously announce plan restructure manufacturing interest payable investment income broadly stable andother activity compare reflect consistent average level net debt proceed disposal divest associate product receive late december minor cost represent group share restructuring cost benefit net interest payablein incur associate quest diagnostic profit taxation divest business operate income disposal interest impact disposal healthcare service business inanassociate add million profit taxation august million million net credit compare million take account restructuring cost incur healthcare service contribution associate comprise share profit share million ofinterest thegroup net interest payable profit tax million compare million increase cent glaxosmithkline operate financial review prospect taxation earning business performance earning merger restructure disposal earning ordinary share p p subsidiary earning ad total taxation adjust earning business performance adjust earning ordinary share p p charge taxation business performance profit amount adjust earning ad million represent effective tax rate cent weight average number share million consistent rate cent expect glaxo wellcome rate cent expect adjust earning adjust earning sharearepresente smithkline beecham order illustrate business performance glaxosmithkline tax rate benefit low rate tax applicable manufacturing operation singapore puerto rico ireland adjust earning increase cent cer adjust earning tax rate benefit additionally reduce uncertainty share increase cent cer reflect low follow resolution glaxo wellcome longstanding uk weight average number share weight average number transfer pricing issue low statutory rate anumber share purpose earning share decrease overseas territory topurchase share employee share ownership trust satisfy future exercise share option transfer pricing issue nonetheless inevitable global business glaxosmithkline integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit fall tax individual territory resolution issue continue fact life glaxosmithkline usa number year glaxo wellcome significant open issue relate transfer pricing issue principally relate success zantac cover year present remain wide variation claim internal revenue service group estimation taxation liability issue currently subject discussion uk tax authority term double taxation convention country glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing issue satisfactory conclusion base external professional advice continue believe adequate provision liability likely arise open assessment merger restructuring charge taxation merger restructuring item amount million reflect estimate actual tax rateapplicable transaction territory theyariseoperate financial review prospectsglaxosmithkline outlook risk factor outlook balance current growth sale investment research development fuel future growth remain major challenge improve pharmaceutical sale growth cent cer thegrowth group ongoing investment research seven cent cent key anddevelopment new product introduction exceed driver glaxosmithkline current business performance correspond sale growth result high cost company expect launch advairin usa proportional increase revenue avandiain europe market pricing pressure usa country world company benefit delivery include rule practice government sponsor health billion cost saving result merger system manage care group judicial decision governmental manufacturing plan place prior merger law regulation relate medicare medicaid healthcare benefit merger performance reform pharmaceutical reimbursement pricing general business lead company forecast ep growth exclude change government law regulation enforcement merger restructuring cost effect currency thereof affect group pharmaceutical vaccine business cent despite adverse effect product divestment reduce dependency profit efficacy safety concern respect market product disposal investment importantly divestment require scientifically justified lead product recall regulatory body order complete merger withdrawal decline sale effect reduce company ep expectation year legal factor include product liability claim antitrust litigation cent additionally company expect trading margin environmental concern patent dispute competitor improvement cent preclude commercialisation product negatively improvement tax rate half cent affect profitability exist product company expect eps growth accelerate lose market opportunity result delay uncertaintie midteen reflect strong business performance boost inthe approval process fda european regulatory cost saving second year row onetime gain authority expect decline change tax law relate taxation group earning immediate focus deliver successful merger outside uk particularly respect jurisdiction company negligible net debt relative market group pay tax rate low overall effective rate capitalisation position advantage opportunity arise build business change applicable accounting standard adverse thegroup risk uncertaintie inherent business discuss risk factor economic factor group control include change inflation interest rate foreign currency exchange risk factor rate control risk uncertaintie relevant group international operation affect change intellectual business factor list group property legal protection remedy trade regulation think cause group actual result differ materially procedure action affect approval production pricing expect historical result factor reimbursement marketing product unstable list adversely affect group government legal system intergovernmental dispute possible nationalisation increase competition proprietary product certain case generic equivalent proprietary product growth cost expense include change product mix patent expiration therapeutic area important group impact acquisition divestiture restructure longterm business performance andother unusual item result evolve business strategy change organisational structure generic competition product face expiration patent protection usa important market commence continued consolidation pharmaceutical industry affect group routinely engage dispute group competitive position patent product process order toprotect intellectual list consider exhaustive statement property right potential risk uncertaintie difficulty uncertaintie high level investment inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process oneor latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy orsafety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor theinfringement patent intellectual property right othersfurthermore sale new product prove disappointing fail reach anticipate level glaxosmithkline operate financial review prospect financial position resource cash flow future cash flow group expect future operating cash flow sufficient summary group cash flow set fund operating debt service cost satisfy normal level capital expenditure routine commitment include tax dividend subsequent year business performance operate cash flow dividendsare expect low proportion cash flow merger restructuring glaxosmithkline intend dividend policy set total operating cash flow shareholder return allow dividend cover earning joint venture toincrease net interest minority dividend subsequent year group expect cash outflow tax payment integrate operation glaxo wellcome smithkline free cash flow beecham unify glaxosmithkline business capital expenditure cash outflow continue implementation manufacture net cash operation restructuring plan dividend ordinary share group expect continue fund purchase esot business acquisition glaxosmithkline share satisfy future exercise share option business disposal time purchase depend market sale purchase equity investment condition sale purchase interest associate purchase share share option group time time additional demand use share exercise share option finance acquisition group access share issue exercise share option source liquidity addition cash flow operation proceed product divestment forsuch need absence special call fund net cash movement include exchange generation allow reduce net debt reduction net debt financial position net cash inflow business performance operating activity summarise reclassify presentation group balance sheet million increase nearly billion set reflects increase operate profit year stock build prepare year new product launch alow increase work capital goodwill intangible fix asset merger restructuring item net interest payment minority tangible fix asset dividend tax payment free cash flow represent cash flow investment discretionary spending amount million work capital increase debtor creditor capital expenditure tangible intangible fix asset provision amount million consist mainly taxation routine investment plant renewal upgrade expenditure defer taxation waslower reflect curtailment project net operating asset pendingcompletion merger disposal realise million share net cash operation million sufficient fund dividend propose payment dividend investment million net debt inthe acquisition minority interest group subsidiary total net asset million realise sale purchase investment equity share shareholder fund minority interest glaxo wellcome smithkline beecham fund purchase finance net asset respective employee share ownership trust esot share glaxosmithkline plc satisfy future exercise option book value group net asset increase million award employee share incentive scheme total atstdecember million st december costof million total million receive significant net effect exchange rate movement employee exercise share option exercise satisfied share increase represent purchase share previously purchase esot yield million exercise esot reduction net debt satisfied issue new share yield million major product divest obtain regulatory approval merger generate proceed million december exclude share option item product divestment group cash generation substantially positive net inflow billion include share option item product divestment movement reduction innet debt millionoperate financial review prospect glaxosmithkline investment market capitalisation glaxosmithkline investment st december overall value company indicate stock carry value million balance sheet financial marketcapitalisation considerably high value statement investment classify partly fix asset shareholder fund show group balance sheet partly current asset investment mainly equity share difference arise group significant internally hold derive directly group business generate intangible asset include arise business divestment connection research balance sheet include intellectual property particularly collaboration access biotechnology development patent create research development process potential interest glaxosmithkline group manage value brand reflect trade mark arise investment resale certain investment restriction group investment marketing value sale market value investment st december group knowledge knowhow employee approximately billion market value volatile payment policy provision group company responsible monitoring managing group carry provision million st december work capital term sale collection supplier respect estimate future liability payment reflect local commercial practice million relate unfunded pension postretirement benefit employee provision cost uk company uk subsidiary operate manufacturing restructuring merger integration extent procedure ensure supplier pay time particular balance sheet date actual constructive obligation uk company seek exist case merger integration majority cost settle term payment supplier agree expect recognise term transaction ensure supplier aware agree term share ofpayment st december esot hold million share abide term payment glaxosmithkline potential commitment employee share incentive plan date million share procedure include arrangement accelerate payment million exercisable small supplier glaxo wellcome behalf uk subsidiarie net debt isasignatory well payment practice code well group net debt st december comprise payment practice group successor code prompt payment code confederation british industry continue thecompany policy follow code respect supplier cash liquid investment copy code obtain department trade borrowing repayable year industry borrowing repayable year net debt smithkline beecham adopt standard code deal specifically payment supplier cash liquid investment include proceed product divestment receive end december year payment performance mediumterm debt instrument approximately million st december average number day purchase redeem maturity finance primarily additional issue represent trade fix asset creditor company commercial paper programme cash generate wasnil day respect company uk subsidiarie operation reduce shortterm debt aggregate day day creditor days stdecember reflect accelerated payment december shareholder fund way contingency planning risk disruption summary movement equity shareholder fund set bank transaction millennium change begin year profit year dividend share issue exercise share option exchange movement overseas net asset goodwill write profit loss end year shareholder fund increase million st december million st december primarily retain profit share issue share option scheme information dividend market capitalisation refer shareholder return glaxosmithkline operate financial review prospect treasury policy glaxosmithkline balance use borrowing liquid asset regard cash flow operating activity merger thecurrencie earn tax cost intragroup glaxo wellcome plc smithkline beecham plc merge distribution currency business asset thdecember form glaxosmithkline plc date denominate posttax cost borrowing compare glaxo wellcome smithkline beecham operate separate totheposttax return liquid asset business management respective board theglaxosmithkline treasury policy note liquid asset surplus immediate operating requirement previously operate glaxo wellcome smithkline group company invest manage centrally corporate beecham exceptwhere indicate treasury requirement group company operating finance meet possible central resource treasury external borrowing mainly manage centrally corporate glaxosmithkline plc ukbased business report sterling treasury comprise portfolio mediumterm instrument pay dividend sterling profit shortterm finance role corporate treasury glaxosmithkline manage glaxosmithkline hold issue derivative financial monitor group external internal funding requirement instrument trading purpose group treasury policy financial risk support group corporate objective specifically prohibit activity transaction financial treasury activity govern policy procedure instrument undertake manage risk arise approve monitor board glaxosmithkline maintain underlie business activity speculation treasury control system procedure monitor foreign exchange interest rate liquidity credit financial risk maturity counterparty risk group invest centrally manage liquid asset primarily liquidity government bond shortterm debt instrument group operate globally primarily subsidiary company minimum aa rating establish market group trade nature group business patent protection group manage net borrowing requirement ofthe product group portfolio group product portfolio mediumterm borrowing include bond compete largely product efficacy price sell shortterm finance commercial paper programme margin sufficient cover normal operating cost group mediumterm borrowing mature date group operating subsidiary substantially cash generative group allow cash generation finance operate cash flow fund investment research repayment mediumterm debt reduce shortterm development new product routine outflow capital borrowing expenditure tax dividend group time time glaxosmithkline longterm debt rating aa standard additional demand finance share purchase poor aa moodys agency shortterm rating acquisition paper issue group commercial paper programme glaxosmithkline operate low level net debt addition p respectively tothe strong positive cashflow normal trading activity additional liquidity readily available commercial interest rate risk management paperprogramme glaxo wellcome operate fixedfloate interestrate profile broadly consistent mediumtermshortterm profile treasury operation borrowing objective treasury activity manage posttax net smithkline beecham policy interest rate management require costincome financial operation benefit group proportion net borrowing fix rate rise earning corporate treasury operate profit centre ratio forecast net interest payable trading profit glaxosmithkline use variety financial instrument include change interest rate profile borrowing take derivative finance operation manage market risk place merger operation financial instrument comprise cash liquid resource foreign exchange risk management borrowing spot foreign exchange contract glaxo wellcome foreign currency transaction exposure normal trade flow arise primarily group company sterle glaxosmithkline use number derivative financial instrument functional currency respect external intragroup manage market risk treasury operation derivative trade hedge glaxo wellcome policy minimise instrument principally comprise forward foreign currency exposure overseas operating subsidiary transaction risk contract interest rate currency swap corporate bymatche local currency income local currency cost treasury swap borrowing liquid asset currency forthispurpose intragroup trading transaction match require group purpose manage exposure market centrally intragroup payment term manage reduce risk change foreign exchange rate interest rate risk exceptional foreign currency cash flow hedge selectively management corporate treasuryoperating financial review prospectsglaxosmithkline smithkline beecham hedge foreign exchange transaction share purchase exposure internal external rolling month group fund market purchase employee share programme forward foreign exchange contract ownership trust share glaxo wellcome plc smithkline glaxosmithkline adopt policy previously follow beecham plc amount million million glaxo wellcome consequence smithkline beecham forward share hold employee share ownership trust contract respect internal transaction merger date satisfy future exercise option award group terminate january forward contract cover external share option award scheme proportion purchase currency sale purchase allow run maturity respect option rule scheme require company satisfy exercise market purchase high proportion group borrowing include commercial issue new share paper programme dollar benefit liquidity denominate capital market certain great purchase represent opportunity borrowing swap currency require group toacquire share satisfy future exercise price purpose group seek denominate borrowing exercise price purchase match option majority currency principal overseas asset borrowing denominate ofwhich exercisable result merger swap foreign currency match investment purchase diminish dilutive effect new share issue overseas group asset treat hedge relevant shareholder capital andearning net asset company expect seek shareholder approval annual general meeting market purchase share derivative financial instrument hedge policy ifsuch purchase consider good interest group use limited number currency swap forward shareholder generally interest rate swap redenominate external borrowing intothe currency interest rate coupon require group purpose duration swap match duration european monetary union theprincipal instrument glaxosmithkline european company make preparation group manage centrally shortterm cash surplus introduction single currency europe borrowing requirement subsidiary company use forward preparation include conversion information system contract hedge future repayment originate training staff new business process local implementation currency contract year duration team support central coordination team derivative instrument account hedge relevant shortterm company expect cost benefit asset liability introduction euro material effect group trading performance equity risk management group use derivative financial instrument manage equity risk equity investment classify current asset available sale group manage disposal optimise market price realisation financial asset liabilitie analysis net debt give note financial statement analysis financial asset liability carry value fair value reconciliation net debt give innote discussion derivative financial instrument quantitative disclosure market riskin accordance requirement financial reporting standard group net debt reduce billion st december st december primarily receipt december proceed billion productdivestment apart glaxosmithkline cash positive group financial asset liability st december representative treasury policy strategy glaxo wellcome smithkline beecham respectively apply consistently year significant change policy year year end significant change glaxosmithkline adopt glaxo wellcome policy hedge foreign exchange transaction exposure normal trade flow glaxosmithkline operate financial review prospect year accordance sec disclosure requirement follow body movement associate levodopa common discussion compare result year st december parkinson disease therapy september group withthe result year st december announce enter licence agreement skyepharma develop oncedaily version requip exchange respiratory average sterling exchange rate weak growth respiratory drive flixotide launch usdollar yen strong european currency seretidein europeglaxosmithkline remain leader asthma thanin currency movement small net product cent share global market favourableeffect sterling result sale operating profit earningsand earning share compare flixotideflovent inhale corticosteroid grow cent overstatingby approximately cent underlie itwa world lead asthma product group performance ofthe business large product growth strong geographic region growth cent usa drive directto growth rate state constant exchange rate consumer television advertising physician education programme follow launch japan november pharmaceutical sale flutide productis available major market glaxosmithkline pharmaceutical sale million october flixotidereceive approval use compare million represent increase treatment chronic obstructive pulmonary disease copd seven cent uncertainty likely germany approval series application flixotideis buy pattern millennium change inhale corticosteroid license use copd aminimal positive effect group sale serevent long act bronchodilator treatment new product launch key franchise asthma copd contribute significantly growth avandiafor metabolic gastrointestinal seretidefor asthma respiratory franchise ziagenand agenerasefor hiv zeffixfor hepatitis b relenza influenza sale product million new asthma product seretidewas launch west growth expect continue europe market contribute nearly million sale uk diskusinhaler novel delivery device asthma pharmaceutical sale therapeutic area treatment queen award technological central nervous system achievement cns franchise decline fourp cent migraine flixonasegrew strongly increase cent usa offset growth cent seroxatpaxil cent group remain leader topical nasal decongestant lamictaland cent wellbutrin market global market share cent seroxatpaxil selective serotonin reuptake inhibitor ssri sale old respiratory product major market approve panic social anxiety disorder record global affect competition generic product newer salesof billion cent number number product growth achieve emerge market ssri country include belgium france ireland italy australia introduction cfcfree version germany greece netherlands spain uk canada brazil ofventolin sale group migraine product imigranimitrexand naramigamerge decline cent usa decline antibacterial stabilise second half year glaxosmithkline augmentincontinue deliver strong performance increase remain market leader migraine product market cent worldwide usa augmentinreached share cent select migraine market billion mark product share rise cent themarket wellbutrin depression continue strong growth substantially generate usa canada europe principally france belgium spain augmentinonce outperform market enhance leadership position lamictal epilepsy continue develop major despite patent expiry number country product strong growth market contribute increase sale cent zinnatgrew strongly emerge market central eastern europe africa middle east latin america sales zyban treat problem smoking addiction increase competition establish market usa decline market decline half west europe cause decline oneper cent sale fortuma year stabilise second half partially offset strong mature product decline amoxil main product growth canada indecember group receive prescription medicine france show growth cent regulatory approval thenetherland acting reference state europe marketzyban requipbenefite continue rollout europe sale rise million increase cent landmark study release july scientific congress parkinson disease show requipis times likely produce dyskinesia involuntaryoperate financial review prospectsglaxosmithkline pharmaceutical sale therapeutic area total usa europe row therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg dermatological arthritis relafen total sale continue business divest product famvir kytril total pharmaceutical sale cer represent sale growth constant exchange rate sterling growth calculate figure give glaxosmithkline operate financial review prospect antiviral year sale lymerix world vaccine viral infection franchise benefit launch new prevention lyme disease reach million lyme disease hiv product growth combivir group apotentially debilitate condition particularly prevelant part hiv portfolio show growth cent growth ofnorth america cause bite infected tick accelerate second half year oncology emesis glaxosmithkline remain market leader hiv combivir growth oncology area drive zofranand particular large group hiv product reflect orally disintegrate tablet odt formulation launch conversion epivirand retrovir market product launch ziagenand ageneraseadde million hycamtingrew cent million approve tosale growth ziagen new generation reverse country secondline treatment ovarian cancer transcriptase inhibitor launch usa countries secondline treatment small cell lung cancer receive regulatory approval european launch july agenerase protease inhibitor launch usa therapeutic area cardiovascular sector sale coreggrew cent december group submit regulatory application million market trizivir new triple combination therapy combine ziagen sale dermatological product increase cent combivir european union usa triziviris medicine combine antihiv therapie tablet sale arthritis treatment relifexrelafennabumetone offer simple dosing regime assist adherence treatment nonsteroidal antiinflammatory drug decline cent result increase competition cox inhibitor herpe area strong sale growth valtrex notably usa france italy offset modest decline sale zovirax sale product decline largely disposal generic competition despite competition generic old product certain market cessation aciclovir glaxosmithkline remain leader global herpe salesunder contract manufacture otc product market market share cent warnerlambert group influenza treatment relenza launch north divest products america west europe markets approval receive sale product divest result glaxo wellcome japan uk national institute clinical excellence issue smithkline beecham merger million guidance discourage prescribing relenzaunder main product kytril antiemetic treat chemotherapy national health service extensive datum product radiotherapy induce nausea vomit famvir available antiviral sale kytrilwere million sale famvir zeffix treatment chronic hepatitis b launch million number market include europe usa principal markets product asia pacific pharmaceutical sale geographic area launch korea china taiwan later usa year sale growth fuel paxil augmentin avandia flixotide combivir ziagen coreg andflonase sale benefit metabolic gastrointestinal launch new product support high directtoconsumer sale zantacreduce cent overall cent advertising growth affect wholesaler buy pattern usa rate decline slow follow generic competition continue affect zantacand patent expiry generic competition continue impact number old product productdisposal cause yearon sale zantacwa cent group sale year loss sale onlytwoper cent sale usa respiratory therapeutic area sale growth drive sale avandiain million increase cent flixotide reflect implementation launch market avandiadirecttoconsumer campaign directtoconsumer advertising campaign cent launch usa late september campaign direct inflonase hiv portfolio contribute sale growth patient world wide web avandiaand telephone cent launch ziagenand ageneraseand combivir number receive information help manage increase market share expand market type diabete avandiawas launch treatment type diabete vaccine drug target insulin resistance receive approval twinrix world combine hepatitis b fda monotherapy combination metformin vaccine adult paediatric strength lead performer sale increase cent europe launch country worldwide twinrixis currently growth european region represent cent total review fda overall sale hepatitis vaccine sale drive large west europe market significant million decline cent individual contribution france italy germany spain infanrix range combination vaccine diphtheria tetanus pertussis whoop cough grow cent million help strong performance infanrixin usa infanrix hep b provide additional protection hepatitis b cinquerix italyoperate financial review prospectsglaxosmithkline pharmaceutical sale geographic area consumer healthcare sale region cer consumer healthcare sale grow cent million major market total growth usa europe otc medicines france oral care uk italy nutritional healthcare germany divest product spain central eastern europe europe otc medicine sale otc medicine increase eightpercent growth rest world asia pacific sale smoking cessation product drive launch japan nicorette cqnicabatein europe australia analgesics sales latin america increase cent panadolgrew cent fuel middle east africa canada strong performances australia middle east offset decrease sale solpadeine cer represent sale growth constant exchange rate sterling growth calculate oral care figure give sale oral care product reach million increase ofsixper cent performance drive strong sale aquafreshinthe international market odoland infrance group second large individual market drbestin germany global sale aquafreshline key franchise respiratory antiviral cns contribute toothpastesand toothbrushe million cent significantly growth italy respiratory antiviral product lead growth spain strong performance respiratory nutritional healthcare area sereventand flixotidedrove growth uk nutritional healthcare business turn strong growth affect paralleltrade performance drink horlick lucozadeand ribena europe cns respiratory antiviral lead help advance sale million increase seven growth strong performance seroxatpaxilflixotide percent sereventseretide combivirand requip central eastern europe poland show strong growth respiratory sale healthcare service sale benefit acquisition polfa poznan january healthcare service principally comprise diversified pharmaceutical continue flow service pharmaceutical benefit management company whichwas sell st april clinical laboratory rest world wassold th august sale healthcare service strong performance number market include australia million canada mexico offset effect adverse economic condition market region growth trading profit business performance particularly strong respiratory area notably flixotide good growth cns dermatological vaccine order illustrate business performance analysis trading profit follow discussion exclude sale grow asia pacific region significant contribution manufacturing restructuring cost dermatological respiratory antiviral therapy area australia india group significant market inthisregion japan strong growth offlixotidewas offset sale decline inzantac cost sale number market latin america region experience sell general administration difficult economic condition mexico brazil provide growth research development sale market decline strong growth operating cost retain business achieve region combivir offset effect operating cost healthcare service sale epivirand retrovir middle east africa area good trading profit performance achieve inanumber market egypt acquisition local pharmaceutical company contribute strong growth cost sale cost sale percentage sale increase cent sale canadian market grow strongly dominate growth reflect offset change product mix high respiratory franchise successful launch zybancaptured cost particularly respiratory device new hiv product cent prescription smoking cessation market increase sale high margin product change geographic contribute million sale growth mix sale benefit generate global supply initiative glaxosmithkline operate financial review prospect sell general administration group continue investment affymetrix inc sell general administrative expenditure increase dispose share gain million percent sale reflect planned acceleration marketing consideration disposal healthcare service investment support new product launch particularlyavandia business clinical laboratory group acquire cent seretide relenzaand lotronex directtoconsumer advertising equity interest quest diagnostic incorporate inthe usa expense partially offset strict managementof infrastructure cost net interest payable net interest payable million decrease research development million compare reflect low level net research development rd expenditure increase borrowing cash inflow sale healthcare billion cent sale increase partly service business low interest rate expense include moreproduct undergo latestage clinical trial include avandia million relate group share quest interest expense arifloand factivea continue investment drug discovery pharmaceutical rd million consumer healthcare restructuring cost divest business rd million manufacturing restructuring divest business healthcare service group announce restructuring manufacturing sale year million trading profit million operation objective optimise capacity utilisation trading margin decline cent higher manage andimprove factorytomarket lead time group supply care billing cost cost associate incident chain cost million recognise paloalto facility divest business healthcare service trading profit healthcare service business divest year trading profit increase cent increase sale diversify pharmaceutical service diversify prescription mainly increase sell general administration delivery sell express script inc clinical laboratory expenditure cent sell quest diagnostic manufacturing restructuring cost include million restructure healthcare service profit taxation business performance operation analysis discussion profit taxation relate taxation business performance taxation charge business performance year operating incomeexpense million percentage profit taxation represent rate taxation cent compare royalty income cent reflect low tax rate number operate expense country change profit mix net tax credit respect restructure disposal subsidiary total taxation income equity investment charge year million earning group realise profit million disposal shareholde biochem pharma inc hold earning acquire group enter earning ordinary share p p researchcollaboration biochem collaboration lead earning ad successful development marketing epivir combivirand adjust earning zeffix disposal represent realisation value earn adjusted earning ordinary share p p group collaboration glaxosmithkline commit adjust earning ad retain residual hold st december weight average number share million group dispose range anaesthetic product usa minor products europe adjust earning adjust earning share present order illustrate business performance glaxosmithkline additionally group recognise cost termination adjust earning share increase cent year rearrangement certain supply contract include cost arise withdrawal raxar joint ventures associates group reduce interest joint venture glaxo wellcome warnerlambert otc joint venture dissolve december healthmatic joint venture usa closed group interest associate company market sale give rise charge profit loss account goodwill previously write reserve associate company group reduce holdingoperating financial review prospectsglaxosmithkline select financial datum ukus gaap profit loss account amount accordance uk gaap business performance retain business sale operate profit profit taxation earningsnet income business performance result exclude merger item restructure cost early year exclude healthcare service total result sale operate profit profit taxation earningsnet income earning ordinary share p p p p p weight average number share million dividend glaxosmithkline ordinary share p glaxo wellcome shareholder smithkline beecham shareholder dividend glaxosmithkline ad glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline sharead amount accordance gaap total result sale lossincome operation lossprofit tax net lossincome balance sheet amount accordance uk gaap total asset net asset equity shareholder fund amount accordance gaap total asset net asset shareholder equity exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate th march glaxosmithkline operate financial review prospect result accounting principle review discuss result glaxosmithkline plc year charge amortisation respect shareholders equity st december acquire intangible asset goodwill smithkline beecham prepare accounting principle accounting purpose effective date acquisition take st december merger glaxowellcome plc smithkline beecham plc glaxosmithkline plc acquire glaxo wellcome plc smithkline shareholders equity st december beecham plc way scheme arrangement merger company effective th december change shareholder equity beginning year net lossincome ukgaap financial statement glaxosmithkline plc share issue acquisition period st december prepare merger share issue share option glaxowellcome plc smithkline beecham plc result treasury stock glaxo wellcome plc smithkline beecham plc year dividend st december balance sheet st december combine comparative figure prepare similar basis year st december st end year december st december shareholders equity st december ukgaap usgaap business combination qualify respect glaxowellcome million pool interest account financial acquisition smithkline beecham th december statements glaxosmithkline plc period st december finance issuance common stock premium par prepare acquisition smithkline beecham increase shareholder equity billion considerationi plc glaxo wellcome plc th december result represent billion asset book value smithkline beecham period prior date gaap basis billion ukgaapbasis billion fair value consolidate net asset smithkline beecham adjustment principally respect intangible asset goodwill incorporate consolidated balance sheet glaxosmithkline value billion ascribe inprocess research plc st december fair value development write income statement result book value glaxo wellcome smithkline beecham net assets ukgaap basis adjust normal ukus summary result gaap difference principal adjustment unamortise goodwill intangible asset glaxos acquisition wellcome sale dividend pay payable basis treatment share trading profit hold employee share ownership trust treasury stock operate lossprofit lossprofit tax net lossincome prospect basic earning share pence glaxo smithkline publish expectation future growth earning share ukgaapbasis exclude merger result reflect trading operation glaxo wellcome restructure item refer outlook certain purchase acquisition accounting adjustment glaxo smithkline expect incur cost deliver expense sale million represent increase saving synergy integration glaxo wellcome cent constant exchange rate sale million smithkline beecham operation uk represent increase cent gaap cost expense usgaap certain demonstrate accelerate trend sale growth glaxo cost expense represent wellcome expect achieve follow period low growth adjustment value acquire goodwill aftermath zantac zovirax patent expiry acquire smithkline beecham intangible asset goodwill trading profit increase low rate growth sale amortise estimate useful life case reflect high manufacturing cost new goodwill expect year upcoming year product investment sell support product launch expect additional annual charge relate amortisation trading profit low usgaapbasis uk gaapbasis intangible goodwill approximately billion result primarily charge fas stockbase compensation fas operating lossprofit include annual charge glaxosmithkline intend adopt fas accounting amortisation goodwill intangible asset arise glaxos derivative instrument hedging activity st january acquisition wellcome asset recognise order determine impact adopt usaccounte balance sheet usgaap ukgaap additionally standard group undertaken review derivative onetime charge million write instrument contract agreement inprocess research development acquire contain possible embed derivative base result acquisition smithkline beecham effect charge review group determine impact adopt fas produce loss tax million tax material impact group financial result minority interest net loss year million financial position prepare usgaap description compare profit tax million net income requirement fas include note million financial statementsglaxosmithkline financial statement section comprise director statement auditor report financial statement financial statement consist principal financial statement support note additional financial data director statement responsibility report auditor financial statement consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement presentation financial statement post balance sheet event accounting policy new accounting policy requirement exchange rate merger glaxo wellcome smithkline beecham segment information merger item restructuring cost divest business operate incomeexpense operating profit joint venture associate undertaking net interest payable taxation earning ordinary share dividend goodwill intangible asset tangible fix asset fix asset investment equity investment stock debtor creditor provision liability charge contingent liability net debt commitment share capital share premium account nonequity minority interest reserve legal proceeding acquisition disposal employee share scheme financial instrument relate disclosure employee cost director remuneration reconciliation accounting principle group company principal financial statement financial record consist quarterly trend year record glaxosmithkline director statement responsibility glaxosmithkline plc acquire glaxo wellcome plc smithkline directors remuneration beecham plc way scheme arrangement merger remuneration report page report describe ofthe company effective th december board policy director remuneration apply date glaxo wellcome smithkline beecham glaxosmithkline plc set detail remuneration operate separately management respective earn director glaxo wellcome plc smithkline board directors beecham plc respective remuneration policy statement set give director ofthe board company glaxosmithkline plc respect glaxosmithkline plc convenience remuneration report include disclosable thdecember regard arrangement information relate director officer interest operation glaxowellcome plc smithkline beecham plc uptothat date statutory disclosure respect remuneration attributable todirector glaxosmithkline plc set note director statement responsibility relation financial statement tothefinancial statement remuneration report comply section b combine director code responsible ensure maintenance proper accounting go concern basis record disclose reasonable accuracy financial position group time financial make enquiry director reasonable statement beprepare comply company expectationthat group company adequate resource act continue operational existence foreseeable future require law prepare financial statement financial forthis reason continue adopt go concern basis period true fair view state affair inprepare accounts company group end financial period ofthe profit loss period internal control responsible ensure operation system board audit committee review internalcontrol take reasonable step safeguard assessment risk internal control framework asset group prevent detect fraud nowoperates glaxosmithkline plc consider irregularity effectiveness system internal control operation financial statement year end st december inthegroup period cover account comprise principal statement support note set infinancial statement page report combine code director confirm suitable accounting policy board consider glaxosmithkline plc apply consistently apply preparation financial statement toth december glaxo wellcome plc smithkline support reasonable prudent judgement estimate beecham plc apply principle combine code asnecessary applicable accounting standard follow asdescribed corporate governance page financial statement prepare go andwiththeexception code provision relate concern basis appointment senior independent director responsibility auditor relation financial company position describe board executive statement set report auditor director service contract pensionable bonus opposite terminationcommitment company position describe remuneration report financial statement year end st december include annual report publish comply provision combine code company hardcopy print form company website require london stock exchange auditor internet director responsible maintenance haveconsidere director statement compliance relation integrity annual report website accordance point combine code specify uk legislation govern preparation dissemination theirreview financial statement access website available outside uk comparable legislation different annual report annual report year end st december comprising report director financial statement additional information investor approve board director sign behalf sir richard syke chairman nd march glaxosmithkline report auditor members glaxosmithkline plc audit financial statement comprise profit united kingdom opinion loss account statement total recognise gain loss opinion financial statement true fair view cash flow statement balance sheet relate note state affair company group st december prepare historical cost convention profit total recognise gain loss cash accounting policy set statement accounting policy flow group year end properly examine amount disclose relate prepared accordance united kingdom company emolument share option longterm incentive act director form remuneration report united states opinion respective responsibility director auditor opinion financial statement present fairly material director responsible prepare annual report respect consolidated financial position group financial statement accordance applicable united stdecember result operation kingdom law accounting standard set statement andit cash flow year period end director responsibilitie st december conformity accounting principle generally accept united kingdom responsibility audit financial statement accordance relevant legal regulatory requirement united kingdom accounting principle generally accept united kingdom auditing standard issue auditing practice board vary certain significant respect accounting principle list rule financial service authority generally accept united states application affect determination net income express report opinion financial insterle year period end statement true fair view properly prepare stdecember determination shareholder equity inaccordance united kingdom company act express sterling st december wealso report opinion report director extent summarise note financial statement consistent financial statement company hasnot keep proper accounting record receive pricewaterhousecooper information explanation require audit charter accountant register auditor information specify law list rule director london england remuneration transaction disclose nd march read information contain annual report consider implication report aware anyapparent misstatement material inconsistency financial statement information comprise director report joint statement chairman chief executive officer operate financial review corporate governance statement review corporate governance statement reflect company compliance seven provision combine code specify review list rule report require consider board statement internal control cover risk control form opinion effectiveness company group corporate governance procedure risk control procedure basis audit opinion conduct audit accordance auditing standard issue united kingdom auditing practice board withaudite standard generally accept united states anaudit include examination test basis evidence relevant amount disclosure financial statement include assessment significant estimate judgement director preparation financial statement accounting policy appropriate company circumstance consistently apply adequately disclose planned perform audit obtain information explanation consider necessary order provide sufficient evidence reasonable assurance financial statement free material misstatement cause fraud irregularity error form opinion evaluate overall adequacy presentation information financial statement glaxosmithkline consolidate statement profit lossglaxosmithkline consolidate statement profit loss merger business performance business performance restructure restructuring restructure business disposal retain divest disposal retain divest disposal performance subsidiary total business business total subsidiary total business business total subsidiary total note turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate profit dissolution joint venture product divestment merger transaction cost disposal business provision loss disposal loss disposal utilisation provision profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning ordinary share p p p adjust earning ordinary share p p p dilute earning ordinary share p p p profit attributable shareholder dividend retain profit item deal arrive operating profit relate continue activity difference profit ordinary activity taxation retain profit state historical cost equivalent consolidate statement total recognise gain loss profit attributable shareholder exchange movement overseas net asset uk tax exchange movement total recognise gain loss glaxosmithkline consolidate statement cash flow reconciliation operating profit operating cash flow note business performance operate profit depreciation impairment exclude restructuring amortisation goodwill intangible fix asset loss sale tangible fix asset income equity investment increase stock increase trade debtor increase trade creditor decreaseincrease pension provision net cash inflow business performance operating activity manufacture restructuring cost pay integration provision movement integration cost pay merger transaction cost net cash inflow operating activity cash flow statement net cash inflow operating activity earning joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash inflowoutflow management liquid resource finance management liquid resource finance increasedecrease cash year reconciliation net cash flow movement net debt net debt begin year increasedecrease cash year cash inflow management liquid resource net increase inrepayment longterm loan net repayment shortterm loan net increase inrepayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flow return investment servicing finance interest receive interest pay dividend pay minority shareholder dividend pay preference share taxation pay capital expenditure financial investment purchase tangible fix asset sale tangible fix asset include integration purchase intangible asset sale intangible asset proceed product divestment purchase share proceed share staff option purchase equity investment sale equity investment acquisition disposalsnote purchase business disposal business investment joint venture associate undertaking disposal interest associate financing issue ordinary share capital financing cash flow increase longterm loan repayment longterm loan net repayment shortterm loan net increase inrepayment obligation finance lease analysis change net debt cash flow exchange cash repayable demand overdraft debt year commercial paper debt year euro bond euro note management liquid resource cash balance repayable demand liquid investment net debt glaxosmithkline consolidated balance sheet note goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset call share capital share premium account reserve equity shareholder fund nonequity minority interest equity minority interest capital employ approve board sir richard syke chairman nd march reconciliation movement equity shareholder fund note equity shareholder fund begin year total recognise gain loss year dividend ordinary share issue exchange movement goodwill write reserve goodwill write profit loss account equity shareholder fund end year glaxosmithkline company balance sheet note share subsidiary company cost cash bank net asset call share capital share premium account equity shareholder fund company incorporate th december accounting period date st december profit period nil company acquire glaxo wellcome plc smithkline beecham plc th december hold company glaxosmithkline group company expect receive dividend subsidiary company order pay dividend shareholder approve board sir richard syke chairman nd march glaxosmithkline note financial statement presentation financial statement merger glaxowellcome plc smithkline beecham plc glaxosmithkline plc acquire glaxo wellcome plc smithkline description business beecham plc way scheme arrangement merger glaxosmithkline major global healthcare group company effective th december engage creation discovery development manufacture marketing pharmaceutical product vaccine overthe ukgaap financial statement glaxosmithkline plc counter otc medicine healthrelate consumer product forthe period st december prepare glaxosmithkline principal pharmaceutical product include merger glaxowellcome plc smithkline beecham plc medicine follow therapeutic area central nervous system result glaxo wellcome plc smithkline beecham plc disorder respiratory antibacterial antiviral metabolic include year st december comparative gastrointestinal vaccine oncology emesis cardiovascular figure similar basis year st december arthritis dermatological andst december gaap financial statement glaxosmithkline plc financial period forthe period st december prepare account cover financial year st january acquisition smithkline beecham plc glaxo wellcome plc stdecember comparative figure financial th december accordingly result smithkline year st january st december st january beecham periods prior date consolidate tost december presentation statement profit loss composition group columnar presentation adopt statement list subsidiary associate undertaking profit loss order illustrate underlie business performance opinion director principally affect purpose certain item identify separately profit net asset group give group company exclude business performance comprise merger page item include product divestment cost relate previously announce manufacturing restructuring theeffect composition financial statement business disposal prior year consolidated financial statement draw accordance uk generally accept accounting principle ukgaap trading profit reflect sale lesscost sale comprise cost uk accounting presentation ofmanufacture external royalty sell general administrative expenditure comprise cost sell financial statement comprise medical support currently market product cost consolidate statement profit loss administration cost research development create consolidated statement total recognise gain loss future product sale consolidate statement cash flow consolidated balance sheet accounting convention reconciliation movement equity shareholder fund financial statement prepare historical company balance sheet cost convention note financial statement accounting standard permit section company act financial statement comply applicable uk accounting profitand loss account company present standard statement total recognise gain loss comprise accounting principle policy realise profit attributable shareholder reflect preparation financial statement conformity generally theconsolidate profit loss account accept accounting principle require management unrealised gain loss value company estimate assumption affect report amount overseas net asset related foreign currency borrowing asset liability disclosure contingent asset attributable currency movement period liabilitie date account report amount reconciliation movement equity shareholder fund revenue expense report period actual result comprise item contribute increase decrease differ estimate period shareholder fund item include financial statement prepare accordance total recognise gain loss period company accounting policy describe note company dividend pay propose implement new financial reporting standard proceed share issue period describe innote change goodwill arise acquisition prior st january set directly reserve post balance sheet event additional information accordance requirement th january glaxosmithkline complete acquisition usgenerally accept accounting principle gaap include block drug company inc manufacturer toothpaste note financial statement note statement oral healthcare consumer product million difference reconciliation net income shareholder million pay cash block drug consolidated equity uk gaap provide principal thefinancial statement glaxosmithkline date financial statement present accordance gaap acquisition add scale glaxosmithkline consumer andin usgaap format healthcare business provide additional annual sale million expect enhance earning sharenote financial statement glaxosmithkline accounting policy foreign currency transaction foreign currency transaction group company book consolidation inlocal currency exchange rate ruling date consolidate account include transaction forward rate hedge forward asset liability result cashflow exchangecontract foreign currency asset liability company subsidiary undertaking include employee translate local currency rate exchange ruling share ownership trust esot balance sheet date forward rate exchange difference group share net asset result joint venture areinclude trading profit associate undertaking revenue account undertaking consolidate revenue recognise profit loss account good st december service supply external customer order undertaking group material interest receive turnover represent net invoice value account subsidiary group exercise dominant deduction standard discount give point sale influence joint venture group exercise joint control product despatch available collection customer associate group exercise significant accrual estimate future rebate return value influence esot account subsidiary ground add tax sale taxis exclude revenue group de facto control expenditure interest acquire undertaking consolidated expenditure recognise respect good service effective date acquisition interest sell consolidated receive supply accordance contractual term upto date disposal provision obligation exist future liability transaction balance subsidiary undertaking respect past event obligation eliminate profit take sale subsidiary reliably estimate restructure cost recognise undertaking sale joint venture associate undertaking respect direct expenditure business reorganisation product sell customer outside group plan sufficiently detail advanced appropriate communication affect goodwill arise acquisition interestsin subsidiary undertake balance sheet date undertaking joint venture associate undertaking represent excess purchase consideration research development group share separable net asset acquire capitalise research development expenditure charge profit asa separate item case subsidiary undertaking loss account period incur tangible cost investment case joint venture fix asset research development depreciate associate undertaking goodwill denominate currency accordance group policy inwhich acquisition finance case acquisition prior goodwill write environmental expenditure reserve subsequent disposal asset acquisition environmental expenditure relate exist condition result related goodwill remove consolidated reserve past current operation current charge consolidated profit lossaccount future benefit discernible charge profit loss group interest joint venture account account group determine liability sitebysite basis thegross equity method group interest associate record liability time probable undertaking account equity method reasonably estimate liability include group portion cost group portion defer taxation relief unrealise intragroup profit potentially responsible party probable account extent relate taxation effect able satisfy respective share cleanup isexpecte reverse obligation recovery reimbursement virtually asset liability overseas subsidiary joint venture certain record asset associate undertaking include related goodwill translate sterling rate exchange rule balance sheet date pension postretirement benefit result cash flow overseas subsidiary joint venture cost provide pension employee post associate undertaking translate sterling average retirement benefit charge consolidated profit loss rate exchange exchange adjustment arise open account systematic rational basis base actuarial net asset profit theyear retain overseas assumption period benefit derive subsidiary joint venture associate undertaking translate employee service difference charge sterle exchange difference arise relate foreign contribution pay include asset liability currency borrowing take directly reserve report consolidated balance sheet statement total recognise gain andlosse translate sterling asset liability result cash flow ofoverseas subsidiary joint venture associate undertaking report currency hyperinflationary economy adjustment aremade reflect current price level loss net monetary assetsis charge consolidated profit loss account glaxosmithkline note financial statement account policiescontinue depreciationi calculate write cost tangible fix asset exclude freehold land equal annual instalment employee share plan expect useful life normal expect useful life incentive form share provide employee major category tangible fix asset share option share award scheme respect award scheme certain share option grant company provide freehold building year finance employee share ownership trust purchase company leasehold land buildingsthe short lease term year share open market meet company obligation plant machinery year provide share employee exercise option award fixture equipment year thedifference purchase price share computer software year exercise price option award charge credit profit loss account period service respect ondisposal tangible fix asset cost relate option award grant respect share accumulate depreciation remove account option grant share option exercise account net proceed take consolidated profit share issue exercise price additional employer cost respect loss account option award charge profit loss account period service investment joint venture associate investment joint venture associate undertaking cost run employee share ownership trust charge carry consolidated balance sheet group share profit loss account oftheir net asset date acquisition post share hold employee share ownership trust account acquisition retain profit loss goodwill fix asset investment cost accrual cost charge arise acquisition net amortisation goodwill impairment fix asset goodwill state cost provision amortisation carry value fix asset review impairment amortisation calculate write cost equal annual indication asset impair instalment expect useful life normal expect useful firstyear impairment review conduct acquire goodwill life expect exceed year intangible asset certain intangible consider anindefinite life amortise intangible intangible fix asset subject annual impairment test impairment determine intangible asset state cost provision amortisation byreference high net realisable value value use measure reference discount future cash flow acquire licence patent knowhow marketing right provision impairment charge profit amortise estimate useful life equal instalment yearconcerne long year item capitalise restrict related specific compound product stock develop commercial application estimate useful life stocksare include account low cost include determine amortisation charge review annually manufacture overhead appropriate net realisable andtake account estimate time take bring value cost generally determine basis compound product market marketable product anydevelopment cost incur group lease areassociate acquire licence patent knowhow leasing agreement transfer group substantially market right write profit loss account benefit risks ownership asset treat finance whenincurre lease asset purchase outright asset brand value independently fair value include intangible fix asset capital element business acquire party brand value leasing commitment show obligation finance lease substantial longterm brand asset hold finance lease depreciate shorter sell separately rest business acquire brand ofthe lease term useful life asset interest areamortise estimated useful life long element lease rental charge profit year end useful economic life lease operating lease annual rental brand forseen charge profit straightline basis lease term prior acquire minor brand similar intangible eliminate group balance sheet reserve year taxation acquisition defer taxation calculate liability method account group company taxation defer tangible fix asset accelerate reason time difference defer taxation relief tangible fix asset state cost provision account onlongterm time difference respect depreciation ofprovision unfunded retirement benefit taxation defer oraccelerate reason shortterm time difference cost acquire develop computer software account extent probable liability internal use internet site external use capitalise asset crystallise tangible fix asset software site support significant business system expenditure lead creation durable assetnote financial statementsglaxosmithkline accounting policiescontinue new accounting policy requirement current asset investment company implement financial reporting standard current asset investment state low cost net tangible fix asset financial reporting standard current realisable value tax frss update provide additional guidance exist accounting practice frs significant effect case security acquire significant premium measurement classification asset liability frs permit discount maturity value intend hold redemption require revaluation property cost adjust amortise premium discount life capitalisation interest capital project progress company tomaturity security float rate bond state cost adopt policy revaluing property capitalise interest income take consolidated profit loss account interest receivable basis company require implement financial equity investment include current asset regard report standard accounting policy frs update asavailable sale exist standard provide new guidance expect significant effect measurement result asset debt instrument liabilitie company debt instrument state net proceed adjustedto amortise finance cost debt evenly term frs retirement benefit fall implement debt company term disclosure interm measurement frs adopt market value approach derivative financial instrument measurement retirement benefit require expand group hold issue derivative financial instrument disclosure trading purpose frs defer tax fall implement company derivative financial instrument manage exposure frs require defer tax account market risk treasury operation principal derivative provision basis partial provision basis present instrument currency swap forward exchange contract st december effect provision basis interest rate swap derivative contract treat reduce deferred tax asset approximately million inception economic hedge underlie financial instrument matching accounting treatment cash flow exchange rate derivative contract high correlation specific group use average exchange rate prevail financial instrument hedged inception period translate result cash flow overseas group hedge period derivative instrument long subsidiary joint venture associate undertaking sterling designate hedge restate market value change period end rate translate net asset value take directly profit loss account undertaking thecurrencie influence currency swap forward exchange contract fix translation relevant exchange rate value relate asset liability contract currency contract rate accrue profit loss account life contract gain loss foreign exchange contract average rate designate hedge forecast foreign exchange transaction defer include measurement relate foreign euro currency transaction period occur gain loss yen balance sheet hedge accrue take directly reserve period end rate forward premiumdiscount recognise interest life contract euro yen interest differential interest swap agreement recognise consolidated profit loss account adjustment ofinter expense life agreement glaxosmithkline note financial statement merger glaxo wellcome smithkline beecham glaxosmithkline plc glaxo wellcome plc smithkline beecham plc accounting reference date st december term merger inview proximity merger date financial yearend glaxosmithkline plc form effect scheme date relative insignificance business activity arrangement merger glaxo wellcome plc smithkline th december st december accounting beecham plc scheme arrangement effective date merger practical purpose take thdecember point glaxosmithkline plc acquire stdecember profit financial year issue share capital glaxo wellcome plc glaxo wellcome plc smithkline beecham plc smithkline beecham plc exchange shares glaxosmithkline plc isdeeme relate period prior merger date term agree propose merger reflect relative stock market valuation company month accounting alignment precede announcement merger thjanuary certain adjustment reflect result envisage shareholder glaxo wellcome plc hold glaxosmithkline align accounting policy classification approximately cent shareholder smithkline previously adopt glaxo wellcome smithkline beecham beecham plc hold approximately cent issue asfollow ordinary share capital glaxosmithkline plc base number accounting policy share glaxo wellcome smithkline beecham issue ainterest finance major construction project previously st december effect shareholder glaxo capitalise smithkline beecham expense wellcome plc smithkline beecham plc receive share bdeferre tax relief unfunded postretirement benefit glaxosmithkline plc follows previously recognise smithkline beecham post glaxo wellcome share glaxosmithkline share retirement healthcare recognise additionally smithkline beecham share glaxosmithkline unfunded pension cost share accounting presentation case share hold american depository share adss cstandard sale discount usa previously classify evidence american depository receipt adr glaxo smithkline beecham sell general administrative wellcome ad represent glaxo wellcome share expenditure reclassify deduction sale smithkline beecham ad represent smithkline beecham droyalty similar recur income significant oneoff share glaxosmithkline ad represent item operating incomeexpense previously classify glaxosmithkline share accordingly holder glaxo wellcome smithkline beecham sell general administrative adrs holders smithkline beecham adrs receive expenditure classify operating incomeexpense glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss balance sheet reclassification ecertain item reclassify consistency merger date glaxosmithkline plc issue ordinary share p par acquire investment reclassification ordinary share p glaxo wellcome plc fcertain equity investment hold smithkline beecham ordinary share p smithkline reclassify fix asset current assets beecham plc nominal value share issue write current market value reflect fact million market value share glaxosmithkline consider investment available datewasbillion sale consolidation adjustment accounting merger groyaltie pay glaxo wellcome smithkline beecham reflect intention respective size merge eliminate consolidation party combination glaxo wellcome plc smithkline beecham plc treat merger th december segment reclassification uk gaap glaxo wellcome overthecounter product manage inglaxosmithkline consumer healthcare sale merger accounting share issue glaxosmithkline plc profitsof product classify consumer acquire glaxo wellcome smithkline beecham account healthcaresector par share premium arise share acquire glaxosmithkline glaxo wellcome smithkline beecham adjustment year present similarly account nominal value share issue theexception investment reclassification inthe consolidated account glaxosmithkline result date merger accounting policy netasset glaxo wellcome smithkline beecham adjustment investment reclassification affect book combine book amount subject alignment value net asset adjustment identify relevant adjustment discuss letter follow table balance sheet profit lossaccountnote financial statement glaxosmithkline merger glaxo wellcome smithkline beecham continue glaxo consolidated balance sheet smithkline adjustment smithkline consolidation glaxo glaxo wellcome beecham plc elimination smithkline st december key goodwill intangible asset tangible asset investment e fix asset equity investment f stocks debtor liquid investment cash bank current asset loan overdraft creditor e creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge e net asset call share capital share premium account reserve abf equity shareholder fund nonequity minority interest equity minority interest capital employ key interest previously capitalise b defer tax e reclassification f investment reclassification glaxosmithkline note financial statement note financial statement glaxosmithkline merger glaxo wellcome smithkline beecham continue business performance merger business performance business performance restruct total restruct total restruct total glaxo smithkline adjustment glaxo disposal glaxo glaxo smithkline glaxo disposal glaxo glaxo smithkline glaxo disposal glaxo wellcome beecham smithkline subsids smithkline wellcome beecham adjustment smithkline subsids smithkline wellcome beecham adjustment smithkline subsids smithkline consolidated profit loss account key turnover c cost sale g gross profit sell general administrative expenditure acd research development expenditure trading profit operating incomeexpense dfg operating profit share profitslosse joint venture associate undertaking profit disposal interest associate profit dissolution joint venture product divestment merger transaction cost disposal business provision loss disposal loss disposal utilisation provision profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder key interest previously capitalise c discount operating incomeexpense f investment reclassification g royalty elimination glaxo smithkline glaxo glaxo smithkline glaxo glaxo smithkline glaxo wellcome beecham adjustment smithkline wellcome beecham adjustments smithkline wellcome beecham adjustments smithkline consolidate statement total recognise gain loss profit attributable shareholder exchange movement overseas net asset uk tax exchange movement total recognise gain loss glaxosmithkline note financial statement segment information analysis turnover profit taxation total asset net asset tangible fix asset geographical business segment areset belowthe business segment consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oralcare otc medicine nutritional healthcare healthcare services clinical laboratory testing pharmacy benefit management thegeographical segment reflect group significant regional market consistent group regional market management reportingstructure follow sale diversify pharmaceutical service clinical laboratory healthcare service segment long form ongoing business group business segment datum include charge allocate corporate cost segment intrasegment sale group activity organise global basis geographical segmental figure influence location group operate resource particular manufacture research variation time intragroup trading funding arrangement turnover business sector pharmaceutical consumer healthcare healthcare service external turnover turnover location customer usa europe rest world external turnover profit tax business sector pharmaceutical consumer healthcare healthcare service operating profit share profitslosse joint venture associate undertaking profit disposal associate dissolution joint venture divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset business sector pharmaceutical consumer healthcare total asset net asset business sector pharmaceutical consumer healthcare net asset note financial statementsglaxosmithkline segment informationcontinue turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operating profit share profitslosse joint venture associate undertaking profit disposal associate dissolution joint venture divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset location subsidiary undertaking usa europe rest world total operating asset cash bank liquid investment total asset net asset location subsidiary undertaking usa europe rest world net operating asset net debt net asset glaxosmithkline note financial statement segment informationcontinue plant land equipment computer asset building vehicle software construction total tangible fix asset location subsidiary undertaking usa europe rest world total uk segment information give separately respect uk include group europe market region consider group home segment purpose segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset net asset merger item restructuring cost divest business restruc disposal restruc disposal merger ture associate subsidiary total ture associate subsidiary total manufacturing restructuring merger integration cost healthcare service restructuring effect operate profit share associate product divestment merger transaction cost disposal business loss disposal utilisation provision effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning manufacturing restructuring cost incur glaxo wellcome smithkline beecham implementation previously announce plan restructure manufacturing activity merger integration cost incur relate integration glaxo wellcomeand smithkline beecham unify glaxosmithkline business cost include consultancy fee respect integration planning initialseverance cost initial asset write off cost relate early vest lapse performance condition share option share incentive award product divestment income arise disposal famvir kytrilandother product require order obtain regulatory approval merger merger transaction cost incur order effect themerg cost comprise fee expense incur prepare implement scheme arrangement merger disposal business relate disposal healthcare service restructuring cost incur healthcare service disposal share associate relate restructure cost incur quest diagnosticsnote financial statementsglaxosmithkline merger item restructuring cost divest business continue cost incur respect restructure amount million respect litigation amount million aprovision loss disposal healthcare service business amount million tax relief item million million million respectively operate incomeexpense royalty income operate expense income equity investment royalty income comprise core recur income form royalty outlicense intellectual property andincome disposal outlicense noncore commercial asset old product operate expense comprise nonrecurre cost defend intellectual property commercial asset income investment arise management disposalof investment group equity investment portfolio operating profit follow item charge operating profit employee cost note advertising depreciation tangible fix asset own asset lease asset amortisation goodwill amortisation intangible fix asset loss net monetary asset hyperinflationary economy exchange lossesgain foreign currency depositsloans operate lease rental plant machinery land building audit fee fee auditor work auditor ukfirm auditor overseas firm include audit fee fee relate company audit glaxosmithkline plc include fee auditor work million relate merger glaxo wellcome smithkline beecham glaxosmithkline note financial statement joint venture associate undertaking share profitslosse joint venture glaxo wellcome warnerlambert associate undertaking share profit quest diagnostic inc share profitslosse associate undertaking goodwill write share turnover joint venture glaxo wellcome warnerlambert total sale joint venture associate undertaking net interest payable interest payable bank loan overdraft loan respect finance lease share interest payable associate investment income interest income realise gain provision market value adjustment taxation taxation charge base profit period uk corporation tax uk statutory rate double taxation relief overseas taxation defer taxation act writeback million million taxation charge attributable associate undertakingsnote financial statement glaxosmithkline taxationcontinue reconciliation taxation rate ukstatutory rate taxation defer taxation provide fix asset effect special taxation status manufacturing location net cost different rate taxation overseas undertaking share option deduction usa tax loss rd credit previously recognise prior year item act write difference taxation rate business performance merger restructuring costs taxation rate total group result profit arise manufacturing operation singapore puerto rico ireland tax reduce rate effect reduction taxation charge increase earning ordinary share p p p integrate nature group worldwide operation crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit fall tax individual territory resolution transfer pricing issue inevitable continue fact life group number year glaxo wellcome significant open issue relate transfer pricing usa issue principally relate success zantac relate year present remain wide variation claim internal revenue service group estimation taxation liability issue subject discussion uk tax authority termsof double tax convention country take appropriate professional advice seek manage issue satisfactory conclusion director continue believe group adequate provision liability likely arise open assessment save show account provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain st december require way incremental tax arise tax creditor defer tax tax balance st january exchange adjustment chargecredit profit loss account credit reserve cash pay movement st december potential provide defer taxation assetliability accelerate capital allowance unremitte foreign investment income stock valuation adjustment intragroup profit diversify pharmaceutical service disposal pension postretirement benefit manufacturing restructure tax loss time difference category provide defer taxation stock valuation adjustment intragroup profit time difference arecurrent glaxosmithkline note financial statement earning ordinary share p p p basic earning ordinary share adjustment merger item restructuring cost disposal subsidiary merger integration transaction cost product divestment restructuring cost disposal subsidiary associate adjust earning ordinary share dilute earning ordinary share earning ordinary share calculate divide profit attributable shareholder weight average number ofordinary share issue period number calculate basic diluted earning ordinary share reconciledbelow order illustrate business performance exclude merger manufacturing restructuring cost adjust earning adjust earning share present net profit period attributable shareholder earning basic diluted adjustment merger item restructuring cost disposal subsidiary adjust earning weight average number share issue million million million basic adjust dilution share option dilute share hold employee share ownership trust excludednote financial statement glaxosmithkline dividend glaxo wellcome interim second interim final smithkline beecham interim second interim interim fourth interim total dividend state deduct dividend receivable trustee employee share ownership plan trust whereapplicable dividend share p p p glaxo wellcome plc glaxo wellcome share interim second interim final equivalent dividend glaxosmithkline share dividend glaxo wellcome share smithkline beecham plc smithkline beecham share interim second interim interim fourth interim equivalent dividend glaxosmithkline share interim second interim interim fourth interim glaxosmithkline note financial statement goodwill total cost st january exchange adjustment addition cost st december amortisation st january provision year amortisation st december net book value st january net book value st december licence intangible asset patent etc brand total cost st january exchange adjustment addition asset write cost st december amortisation st january exchange adjustment provision year asset write amortisation st december impairment st january impairment loss impairment st december net book value st january net book value st december brand largely comprise portfolio sterling product panadol solpadeineand hedex consider indefinite life give strength durability brand level marketing support accordingly amortise thevaluation brand review annually year cash flow forecast basis original independent assessment acquire impairment loss calculate discount rate centnotes financial statementsglaxosmithkline plant land equipment computer asset tangible fix asset building vehicle software construction total cost st january exchange adjustment addition disposal reclassification cost st december depreciation st january exchange adjustment provision year disposal depreciation st december impairment st january impairment loss disposal reclassification impairment st december net book value st january net book value st december net book value st december group land building comprise freehold property million st january million property lease year million st january million property lease year million stjanuary million include plant equipment vehicle st december lease asset cost million st january million accumulate depreciation million st january million net book value million st january million impairment loss principally relate reduction forecast cash flow result decision close manufacturing facility andhasbeen measure reference value use discount rate cent joint associate equity fix asset investment venture undertaking investment share total st january exchange adjustment addition charge year impairment transfer current asset disposal retain profit year goodwill amortisation st december investments joint venture comprise million share gross asset million nil share gross liability nil principal associate undertaking quest diagnostic incorporate clinical laboratory business list new york stock exchangewith book value million market value million st december group own cent quest cost include goodwill million amortise year amortisation charge million goodwill million relate continue group interest clinical laboratory asset attribute quest remain eliminate group reserve equity investment comprise list investment million unlisted investment million market value list investment million investment share consist share hold employee share ownership trust detail give note glaxosmithkline note financial statement equity investment st january exchange adjustment addition transfer fix asset impairment disposal st december equity investment comprise list investment million million unlisted investment million million themarket value list investment million million stock raw material consumable work progress finish good debtor amount year trade debtor debtor prepay pension contribution prepayment accrue income amount year debtor defer taxation note debtor include trading balance nil million joint venture associate undertaking creditor amount year trade creditor taxation note social security creditor accrual defer income dividend propose amount year taxation note creditor creditor include trading balance million million joint venture associate undertaking accrual include accrual wage salarie million millionnote financial statement glaxosmithkline provision pension indemnify legal postretirement manufacturing merger disposal liability charge benefit restructure integration liability dispute provision total st january exchange adjustment charge year apply movement st december group continue recognise cost respect plan manufacture restructuring initiate implement period cost recognise provision principally respect identify severance site announce manufacturing activity cease expect incur mainly cost asset writedown recognise impairment fix asset group recognise cost respect plan integration glaxo wellcome smithkline beecham business implement largely cost recognise provision principally respect identify severance expect incur provision indemnify disposal liability relate indemnity grant party respect operation dispose prior year include provision indemnity purchase price adjustment respect exit healthcare service business provision legal dispute matter include amount relate antitrust product liability intellectual property right contract termination selfinsurance environmental cleanup property rental amount provide include estimate obligation arise quantify unquantified claim outcome claim legal proceeding matter glaxosmithkline involve predict certainty director take appropriate legal advice expect glaxosmithkline ultimate liability matter take account provision tax benefit insurance material adverse effect financial condition result operation cash flow nature group business number matter subject negotiation litigation year large individual amount expect settle year discussion litigation issue refer legal proceeding note contingent liability contingent liability comprise warranty discount bill performance guarantee item arise normal course business amount st december million million glaxosmithkline note financial statement net debt liquid investment cash bank loan overdraft year bank loan overdraft commercial paper eurobond obligation finance lease loan loan year bank loan eurobond loan stock obligation finance lease loan net debt market value book value liquid investment government equivalent investment investment deposit bank balance sheet date group liquid investment include list investment million million aggregate market value million million loan overdraft year commercial paper comprise billion programme million issue st december million back committed facility day duration million renewable annually liquid investment million weight average interest rate commercial paper borrowing st december cent weight average interest rate loan overdraft year st december cent loan year loan year repayable period follow year year year year year loan carry interest effective rate cent centnote financial statement glaxosmithkline net debt continue secure loan loan amount million million secure charge fix current asset finance lease obligation rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation financial instrument information give note commitment capital commitment contract provide account intangible fix asset tangible fix asset acquisition block drug company inc commitment license agreement purchase intangible asset payable number year series future milestone achieve commitment operating lease pay rental year operating lease land building expire year year year operating lease plant equipment expire year year commitment operating lease pay rental future year glaxosmithkline note financial statement share share capital share premium account redeemable preference share ordinary share p p ccm oi uu nm number number share capital authorise st december share capital issue fully pay share capital issue prior scheme arrangement share capital issue scheme arrangement share capital issue share option scheme st december number number share issuable outstanding option note st december number unissue share option st december redeemable preference share issue par nonvoting respect resolution wind company vary right redeemable preference share carry right dividend entitle priority repayment asset company wind redeemable company par day notice merger glaxo wellcome smithkline beecham take place effect st december nominal value issue share capital date million detail substantial shareholding refer substantial shareholding nonequity minority interest sb holdings corporation sbh corp subsidiary incorporate delaware usa issue million flexible auction market prefer stock flex amp comprise share issue series dividend fix issuance seven year period respectively series sbh corp issue million auction rate preference stock arp comprise share issue series dividend vary predominately prevail interest rate set seven week auction share trade smithkline beecham corporation sb corp subsidiary incorporate pennsylvania usa issue st december million arp comprise share issue series dividend rate series vary predominately prevail interest rate set seven week auction share trade arp flex amp constitute preference share represent nonequity minority interest smithkline beecham plc certain circumstance guarantee payment dividend declare preference share smithkline beecham plc agree sb corp sbh corp certain circumstance provide support sb corp sbh corp relation principal guarantee support limit circumstance holder preference share favourable position holder preference share glaxosmithkline plc preference share represent longterm nonequity minority interest group balance sheet accordance frs capital instrument sbcorp arp repay february march note financial statement glaxosmithkline profit reserve reserve loss account total st december goodwill offset profit loss account reserve goodwill write profit loss account exchange adjustment relate net asset subsidiary associate undertaking retain profit subsidiary associate undertaking goodwill borrowing designate hedge uk tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange st december goodwill write profit loss account exchange adjustment relate net asset subsidiary associate undertaking retain profit subsidiary associate undertaking goodwill borrowing designate hedge uk tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange st december goodwill write profit loss account exchange adjustment relate net asset subsidiary associate undertaking retain profit subsidiary associate undertaking goodwill borrowing designate hedge uk tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange st december goodwill arise acquisition st january write reserve amount million include goodwill million previously hold goodwill reserve offset reserve goodwill denominate local currency subject revaluation amount million st december goodwill acquisition st january capitalise accordance accounting policy set note exchange adjustment debit reserve cumulatively million reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million st december million million total reserve amount million st december million million nil nil nil relate company million million million relate subsidiary undertaking million million million negative relate joint venture associate undertaking glaxosmithkline note financial statement legal proceeding respect pende litigation usa relate paxil group believe patent valid group involve legal administrative party compound infringe group patent intend proceeding consider normal business principally vigorously litigate position intellectual property case product liability governmental investigation significant describe follow expiration datum exclusivity period europe glaxosmithkline commit ensure safety product glaxosmithkline understand authorisation issue world notwithstanding high standard quality synthon regulatory authority denmark paroxetine mesylate control product liability significant commercial risk different salt form paroxetine hydrochloride active ingredient glaxosmithkline common pharmaceutical seroxatpaxil authorisation assessment industry group expose ongoing development european country mutual recognition process group strict liability continue readiness consumer initiate litigation challenge approval danish medicine particularly usa enter individual class action agency ground authorisation havebeen litigation grant abridge procedure paroxetine mesylate essentially similar seroxat addition glaxosmithkline understand intellectual property marketing authorisation issue denmark july group file action torpharm apotex paroxetine hydrochloride anhydrate variant group inc apotex corp district court northern product recently launch glaxosmithkline believe district illinois charge infringement group patent marketing paroxetine hydrochloride anhydrate product paroxetine hydrochloride hemihydrate paxilseroxat torpharm paroxetine mesylate product thirdpartie european agent apotex corp file abbreviate new drug country infringe patent vigorously litigate position application anda food drug administration july emory university obtain grant patent fda seek approval introduce generic form paxilinto claim purport cover compound lamivudine tc theus market prior expiration group patent active ingredient epivir active ingredient component torpharm assert anda compound combivirand trizivir emory sue glaxosmithkline infringe group patent february challenge licensor biochem patent infringement district court validity patent party engage discovery northern district georgia litigation stay july process trial date set pende outcome interference proceeding group file action geneva pharmaceuticals patent trademark office uspto intend establish zenith goldline district court subject matter emorys patent rightly belong emory theeastern district pennsylvania charge infringement biochem uspto rule favour biochem invalidity thegroup patent paroxetine hydrochloride hemihydrate emorys patent leave issue unresolved glaxosmithkline paxilseroxat geneva zenith goldline file anda seek resolution issue appeal district paroxetine hydrochloride assert compounds court district columbia notinfringe groups patent patent invalid distributor generic pharmaceutical product file inaddition group file new action torpharm andas sustain release bupropion hydrochloride tablet intheeastern district pennsylvania base new patent wellbutrin andzyban usa accompanied case issuedin cover paroxetine new patent acertification invalidity group patent group include action geneva zenith hasbrought suit file party ground goldline proceeding action defer patent infringement glaxosmithkline file suit andrx pendinga decision glaxosmithkline motion consolidate pharmaceutical file anda district court allpennsylvania litigation southern district florida action file march glaxosmithkline file action pentech watson pharmaceutical district court inthe district court northern district illinois southern district ohio eon labs manufacture district infringement group patent paroxetine hydrochloride court eastern district new york impax laboratory pentech file anda capsule version paxil assert district court northern district california compound presentation infringe group patent case early stage patent invalid matter discovery minnesota mining manufacture company allege october glaxosmithkline file action synthon certain glaxosmithkline respiratory product launch district court middle district north carolina infringe ms patent cover inhaled product contain infringement group patent paroxetine hydrochloride hfa noncfc propellant glaxosmithkline initiate action paroxetine mesylate synthon file b application foradeclaratory judgement invalidity noninfringement apaper nda fda different salt form district court middle district paroxetine market form paxil northcarolina separate action initiate action matteris early stage adeclaratory judgement invalidity noninfringement glaxosmithkline patent district court minnesota january glaxosmithkline file action alphapharm action remain discovery phase district court eastern district pennsylvania infringement group patent paroxetine hydrochloride alphapharm file anda paroxetine hydrochloride assert product infringe group patent patent invalid matter early stagesnote financial statementsglaxosmithkline legal proceeding continue antitrust individual chain drug store file suit october glaxosmithkline file action infringement patent pharmaceutical company smithkline forcefuroxime axetil active ingredient group ceftin beecham glaxo wellcome drug manufacturers antiinfective product ranbaxy pharmaceuticals mail order pharmacy district court middle district district court new jersey preliminary injunction grant pennsylvania complaint allege smithkline beecham favour glaxosmithkline ranbaxy appeal decision glaxo wellcome manufacturer defendant violate interim bar marketing cefuroxime axetil product federal antitrust law sell conspire sell prescription glaxosmithkline file similar action apotex second drug mail order pharmacy favour purchaser distributor generic pharmaceutical product district court price price plaintiff charge accord northern district illinois case early stage complaint price discrimination manufacturer distributor generic pharmaceutical product file defendant enable favour purchaser sell drug price andas nabumetone active ingredient relafen accompany low price plaintiff able charge case certification patent invalidity group drug cause plaintiff lose sale cut profit bring suit file party ground patent margin plaintiff seek declaratory injunctive relief treble infringement case consolidate trial damage cost attorney fee district court district massachusetts trial conclude subsequent filing initial complaint similar injanuary trial judge issue decision antitrust suit file different federal judicial courtordere stay generic file district state pharmaceutical business ananda expire march generic product smithkline beecham glaxo wellcome case beenlaunche drug manufacturer wholesaler federal case bring district court product liability northern district illinois pretrial purpose food drug administration aware ofreport cardiac valvular problem individual state complaint include allegation fenfluramine dexfenfluramine combination purport consumer class action california district phentermine prescribe regimen weight reduction ofcolumbia certify class federal class action request voluntary withdrawal fenfluramine component include pharmacy represent approximately dexfenfluramine market report cardiac valvular twothird total retail sale volume settle problem subsequent withdrawal product glaxo wellcome smithkline beecham defendant elect market spawn numerous product liability lawsuit file try case verdict direct favour manufacturer distributor fenfluramine dexfenfluramine largely affirm appeal glaxo wellcome smithkline phentermine number manufacturer phentermine beecham settle large number remain case group defendant numerous lawsuit state majorexception include group separate lawsuit bring federal district court usa file common group lawyer boie group behalf asclass action lawsuit seek relief include approximately independent retail pharmacy combination compensatory punitive damage medical notbeen settle smithkline beecham glaxo wellcome monitoring refund purchase drug judicial settle socalle rite aid case original case file panel multidistrict litigation issue order consolidate middle district pensylvania litigation plaintiff transfer federal action district court eastern continue district pennsylvania court approve global settlement propose defendant american home products ahp sell governmental investigation fenfluramine dexfenfluramine settlement include glaxosmithkline receive subpoena attorney office phentermine defendant include group appeal boston massachusetts request group produce settlement schedule hear circuit document period present relate court appeal ahp continue settle individual anyrepackaging relabelle private label arrangement statecourt case trial glaxosmithkline discuss thirdparty customer period issue price charge withdrawal product pharmaceutical consumer party glaxosmithkline product count healthcare business spark product liability claim litigation medicaid good price purpose group provide document follow voluntary withdrawal lotronexin response subpoenas november number lawsuit file glaxosmithkline suit individual personal injury glaxosmithkline respond subpoenas office action file class action seek medical theinspector general department health human monitoring compensation personal injury damage state service department justice state texas consumer protection statute action early stage california nevada connection allegation similarly follow voluntary withdrawal consumer healthcare pharmaceutical company include glaxosmithkline product inwhich phenylpropanolamine ppa active violate federal fraud abuse law federal false ingredient group receive notice purport national claim act respect texas california nevada class action seek relief medical monitoring refund comparable state law result way certain drug compensation personal injury increase risk injury price way medicare medicaid programmes member nationwide class take ppa product group reimburse drug receive lawsuit california allege personal injury increase risk injury unfair deceptive business practice claim action early stage glaxosmithkline note financial statement legal proceedingscontinue environmentally responsible member local national worldwide community operate group believe november federal trade commission staff advise operation comply material respect applicable environmental glaxosmithkline staff conduct nonpublic law regulation investigation determine group violate section federal trade commission act monopolizing glaxosmithkline notify potential responsibility attempt monopolize market paroxetine hydrochloride relate past operation past waste disposal practice prevent generic competition paxiland request atcertain site primarily usa matter group submit certain information connection thesubject litigation include proceeding initiate investigation group cooperate staff usfederal state government waste disposal site remediation investigation early stage cost tort action bring private party include notification group rohm haas company company sbcl indemnity incorporate usa responsibility relate joint connection sale smithkline beecham clinical laboratory cleanup whitmoyer laboratory site pennsylvania sbcl quest diagnostic incorporate group agree company remediate site pursuant consent decree indemnify quest diagnostic aftertax basis respect environmental protection agency epa certain liability arise conduct sbcl business prior smithkline beecham corp file legal action rohm toclosing significant legal proceeding subject haas seek indemnification respect whitmoyer indemnity governmental private claim arise laboratory cleanup cost term agreement usgovernment investigation sbcls billing marketing sb corp purchase site rohm haas practice liability arise misconduct phlebotomist apanel court appeal circuit reverse ata patient service centre palo alto california order district court find favour group remand matter proceeding group continue respond claim lawsuit allocate proportionate responsibility new trial nongovernmental party include private insurer selffunde postpone basis possible administrative legislative employer plan patient concern billing marketing practice reliefthat reduce remediation cost responsibility sb clinical laboratory practice relate amount thepartie pay party lawsuit include purport class action file jurisdiction usa nonclass action complaint glaxosmithkline advise responsible party number insurance company seek damage allegedly atapproximately site few site include arise payment clinical laboratory testing service whitmoyer site appear national priority list create purport class action consolidate pretrial comprehensive environmental response compensation liability proceeding nonclass action suit file act superfund theinsurer district court district connecticut proceeding seek require operator hazardous waste inaugust insurer lawsuit enjoin facility transporter waste site generator shortlythereafter stay follow party hazardous waste dispose site clean site representation district court connecticut agreement toreimburse government cleanup cost instance principle settle insurer case reach respect glaxosmithkline involve allege generator hazardous class action litigation file behalf individual patient waste site glaxosmithkline entity district connecticut settlement preliminarily involve current operator facility approve court february february superfund provide defendant jointly severally asettlement sole nonconsolidate class action suit liable cleanup cost proceeding frequently resolve alsopreliminarily approve illinois state court judge basis nature quantity waste dispose march group learn employee sbcl thesite generator group proportionate liability patientservice centre palo alto california times reuse cleanup cost substantially determined needle draw blood patient phlebotomist ofthe site referred immediately suspend dismiss group glaxosmithkline potential liability vary greatly site cooperate local state federal health agency address sitewhile cost investigation study remediation public health issue arise employee breach standard suchsite time substantial glaxosmithkline medical practice offer free testing approximately routinely accrue amount related share liability patient blood draw phlebotomist matter glaxosmithkline expect share liability determine patient expose hepatitis b matter amount accrue hepatitis c hiv number civil action include purport account material impact financial condition class action file group state court result operation cash flow group california behalf individual affect make ongoing capital expenditure environmental protection thephlebotomist reuse needle allege improper practice equipment cash expenditure site remediation case allege fear disease dismiss case allege operation maintenance environmental facility actual infection enter discovery anticipate expenditure material impact group capital expenditure cash flow environmental matter group worldwide programme corporate environmental tax matter standard standard ensure environmental protection pende tax matter describe note financial key business objective detail purpose scope procedure statement taxation responsibilitie environmental concern group worldwide operation group commit annote financial statementsglaxosmithkline acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture give book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition glaxo wellcome sa acquisition minority interest glaxo wellcome sa group acquire cent equity share capital glaxo wellcome sa polfa poznan sa poland cash consideration million goodwill million capitalise amortise period original acquisition disposal affymetrix inc group sell million share hold affymetrix inc associate undertake cash proceed million realise profit million sb clinical laboratory final cash settlement million million october quest diagnostic incorporate complete sale sb clinical laboratory sb clinical glaxo laboratory affymetrix wellcome sa total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal glaxosmithkline note financial statement acquisition disposal continue book fair value net asset cost value adjustment acquire goodwill acquisition acquisition amoun pharmaceuticals industry co sae glaxo wellcome kk quest diagnostic incorporate amoun pharmaceutical industry co sae apic january groups subsidiary company egypt glaxo wellcome egypt sae acquire cent amoun pharmaceutical industry co sae subsequently increase hold cent take account minority interest cent glaxo wellcome egypt sae effective group interest apic december cent purchase consideration egyptian pound million million pay cash goodwill egyptian pound million million capitalise amortise year acquisition contribute million turnover contribution operate profit material glaxo wellcome kk july group complete merger nippon glaxo limited group wholly own subsidiary japan nippon wellcome kk nw group majorityowne subsidiary japan form glaxo wellcome kk gwkk previous minority shareholder nw cent interest difference minority interest gwkk minority interest nw deal goodwill onconsolidation quest diagnostic incorporate august group acquire cent equity interest quest diagnostic incorporate quest consideration disposal sb clinical laboratory million goodwill arise million remain eliminate group reserve million capitalise disposal diversify pharmaceutical service april group sell diversified pharmaceutical service dps express script inc million million recognise cost expect arise disposal million charge goodwill previously write reserve million loss million provision million date disposal turnover dps million operating loss million charge goodwill amortisation million sb clinical laboratory august group sell sb clinical laboratory quest million million cash cent equity interest quest representing value million million recognise cost expect arise disposal million charge goodwill previously write reserve million profit loss transaction date disposal turnover sb clinical laboratory million operate profit million affymetrix inc august group sell million share hold affymetrix inc associate undertake cash proceed million realise profit million sb clinical laboratory dps affymetrix apic total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal note financial statement glaxosmithkline acquisition disposal continue book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition polfa poznan sa biddle sawyer romanian europharm group acquisition contribute million turnover contribution operate profit material polfa poznan sa glaxo wellcome sa january group acquire cent polfa poznan sa subsequently increase hold cent january polfa poznan sa account subsidiary undertaking total cost million comprising purchase consideration million acquisition expense million purchase consideration pay cash million million january million million subsequently fair value net asset acquire exceed book value million comprising adjustment million reflect value land building million respect defer tax goodwill million capitalise amortise year biddle sawyer january group acquire biddle sawyer indian company purchase consideration r lakh million goodwill rs lakh million capitalise amortise year consideration pay cash romanian europharm group group acquire cent interest romanian europharm group purchase consideration million pay cash million goodwill capitalise amortise year disposal glaxo wellcome warnerlambert joint venture effect st december company dissolve joint venture warnerlambert development marketing ofthe group product otc market term dissolution warnerlambert right market zantac usa canada glaxo wellcome right product previously market joint venture future product potential switch prescription otc additionally glaxo wellcome receive balance cash consideration agreement include release warranty give dissolution glaxo wellcome warnerlambert joint venture base business recognise cost expect arise dissolution exceptional credit million recognise tax attributable approximately million profit attributable group million romanian polfa europharm poznan biddle group sa sawyer total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed dissolution otc joint venture glaxosmithkline note financial statement employee share scheme group operate share option scheme option grant employee acquire share glaxosmithkline plc grant price share award scheme award grant employee acquire share glaxosmithkline plc cost subject tothe achievement performance target detail give relate scheme operate separately glaxo wellcome smithkline beecham date merger scheme glaxosmithkline merger glaxo wellcome option outstanding date merger convert glaxosmithkline option smithkline beecham share option wasconverte glaxosmithkline share option smithkline beecham ad option convert glaxosmithkline adr option corresponding adjustment grant price glaxo wellcome share option scheme glaxo wellcome operate share option scheme savingsrelate share option scheme grant share option scheme normally exercisable year date grant date merger share option grant exercisable performance condition applicable lapsed grant savingsrelate share option scheme normally exercisable threeyear save option share option scheme normally grant market price ruling date grant accordance uk practice themajority option saving relate share option scheme grant price cent market price ruling dateof grant savingsrelate share option scheme share option scheme total weighted weight weight exercise exercise exercise number share issuable outstanding option number price number price number price st december option grant option exercise option cancel st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december glaxo wellcome share award scheme glaxo wellcome operate long term incentive plan annual incentive plan long term incentive plan grant award share director senior staff nominal cost percentage award vest base performance glaxo wellcome threeyear period annual incentive plan performance bonus consist basic award ofshare matching award threeyear retention period result merger awards long term incentive plan payable retention period annual incentive plan lapse number share issuable share award scheme number st december option grant option exercise option cancel st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december note financial statementsglaxosmithkline employee share scheme continue smithkline beecham share option scheme smithkline beecham adopt smithkline beecham uk executive share option plan smithkline beecham executive share option plan smithkline beecham adopt employee share ownership plan employee grant option share adss purchase market employee share ownership trust establish underthe plan formermentione plan plan refer plan plan eligible employee grant option subscribe unissued share adss case plan issue share buy bythe employee share ownership trust price high average middle market price day prior thegrant ortheir nominal option normally exercisable year date grant option exercisable result merger share adss weight weight exercise exercise number share adss issuable outstanding option number price number price st december option grant option exercise option cancel st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december smithkline beecham midterm incentive plan smithkline beecham adopt midterm incentive plan mtip participation mtip grant annually senior staff smithkline beecham designate target number share participant base job grade follow threeyear measurement period rn committee review smithkline beecham total shareholder return relative company comprise ftse index final award proportion target number share cent depend performance measurement period end st december cent cent respectively target number share award receipt award defer case share remain mtip result merger outstanding award payable cent target number share end threeyear cycle share adss number share issuable midterm incentive plan number number st december option grant option exercise option cancel st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december glaxosmithkline note financial statement employee share schemescontinue glaxosmithkline share option scheme option outstanding share option share option saving relate scheme share scheme adss share option scheme st december weight weight weight number exercise number exercise number exercise price price price th december convert gw option convert sb option option exercise option cancel st december range exercise price order encourage employee convert option hold glaxo wellcome smithkline beecham share adr glaxosmithkline share adr programme establish additional cash benefit cent exercise price original option provide employee remain employ group year date merger exercise option early month expiry date original option year date merger option outstanding share option share option saving relate scheme share scheme adss share option scheme st december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share grant saving relate share option grant change effective exercise price outstanding option financial period option grant st december th march option exercisable share option share option saving relate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price st december gw sb st december gw sb st december gsk note financial statement glaxosmithkline employee share schemescontinue glaxosmithkline share option scheme share adss number share adss issuable number number th december convert glaxo wellcome option convert smithkline beecham option option exercise st december award option relate share option relate adss exercisable st december employee share ownership trust group sponsor employee share ownership trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee employee share ownership trust purchase share onthe open market finance provide group way loan contribution expect cost obligation deliver share employee incentive plan share option scheme normally spread period service respect award option grant accelerated charge respect outstanding cost provide share award option exercisable solely result merger glaxo smithkline glaxosmithkline wellcome beecham share share share share hold share award scheme number ordinary share nominal value cost amortisation market value glaxo smithkline glaxosmithkline wellcome beecham share share share share hold share option scheme number ordinary share nominal value cost amortisation market value trustee waive right dividend share hold employee share ownership trust option pricing purpose value option arrive stockbase compensation adjustment reconciliation accounting principle note blackschole option pricing model assumption model follow glaxo smithkline glaxosmithkline wellcome beecham riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year saving relate share option scheme year year glaxosmithkline note financial statement financial instrument relate disclosure concentration credit risk credit exposure financialinstrument policy group believe expose major concentration discussion group objective policy credit risk group expose creditrelate loss event management offinancial instrument associate risk nonperformance counterpartie financial instrument include treasury policy financial review expect counterpartie fail meet obligation group apply boardapprove limit credit investment exposure counterparty employ strict minimum group hold number equity investment frequently credit worthiness criterion choice counterparty entity group enter research collaboration group seek realise value investment fair value financial asset liability inpart research collaboration help create table opposite present carry amount certain investment regard available sale uk gaap fair value group financial asset account foras current asset investment purpose liabilities st december st december ofusgaap investment classify available sale debtor creditor year exclude group liquid investment represent fund surplus fair value financial asset liability include immediate operating requirement account atthe instrument exchange current asset investment purpose usgaap current transaction willing party force investment classify available sale liquidationsale follow method assumption proceed sale investment classify available estimate thefair value show saleunder gaap year end stdecember equity investment market value base quote market weremillion proceed include rollover liquid price case list investment market value fund shortterm deposit gross gain loss reflect reference quote price case material unlisted consolidated profit loss account respect investment investment classify available sale gaap million cash bank approximate carry andnil respectively liquid investment base quote market price case marketable security approximate carry foreign exchange risk management inthe case time deposit short maturity group enter forward foreign exchange contract shortterm loan overdraft approximate carry inorder swap liquid asset borrowing currency short maturity instrument require group purpose st december group mediumterm loan market value base quote market outstanding contract sell purchase foreign currency price case eurobond fix rate total notional principal million borrowing approximate carry case stdecember million majority contract offloate rate bank loan loan period month forward exchange contract base market price end year group number currency swap exchange rate balance sheet date inplace respect mediumterm debt instrument medium currency swap base market valuation balance term note issue japanese yen swap float rate sheetdate dollar cent million euro note interest rate instrument base market valuation cent chf million bond swap balance sheet date float rate yen swap mature date close debtor creditor approximate carry maturity date underlie instrument provision approximate carry borrowing denominate swap foreign currency fair value investment share match investment overseas group asset treat group st december investments share ahedge relevant net asset million million fair value million million difference interest rate risk management carrying fair value represent gross unrealised gain manage fixedfloate interest rate profile debt group million investment exclude financial interest rate swap outstanding commercial bank instrument disclosure fair value market value base st december quote market price share represent purchase employee share ownership trust satisfy future exercise option award employee incentive scheme purchase match option predetermine exercise price gain loss recognise measured exercise price market valuenote financial statementsglaxosmithkline financial instrument relate disclosure continue classification fair value financial asset liability follow table set classification financial asset liability provide reconciliation group net debt note shortterm debtor creditor exclude financial asset liability provision include contractual obligation settle cash carry fair carry fair value value net debt liquid investment cash bank current asset financial instrument sterling note bond yen loan swap sterling currency swap dollar note bond note bond swap dollar currency swap note bond swap yen currency swap mediumterm borrowing shortterm loan overdraft total borrowing interest rate swap forward exchange contract purchase forward exchange contract sell total derivative instrument management net debt total net debt fix asset equity investment current asset equity investment debtor year creditor year provision foreign exchange derivative auction rate preference share subsidiary money market preference share subsidiary flexible auction rate preference share subsidiary total nonequity minority interest total financial asset liability total financial asset total financial liability currency swap present alongside underlie principal instrument difference carry fair value equity fix current asset liquid investment represent gross unrealised gain million million respectively glaxosmithkline note financial statement financial instrument relate disclosure continue currency interest rate risk profile financial liability financial liability take account currency interest rate swap analyse total financial liability comprise total borrowing million million creditor year million million provision million million nonequity minority interest preference share million million creditor year exclude benchmark rate determine interest payment float rate financial liability table libor fix rate noninterest bearing average average st december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency fix rate noninterest bearing average average st december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency currency interest rate risk profile financial asset total financial asset comprise fix asset equity investment million million current asset equity investment million million liquid investment million million cash bank million million debtor year million million exclude foreign exchange derivative million million debtor year exclude st december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency st december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency note financial statementsglaxosmithkline financial instrument relate disclosure continue currency exposure net monetary assetsliabilitie group currency exposure rise net currency gain loss recognise profit loss account arise principally company sterle functional currency monetary asset liability denominate overseas functional currency andborrowing designate hedge overseas net asset exclude table stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen nonequity finance minority total total debt lease interest maturity financial liability year demand year year year gain loss net hedge unrecognise gain loss begin year gain loss arise previous year recognise year gain loss arise beginning year unrecognised end year unrecognised gain loss arise year total unrecognised gain loss end year expect recognise year expect recognise year total unrecognised gain loss end year commit facility group commit facility commercial paper programme million million day duration renewable annually glaxosmithkline note financial statement employee cost wage salary social security cost pension postretirement cost cost sharebase incentive plan severance cost arise integration restructuring activity pension postretirement cost arise integration group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal assurance average number person employ group include director year number number number manufacturing sell general administration research development number group employee end financial year give financial record pension postretirement cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost pension postretirement cost arise integration pension group undertaking operate pension arrangement cover group material obligation provide pension retire employee thesearrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length ofservice define benefit scheme include define contribution section aredescribe hybrid scheme table majority case contribution define benefit scheme determine accordance advice independent professionally qualified actuary formal independent actuarial valuation group main plan undertake regularly normally year theasset fund scheme generally hold separately administer trust insure pension cost accounting purpose assess accordance independent actuarial advice generally project unit method spread surplus deficit average expect remain service live respective membership certain country pension benefit provide unfunded basis scheme administer trustee company whereasset hold specific purpose matching liability unfunded scheme provision include provision pension postretirement benefit charge profit respect benefit aggregate ofthe increase year intheassesse liability member service net movement provision set pension inpayment liability generally assess annually accordance advice independent actuary pension arrangement glaxo wellcome company smithkline beecham company operate separately continue case date accordingly information give deal set arrangement separatelynote financial statementsglaxosmithkline employee cost continue glaxo wellcome market value asset glaxo wellcome fund define benefit pension fund date late actuarial valuation sufficient cover cent cent benefit accrue member allow future salary andpension increase market value million million uk define benefit pension scheme account approximately cent group plan asset valuation project benefit term define benefit pension scheme account approximately cent group plan asset valuation project benefit term relevant assumption calculate pension cost accounting purpose follow uk usa pa pa pa pa rate increase future earning discount rate expect longterm rate return investment additional assumption respect uk scheme increase pension cent cent uk equity dividend growth cent cent assumption result regular cost uk pension arrangement million reduce zero pension cost account allowance spread surplus disclose level percentage salary expect future working lifetime exist member year regular accounting cost scheme million recent triennial actuarial valuation uk scheme funding purpose carry stmarch date asset scheme represent cent actuarial value benefit accrue member date allow future salary pension increase trustee uk pension scheme agree company request grant benefit improvement include cent enhancement entitlement beneficiary allowance improvement funding level fall follow valuation company contribution scheme remain suspend formal valuation expect remain suspend thetotal market value asset hold scheme st march million recent actuarial valuation group usfunded scheme carry date market value scheme asset million value asset represent cent actuarial value benefit accrue member date allow future salary increase smithkline beecham uk defer benefit hybrid scheme cover cent total smithkline beecham employee relevant assumption calculate pension cost accounting purpose follow uk usa pa pa pa pa rate increase future earning discount rate expect longterm rate return investment regular cost uk scheme million reduce accounting cost million allowance spread surplus expect future working lifetime current employee scheme late valuation carry st december date actuarial value scheme asset represent cent actuarial value accrue service liability total market value asset hold scheme st december million regular cost scheme million reduce accounting cost million allowance spread surplus expect future working lifetime current employee scheme late valuation carry st january date actuarial value scheme asset represent cent actuarial value theaccrue service liability total market value asset hold scheme st january million glaxosmithkline note financial statement director remuneration glaxosmithkline policy director remuneration effective financial year detail remuneration receive director glaxo wellcome plc smithkline beecham plc give remuneration report director appoint board company rd receive remuneration glaxosmithkline plc continue remunerate glaxo wellcome plc smithkline beecham plc service company themergerbetween glaxo wellcome smithkline beecham complete th december point glaxo wellcome smithkline beecham subsidiary glaxosmithkline statutory disclosure respect director remuneration attributable director glaxosmithkline plc relation servicesto company subsidiarie th st december set director compensation salary fee benefit emolument bonus total compensation date appointment st december benefit salary fee emolument bonus total emolument individual director executive director dr j p garnier mr j coombe nonexecutive director sir richard syke sir roger hurn sir peter walters mr p allaire dr barzach mr c bonham sir christopher hogg mr p j job mr j h mcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young total compensation note financial statementsglaxosmithkline director remuneration continue director interest follow completion merger glaxo wellcome smithkline beecham th december outstanding glaxo wellcome smithkline beecham share adss convert glaxosmithkline share adss follow basis glaxosmithkline share glaxo wellcome share glaxosmithkline ad glaxo wellcome ad glaxosmithkline share smithkline beecham share glaxosmithkline adss smithkline beecham ad result director interest st december rd date appointment director board glaxosmithkline plc convert glaxosmithkline share adss relevant merger ratio follow beneficial interest director company show register maintain company accordance company act december appointment december appointment date date note share share adss adss dr j p garnier mr j coombe ab sir richard syke ac sir roger hurn sir peter walters mr p allaire dr barzach mr c bonham sir christopher hogg mr p j job mr j h mcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young glaxosmithkline ad represent glaxosmithkline share interest glaxo wellcome smithkline beecham share adss appointment date restate interest glaxosmithkline share adss interest appointment date include deposited share glaxo wellcome annual incentive plan b include nonbeneficial interest trust hold share appointment date c include nonbeneficial interest trust hold share appointment date addition interest show mr mchenry interest defer fee plan relate period mrmchenry director smithkline beckman prior merger beecham group defer fee index total return glaxosmithkline share payable seven year follow mr mchenrys retirement total accumulate value defer fee st december restate reflect merger equivalent glaxosmithkline adss fully provide share option ad ad option option appointment option glaxosmithkline adss date dr jp garni share share option option appointment option glaxosmithkline share date mr j coombe sir richard syke option outstanding appointment date restate option glaxosmithkline share adss glaxosmithkline note financial statement reconciliation usaccounte principle accordingly balance sheet present represent consolidated balance sheet glaxo wellcome account financial statement analyse reconciliation present acquirer usgaap st december note page represent financial information glaxosmithkline stdecember prepare require generally accept accounting usgaap acquisition smithkline beecham account principle gaap apply instead ukgaap purchase method account th december significant difference uk gaap fair value acquire asset liability ukgaap combination glaxo wellcome plc include balance sheet st december smithkline beecham plc account merger reconciliation consolidated income statement pool interest accordance uk financial report consolidate statement comprehensive income change standard usgaap transaction account shareholder equity year end st december purchase business combination glaxo wellcome acquire correspondingly reflect purchase method smithkline beecham accounting theacquisition smithkline beecham glaxo glaxosmithkline plc form effect scheme wellcome income statement present arrangement merger glaxo wellcome plc smithkline gaap format certain exceptional item beecham plc scheme arrangement effective product divestment merger integration cost writeoff thdecember point glaxosmithkline plc acquire inprocess research development classify issue share capital glaxo wellcome plc operating profit smithkline beecham plc exchange shares glaxosmithkline consolidate statement cash flow usgaap plc completion merger shareholder usgaapformat present glaxo wellcome hold approximately cent shareholder smithkline beecham hold approximately financial statement reflect purchase method cent issue ordinary share capital glaxosmithkline plc accounting combination glaxo wellcome smithkline reflect relative stock market valuation company beecham material adjustment month precede announcement merger require usgaap apply instead ukgaap thjanuary theperiod present summary purchase accounting adjustment usgaap adjustment provide combination glaxo wellcome smithkline beecham reconciliations profit attributable shareholder equity account merger ukgaap financial statement shareholder fund uk usgaap glaxosmithkline ukgaap represent combine financial statement glaxo wellcome smithkline beecham historical basis period present gaap business combination qualify pool interest account glaxo wellcome determined accounting acquirer purchase acquisition date thdecember gaap financial statement glaxosmithkline prior merger glaxo wellcome view proximity merger date financial year end date relative insignificance business activity th december st december accounting date acquisition practical purpose take st december note financial statementsglaxosmithkline reconciliation accounting principle continue consolidated balance sheet underus gaap asset current asset cash cash equivalent marketable security account note receivable inventory prepaid expense defer income taxis total current asset goodwill intangible asset property plant equipment investment affiliate asset total asset liability shareholder equity current liability cash overdraft account payable shortterm borrowing capital lease obligation income taxis accrue liability total current liability longterm borrowing capital lease obligation liability defer income taxis total liability minority interest contingency commitment note shareholder equity common stock share par value share authorise share issue redeemable preference share share par value share authorise share issue additional paidin capital retain deficitearnings treasury stock total shareholder equity total liability shareholder equity glaxosmithkline note financial statement note financial statementsglaxosmithkline reconciliation accounting principle continue smithkline smithkline smithkline glaxo beecham glaxo glaxo beecham glaxo glaxo beecham glaxo smithkline preacquisition gaap smithkline smithkline preacquisition gaap smithkline smithkline preacquisition gaap smithkline uk gaap uk gaap adjustment gaap uk gaap uk gaap adjustment gaap uk gaap uk gaap adjustment gaap reconciliation consolidated income statement revenue cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense amortisation goodwill intangible asset writeoff inprocess rd acquire product divestment merger transaction cost operate profit share profitslosse joint venture associate undertaking profit disposal interest associate profit dissolution joint venture disposal business provision loss disposal loss disposal utilisation provision profit interest net interest expense profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholdersnet lossincome basic earning ordinary share p gaap pence p p p dilute earning ordinary share p gaap pence p p p basic earning ad usgaap diluted earning ad gaap consolidate statement comprehensive income change shareholder equity usgaap shareholders equity beginning year net lossincome exchange movement overseas net asset unrealise gain equity investment net tax unrealise gain liquid investment net tax uk tax exchange movement total comprehensive income dividend ordinary share issue employee share ownership plan ordinary share issue acquire smithkline beecham shareholders equity end year glaxosmithkline note financial statement reconciliation accounting principle continue consolidated statement cash flow usgaap cash flow operating activity net lossincome adjustment reconcile net income net cash provide operating activity depreciation amortisation writeoff inprocess rd acquire impairment gain sale fix asset productive asset defer taxis change operate asset liability net acquisition decreaseincrease inventory increase trade debtor increase trade creditor increasedecrease pension provision net cash provide operating activity cash flow invest activity acquisition fix asset acquisition intangible asset acquisition smithkline beecham cash receive acquisition acquisition new business net cash acquire proceed disposition fix asset business increase liquid investment decreaseincrease equity investment net cash provide byused investing activity cash flow financing activity proceed additional borrowing reduction debt purchase treasury stock dividend net repayment ofincrease shortterm loan net repayment ofincrease cash overdraft issue ordinary share capital net cash financing activity net increase cash cash equivalent exchange rate movement cash cash equivalent begin year cash cash equivalent end year supplemental cash flow information cash pay year interest income taxis noncash investing financing activity group acquire outstanding share smithkline beecham exchange share glaxosmithkline conjunction acquisition liability assume follow fair value asset acquire fair value share issue fair value liability assume note financial statementsglaxosmithkline reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap apply instead uk gaap adjustment reflect balance sheet income statement present accordance usgaap profit profit attributable shareholder uk gaap smithkline beecham preacquisition profit attributable shareholder uk gaap merger alignment adjustment usgaap adjustment writeoff smithkline beecham inprocess rd acquire capitalise interest computer software amortisation goodwill amortisation intangible asset pension stockbase compensation provision esot share merger transaction cost defer taxation defer tax effect gaap adjustment net lossincome gaap equity shareholder fund equity shareholder fund uk gaap smithkline beecham equity shareholder fund uk gaap merger alignment adjustment effect acquisition smithkline beecham purchase accounting inventory tangible fix asset investment pension asset workforce product right goodwill defer tax purchase price adjustment smithkline beecham ukgaap preacquisition net asset goodwill gaap adjustment capitalise interest computer software goodwill wellcome acquisition cost million million amortisation million million intangible asset unrealise gain marketable security pension postretirement benefit employee share ownership trust restructuring cost foreign currency hedge ordinary dividend defer taxation defer tax effect gaap adjustment shareholder equity gaap glaxosmithkline note financial statement reconciliation accounting principle continue dthe fair value attribute pension obligation reflect recognition previously unrecognised actuarial gainslosse acquisition smithkline beecham prior service cost transition amount amount recognise gaap financial statement glaxosmithkline prior tothe base actuarial assessment acquisitiondate merger glaxo wellcome gaap accounting acquirer ethe fair value attribute intangible asset relate acquisition smithkline beecham account primarily management estimate value product purchase method date merger thdecember right inclusive respective patent trademarks onexisting product assemble smithkline beecham purchase accounting adjustment workforce thefair value product right order determine proper allocation purchase price relate determined base discount net future cash flow analysis acquire asset smithkline beecham gaap current approve product portfolio include purchase accounting cost acquisition calculate exist approve product pharmaceutical market value share issue fair value vest option therapeutic area consumer healthcare product portfolio exchange direct external acquisition cost allocate supplemental product development process fair value net asset acquire result fair value build exist chemical entity exist area exercise increase value smithkline beecham inventory andwhich subject separate food drug tangible fix asset investment pension obligation administration approval include management recognise fair market value attribute intangible base estimate weight average useful life asset mainly product right inclusive patent trademark product right future period substantial assemble smithkline beecham workforce inprocess research majority estimate net future cash flow value expect development appropriate defer taxation realise approximately year aggregate fair effect difference cost acquisition fair value assemble workforce amortise year value asset liability smithkline beecham period base smithkline beecham historical turnover rate record asgoodwill allocate inprocess research development require gaap expense f total consideration allocate smithkline immediately thefirst report period business beecham inprocess research development project iprd combination glaxosmithkline period end estimate smithkline beecham current stdecember fair value adjustment record estimate status prospect rd portfolio inventory expense period inventory contain smithkline beecham strategic plan iprd utilise additional amortisation depreciation include identify project advanced stage berecorde respect fair value adjustment tangible development management believe reasonable estimate intangible asset result goodwill period project cash flow prepare include respective economic useful life effort associate withbasic discovery portfolio gene patent report iprd value intend reflect adjustment asset liability smithkline beecham present value development activity currentlyunderway reflect fair value allocation excess purchase smithkline beecham iprd project involve rd effort consideration fair value net asset acquire base related new product project involve supplemental onmanagement good estimate fair value summarise new drug application exist product product extension thetable opposite discuss development activity require fda approval value athe total assume purchase consideration calculate allocate iprd determine utilise risk adjust bymultiplye number glaxosmithkline share issue income approach include earning discount tosmithkline beecham shareholders outstanding appropriate cost capital investment estimate smithkline beecham share average fair value glaxo future cash flow related individual iprd project base wellcome security average fair value glaxo wellcome exist estimate revenue contribution margin security calculate period day prior project iprd write acquisition accordance subsequent theannouncement merger th gaap purchase accounting january total assume purchase consideration gdeferre taxis compute excess fair value include fair value smithkline beecham vest option book value goodwill inprocess research exchange vested option glaxosmithkline total development applicable weighted average number smithkline beecham vest option multiply statutory tax rate bythe respective fair value ordinary share adr plan determine thjanuary hgoodwill represent remainder unallocated purchase consideration goodwill amortise expect bthe increase fair value inventory fix asset economic life year glaxosmithkline finalise determine base difference carry value mergerrelate restructuring plan anticipate market value asset thatadditional adjustment goodwill cthe market value investment include book additional liability record restructuring value smithkline beecham net asset gaap theformer smithkline beecham operation increase investment relate increase fair market value nonmarketable security st december include inthis increase smithkline beecham equity investment equity investment measure fair value excess fair value underlie tangible asset liability recognise goodwill investment goodwill amortise yearsnote financial statement glaxosmithkline reconciliation accounting principle continue purchase accounting adjustment total assume purchase consideration outstanding share cost fee transaction book value smithkline beecham net asset gaap goodwill estimate excess fair value inventory b estimate excess fair value tangible fix asset b estimate excess fair value investment c estimate excess fair value pension asset estimate fair value attribute intangible asset e estimate fair value attribute workforce e estimate fair value attribute inprocess rd project f defer tax liability relate purchase price adjustment g goodwill h acquisition smithkline beecham pro forma result unaudite follow table reflect result operation gaap pro forma basis acquisition smithkline beecham complete st january pro forma result operation include amortisation acquire goodwill intangible butdonot include writeoff inprocess rd orinventory adjustment net sale earning interest income taxis minority interest net incomeloss pence pence earningsloss ordinary share dilute earningsloss ordinary share earningsloss ad dilute earningsloss ad pro forma financial information necessarily indicative theoperating result occur acquisition consummate date indicate necessarily indicative future operating result glaxosmithkline note financial statement reconciliation accounting principle continue marketable security marketable security consist primarily equity security summary material difference uk gaap certain liquid investment ukgaap security state low cost net realisable value capitalise interest gaap security available sale statement uk gaap group capitalise interest usgaap financial accounting standard fas accounting require interest incur cost construct fix certain investment debt equity security carry asset capitalise amortise life asset fair value unrealise gain loss net tax report computer software separate component shareholder equity uk gaap company capitalise cost incur acquire pension postretirement benefit develop computer software internal use key difference uk usgaap relation software support significant business system expenditure define benefit pension plan lead creation durable asset gaap company apply sop accounting cost computer software ukgaap effect variation cost develop obtain internal use restrict accumulate successive valuation amortise category cost capitalise aggregate basis gaap amortisation transition asset cost past service benefit goodwill intangible fix asset improvement separately track experience gainslosse begin company change accounting policy deal aggregate basis amortise outside forgoodwill intangible asset ukgaap respect cent corridor acquisition material difference exist uk gaap allow measurement plan asset liability uk usgaap difference continue exist base result late actuarial valuation usgaap respect prior year goodwill intangible asset fully require measurement plan asset liability amortise usgaap goodwill arise acquisition date financial statement month prior st january set shareholder fund uk date gaap gaap goodwill capitalise amortise expect useful economic life charge income disclosure require fas include note intangible asset recognise st january stockbase compensation purchase accounting requirement amortise uk gaap share option account equity estimate revenue earn life take patent exercise value issuance price usgaap group lifeplusfive year carry value intangible asset apply fas accounting stockbase compensation isreviewe annually impairment value relate accounting interpretation accounting option plan uk gaap cost incur integrate require option fair value grant date restructuring glaxo wellcome business single include profit loss vest period option business follow acquisition charge result merger certain group option vest profit loss account post acquisition gaap certain immediately require acceleration compensation expense ofsuch cost consider allocation purchase stockbase compensation expense relate consideration affect goodwill arise acquisition accelerate vest million disclosure require fas include note additionally group entitle merger transaction cost receive tax deduction treat compensation group incur total mergerrelate transaction cost tax rule employee stock option million exclude integration restructuring cost exercise usemployee year ukgaap uk gaap merger transaction cost expense incur treat reduction tax expense usgaap usgaap direct acquisition cost credit equity acquire company include portion purchase consideration employee share ownership trust esot uk gaap share group stock hold esot restructuring cost arerecorde cost account fix asset investment prior adoption frs provision contingent liability project loss exercise option cover share andcontingent asset requirement recording provision record profit loss account life restructuring cost prescriptive usgaap theoption gaap share group stock purchase ukgaap accordingly adjustment esot account shareholder equity eliminate ukgaapprovision restructuring cost gainsorlosse arise subsequent issuance share notmeet usgaaprequirement employee satisfy share option record adjustment toshareholder equitynote financial statementsglaxosmithkline reconciliation accounting principle continue comprehensive income statement requirement fas report comprehensive income foreign currency hedging provide comprehensive income statement meet ukgaap group enter forward exchange contract statement total recognise gain loss page financial instrument ukgaap treat hedge statement comprehensive income usgaap future income matching principle match gain year period end st december present loss hedge contract foreign currency page usgaap statement include transaction profit relate gaap net impact gain loss equity liquid investment instrument qualify hedge accounting unrealised translation adjustment gain loss hedge future profit transaction value year end market rate recognise net recent fasb pronouncement income current year fas accounting derivative instrument hedging activity defer fas amend fas ordinary dividend injune require implement effect uk gaap ordinary dividend propose provide stjanuary fas require derivative instrument year respect recommend board record asset liability balance sheet ofdirector approval shareholder usgaap measure fair value change fair value derivative suchdividend provide declare board record period current earning comprehensive ofdirector income depend derivative designate defer taxation hedge transaction type hedge transaction uk gaap defer taxation account group undertaken review derivative instrument extent probable taxation liability benefit contract contain possible embed derivative payable crystallise foreseeable future fair value book value derivative instrument respect gaap fas accounting income taxis require financial asset liability stdecember isdisclose defer taxation account temporary difference classification fair value financial asset liabilitie valuation adjustment provide liability basis table note expect adoption fas establish respect defer asset derivative embed derivative material impact likelythan portion realise onthe financial result orfinancial position group exceptional item september fasb issue fas accounting item classify exceptional uk gaap meet transfer service financial asset extinguish definition extraordinary gaap liabilitie effective transfer service classified operate expense financial asset extinguishment liability occur st march statement provide accounting report consolidate statement cash flow standard transfer transfer service financial asset usgaap cash flow statement report change cash andcash extinguishment liability expect equivalent include shortterm highly liquid investment adoption statement material effect category cash flow report operating company result operation financial position activity include tax interest investing activity include capital expenditure acquisition disposal cashflow available sale current asset investment andfinance activity include dividend pay statement ofcash flow present cash cash equivalent uk gaap cash balance include cash bank cash balance usgaap cash cash equivalent include cash bank certain liquid investment original maturity month glaxosmithkline note financial statement reconciliation accounting principle continue earning share gaap weight average number share issue million million million basic adjustment share option dilute adsshare hold employee share ownership trust exclude taxation total tax expense uk gaap current tax expense defer tax expense total tax expense gaap current tax expense defer tax expense total tax expense defer taxation usgaap classification glaxosmithkline defer taxation liability asset gaap st december glaxo wellcome defer taxation liability asset gaap st december follow liability stock valuation adjustment current defer taxation liability accelerate capital allowance unremitte foreign investment income product right time difference total defer taxation liability asset intragroup profit time difference current defer taxation asset asset disposal pension postretirement benefit manufacturing restructure tax loss total defer taxation asset net defer taxation gaap note financial statementsglaxosmithkline reconciliation accounting principle continue segment information usgaap uk gaap segment information present note include result operation information historical combine glaxo wellcome smithkline beecham basis period present gaap segment information relate glaxo wellcome result operation relate glaxo wellcome asset relate glaxo wellcome smithkline beecham consolidate basis segment information result operation present business sector glaxo wellcome operate segment pharmaceutical turnover location customer usa europe rest world external turnover turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operate lossprofit share profit joint venture associate undertaking profit disposal associate dissolution joint venture net interest payable lossprofit taxation lossprofit taxation taxation minority interest earningsnet lossincome glaxosmithkline note financial statement reconciliation accounting principle continue total asset business sector pharmaceutical consumer healthcare total asset total asset location subsidiary undertaking usa europe rest world total operating asset cash cash equivalent marketable security total asset plant land equipment computer asset building vehicle software construction total tangible fix asset location subsidiary undertaking usa europe rest world total uk segment information give separately respect uk include group europe market region consider group home segment purpose segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset note financial statement glaxosmithkline reconciliation accounting principle continue pension usgaap fas disclosure year end st december provide relation employee glaxo wellcome income statement disclosure provide relation employee glaxo wellcome balance sheet disclosure provide consolidated basis relation employee glaxo wellcome smithkline beecham average number person employ group include director year number number number manufacturing sell general administration research development pension postretirement cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost disclosure include additional information require fas pension cost uk major overseas define benefit pension plan restate follow table accordance gaap pension cost million million million respect minor retirement plan recalculate accordance requirement fas exclude net periodic pension costincome major retirement plan comprise service cost interest cost expect return plan asset amortisation prior service cost amortisation transition obligation recognise net actuarial gain net periodic pension costincome gaap termination benefit curtailment cost major assumption compute pension incomecost pa pa pa rates future pay increase discount rate expect longterm rate return plan asset aggregate average international plan assumption vary significantly assumption glaxosmithkline note financial statement reconciliation accounting principle continue change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial loss benefit pay acquisition termination benefit curtailment cost exchange benefit obligation end year benefit obligation end year pension plan accumulate benefit obligation excess plan asset change plan asset fair value plan asset begin year actual return plan asset employer contribution plan participant contribution benefit pay acquisition exchange fair value plan asset end year fair value plan asset end year pension plan accumulate benefit obligation excess plan asset plan asset consist primarily investment uk overseas equity fix interest security security link uk index retail price inflation property st december uk equity include million glaxosmithkline ordinary share million glaxowellcome ordinary share market value million glaxo wellcome ordinary share million fund status fund status unrecognise net actuarial gainloss unrecognise prior service cost unrecognised transition obligation net recognise amount recognise statement financial position consist prepay benefit cost accrue pension liability intangible asset accumulate comprehensive income net recognise note financial statementsglaxosmithkline reconciliation accounting principle continue postretirement healthcare usgaap disclosure provide relation employee glaxo wellcome income statement disclosure provide relation employee glaxo wellcome balance sheet disclosure provide consolidated basis relation employee glaxo wellcome smithkline beecham net healthcare cost service cost interest cost amortisation prior service cost net healthcare cost major assumption calculate net healthcare cost pa pa pa rate future healthcare inflation discount rate change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial lossgain benefit pay acquisition smithkline beecham exchange benefit obligation end year change plan asset fair value plan asset begin year employer contribution benefit pay fair value plan asset end year fund status fund status unrecognise net actuarial gainloss unrecognise prior service cost prepaidaccrue postretirement healthcare cost decrease increase impact cent variation rate future healthcare inflation effect total service interest cost effect provision postretirement benefit glaxosmithkline group company group company glaxosmithkline group company follow represent principal subsidiary associated undertakings glaxosmithkline group stdecember detail give country incorporation principal country operation location headquarters business segment business activity share capital undertaking comprise ordinary share wholly own group interest show region country location subsidiary undertaking segment activity note location subsidiary undertaking segment activity note europe england greenford glaxo wellcome plc ph h brentford smithkline beecham plc phch h r p e glaxo group ltd ph h smithkline beecham swg ltd ch e glaxo wellcome export ltd ph e glaxo research development ltd ph r glaxo investment uk ltd ph f glaxo wellcome vehicle finance ltd ph f wellcome foundation ltd ph h r p wellcome limited ph h stockley park glaxo operation uk ltd ph p glaxo wellcome uk ltd ph p austria vienna glaxo wellcome pharma gmbh ph brunn smithkline beecham markenartikel gmbh ch belgium brussels glaxo wellcome belgium sa ph heppignes beecham sa ph genval smithkline beecham sa phch p rixensart smithkline beecham biologicals sa glaxosmithkline biological sa ph p e smithkline beecham biological biotech sa glaxosmithkline biological biotech sa ph p wavre smithkline beecham biological manufacture sa glaxosmithkline biological manufacture sa ph p e czech republic prague glaxo wellcome sro ph prague smithkline beecham spol sro ph denmark brndby glaxo wellcome ph ballerup smithkline beecham ch finland espoo glaxo wellcome oy ph espoo smithkline beecham oy ch france paris groupe glaxo wellcome ph r p nanterre smithkline beecham laboratoire pharmaceutique sas ph p herouville smithkline beecham liquides industrie sa ch p nanterre smithkline beecham sant et hygiene sas ch germany hamburg glaxo wellcome gmbh co ph p buehl smithkline beecham consumer healthcare gmbh ch munich smithkline beecham pharma gmbh ph greece athens glaxo wellcome aebe ph p athens smithkline beecham cisa phch hungary budapest glaxo wellcome kft ph p budapest smithkline beecham kft phch ireland dublin glaxo wellcome ltd ph p carrigaline smithkline beecham cork ltd ph p glaxo wellcome international ph h ii dungarvan smithkline beecham dungarvan ltd ch p dublin smithkline beecham ireland ltd phch carrigaline smithkline beecham manufacturingltd ph p italy verona glaxo wellcome finanziaria spa ph h f milan smithkline beecham spa ph glaxo wellcome spa ph r p netherlands zeist glaxo wellcome bv ph rijswijk smithkline beecham consumer brand bv ch glaxo wellcome international bv ph h smithkline beecham farma bv ph glaxo wellcome investment bv ph h norway oslo glaxo wellcome ph poland poznan glaxo wellcome sa ph p warsaw smithkline beecham polska sp zoo phch portugal lisbon glaxo wellcome farmaceutica lda ph lisbon instituto lusofarmaco lda ph romania buchar glaxo wellcome srl ph spain madrid glaxo wellcome sa ph r p madrid smithkline beecham sa ph sweden mlndal glaxo wellcome ab ph solna smithkline beecham ab ph switzerland berne glaxo wellcome ag ph thoerishaus smithkline beecham ag ph zug adechsa gmbh ph e turkey istanbul glaxowellcome isas ph p istanbul smithkline beecham ilac ticaret phch note incorporate bermuda business segment phpharmaceutical chconsumer healthcare iiexempt provision section company amendment act ireland business activity ddevelopment eexporte ffinance hholde company iinsurance mmarketing pproduction rresearch glaxosmithkline group company group company glaxosmithkline region country location subsidiary undertaking segment activity note location subsidiary undertaking segment activity note usa usa research triangle park glaxo wellcome inc ph r p pittsburgh smithkline beecham consumer healthcare lp ch p palo alto affymax research institute ph r philadelphia smithkline beecham corporation phch h r p e new york glaxo wellcome americas inc ph h philadelphia smithkline beecham holdings corporation phch h americas bermuda hamilton glaxo wellcome insurance bermuda ltd ph canada mississauga glaxo wellcome inc ph r p oakville smithkline beecham inc phch asia pacific australia boronia glaxo wellcome australia ltd ph p dandenong smithkline beecham australia pty ltd phch bangladesh chittagong glaxo wellcome bangladesh ltd ph p china chongqe chongqe glaxo wellcome ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ph pharmaceuticals ltd suzhou glaxo wellcome suzhou ph p tianjin smithkline beecham tianjin co ltd ph pharmaceuticals ltd hong kong glaxo wellcome china ltd ph hong kong smithkline beecham ltd phch india mumbai glaxo india ltd ph p nabha smithkline beecham consumer healthcare ltd ch p iii burrough wellcome indialtd ph bangalore smithkline beecham pharmaceuticals india ltd ph iii indonesia jakarta pt glaxo wellcome indonesia ph jakarta pt sterling product indonesia ch malaysia kuala lumpur glaxo wellcome malaysia sdn bhd ph p selangor darul ehsan smithkline beecham sdn bhd phch new zealand auckland glaxo wellcome new zealand ltd ph p auckland smithkline beecham nz ltd phch pakistan karachi glaxo wellcome pakistan ltd ph p karachi beecham pakistan private ltd phch philippines manila glaxo wellcome philippines inc ph manila philippines branch smithkline beecham research ltd phch iv duncan pharmaceuticals philippines inc ph singapore singapore glaxo wellcome singapore pte ltd ph jurong beecham pharmaceuticals pte ltd ph p glaxo wellcome manufacturing pte ltd ph p glaxochem pte ltd ph f south korea seoul glaxo wellcome korea ltd ph p seoul smithkline beecham korea ltd phch sri lanka colombo glaxo wellcome ceylon ltd ph p colombo smithkline beecham private ltd phch taiwan taipei glaxo wellcome taiwan ltd ph p taipei taiwan branch smithkline beecham far east bv phch v thailand bangkok glaxo wellcome thailand ltd ph bangkok smith kline french thailand ltd phch samut prakan glaxo wellcome vidhyasom ltd ph p japan japan tokyo glaxo wellcome kk ph r p tokyo smithkline beecham seiyaku kk phch glaxosmithkline kk note iiiconsolidate subsidiary undertaking accordance section company act ground significant influence ivregistere england vregistere netherlands glaxosmithkline group company group company glaxosmithkline region country location subsidiary undertaking segment activity note location subsidiary undertaking segment activity note latin argentina buenos aire glaxo wellcome sa ph p buenos aire smithkline beecham argentina sa phch america brazil rio de janeiro glaxo wellcome sa ph p rio de janeiro smithkline beecham brasil ltda phch bahia smithkline beecham quimica nordeste ltda ph p chile santiago glaxo wellcome farmaceutica ltda ph santiago smithkline beecham chile sa phch colombia bogota glaxo wellcome de colombia sa ph p bogota smithkline beecham colombia sa phch costa rica san jose smithkline beecham costa rica sa phch dominican republic santo domingo smithkline beecham republica dominicana sa phch ecuador quito glaxo wellcome sa ph guayaquil smithkline beecham ecuador sa phch mexico mexico city glaxo wellcome mexico sa de cv ph p civac smithkline beecham mexico sa de cv phch p panama panama city glaxo wellcome centro america sa ph panama city sterling product international sa phch paraguay asuncin glaxo wellcome sa ph peru lima glaxo wellcome sa ph lima peru branch smithkline beecham interamerican corporation phch vi puerto rico san juan glaxo wellcome puerto rico inc ph hato rey sb pharmco puerto rico inc ph p uruguay montevideo glaxo wellcome sa ph montevideo smithkline beecham uruguay ltda phch venezuela caracas glaxo wellcome ph p caracas smithkline beecham venezuela phch p allen hanbury ph p middle east egypt cairo glaxo wellcome egypt sae ph p africa kenya nairobi glaxo wellcome kenya ltd ph p nairobi smithkline beecham consumer healthcare ltd phch morocco casablanca glaxo wellcome maroc sa ph rabat smithkline beecham maroc sa ph p nigeria lagos glaxo wellcome nigeria ltd ph p lagos smithkline beecham nigeria plc phch iii saudi arabia jeddah glaxo saudi arabia ltd ph iii south africa midrand glaxo wellcome south africa pty ltd ph p johannesburg smithkline beecham consumer healthcare pty ltd ch p johannesburg smithkline beecham pharmaceutical pty ph region country location associate undertaking usa usa teterboro quest diagnostic incorporate new jersey activity quest diagnostic clinical laboratory issue share capital comprise share common stock note iiiconsolidate subsidiary undertaking accordance section company act ground significant influence detail group subsidiary associate undertaking attach company annual return file vi register united states registrar ofcompanies glaxosmithkline principal financial statement follow information provide convenience shareholder accordance requirement new york stockexchange principal financial statement prepare ukgaap sterling translate consolidate profit loss account consolidate statement recognise gain loss consolidate cash flow statement average exchange rate consolidate balance sheet period end exchange rate exchange rate give note tothe financial statement consolidated profit loss account business total business total business total turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate profit disposal interest associate profit dissolution joint venture product divestment merger transaction cost disposal business provision loss disposal loss disposal utilisation provision profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning ad adjust earning ad columnar presentation profit loss account adopt order illustrate underlie business performance forthispurpose certain item exclude business performance business column present column item comprise merger item include product divestment cost relate previously announce manufacturing restructuring effect business disposal prior year consolidated statement total recognise gain loss profit attributable shareholder exchange movement overseas net asset uk tax exchange movement total recognise gain loss principal financial statement usglaxosmithkline consolidated cash flow statement net cash inflow operating activity earning joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash inflowoutflow management liquid resource finance management liquid resource finance increasedecrease cash year consolidated balance sheet goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset call share capital share premium account reserve equity shareholder fund nonequity minority interest equity minority interest capital employ glaxosmithkline financial record glaxosmithkline financial record quarterly trend analysis provide quarter group result sterle financial year analysis business performance result total result pharmaceutical sale therapeutic area profit loss account business performance month q month q month q q cer cer cer cer cer cer cer sales pharmaceutical consumer healthcare sale retain business cost sale sell general administrative expenditure research development expenditure operating cost trading profit retain business healthcare service total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning ordinary share p p p p p p p profit loss account total sale pharmaceutical consumer healthcare total sale cost sale sell general administrative expenditure research development expenditure operating cost trading profit retain business healthcare service total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate loss disposal business product divestment merger transaction cost profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning ordinary share p p p p p p p glaxosmithkline financial record pharmaceutical sale total group q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritisrelafan dermatological pharmaceutical sale continue business divest product famvir kytril total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale usa q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritisrelafan dermatological pharmaceutical sale continue business divest product famvir kytril total pharmaceutical sale glaxosmithkline financial record pharmaceutical sale europe q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafan dermatological pharmaceutical sale continue business divest product famvir kytril total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale rest world q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritisrelafan dermatological pharmaceutical sale continue business divest product famvir kytril total pharmaceutical sale glaxosmithkline financial record fiveyear record record financial performance provide analysed accordance current reporting practice sale business segment pharmaceutical consumer healthcare retain business healthcare service pharmaceutical sale therapeutic area central nervous system disorder respiratory antibacterial antiviral metabolic gastrointestinal vaccine oncology emesis cardiovascular dermatological arthritis continue business divest product pharmaceutical sale geographic area usa europe rest world asia pacific japan latin america middle east africa canada total rest world consumer healthcare sale otc medicine oral care nutritional healthcare continue business divest product financial recordglaxosmithkline business performance result retain business sale rd expenditure cent sale trading profit cent sale net interest payable profit taxation earning profit attributable shareholder merger restructure disposal subsidiary manufacture restructuring merger cost product divestment item profitloss taxation profitloss attributable shareholder total result sale profit taxation earning profit attributable shareholder dividend retain profit return capital employ cent return capital employ calculated total profit taxation percentage average capital employ year share statistic earning ordinary share p dividend glaxosmithkline ordinary share p glaxo wellcome shareholder smithkline beecham shareholder dividend glaxosmithkline ad glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline sharead merger glaxo wellcome smithkline beecham thdecember shareholders adr holder receive share glaxosmithkline follow ratio glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline share glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss glaxosmithkline ad represent glaxosmithkline share glaxosmithkline financial record net asset fix asset asset liability net operating asset net debt capital employ share capital share premium goodwill reserve reserve equity shareholder fund minority interest capital expenditure tangible fix asset number employees usa europe rest world asia pacific japan latin america middle east africa canada total rest world manufacturing selling administration research development number employee number employ staff end financial periodglaxosmithkline investor information section discuss shareholder return return shareholder form dividend share price movement provide information shareholder shareholder return taxation information shareholder shareholder information share capital glaxosmithkline shareholder return merger glaxo wellcome smithkline beecham dividend glaxo wellcome smithkline beecham board glaxo wellcome plc smithkline beecham plc dividend announce th january agree term glaxo wellcome smithkline beecham announce propose merger equal company subject dividend respect year prior effective date shareholder approval regulatory clearance base merger th december relativestock market valuation glaxo wellcome smithkline beecham month precede announcement glaxo wellcome pence pence merger shareholder glaxo wellcome hold approximately interim cent shareholder smithkline beecham second interim approximately cent combine group final follow shareholder approval clearance regulatory total dividend glaxo wellcome share authority merger effective th december equivalent dividend glaxosmithkline share merger implement way scheme arrangement dividend glaxo wellcome share new hold company glaxosmithkline plc acquire glaxo wellcome smithkline beecham accordance agree record date second interim dividend merger term shareholder glaxo wellcome smithkline nddecember relation glaxo wellcome share beecham receive exchange exist share share andth december relation glaxo wellcome adss glaxosmithkline follow thesecond interim dividend pay th april glaxo wellcome ordinary share glaxosmithkline shareholder glaxo wellcome record date ordinary share thapril adr holder glaxo wellcome record date smithkline beecham ordinary share glaxosmithkline ordinary share smithkline beecham pence pence interim case share hold american depositary share adss second interim evidence american depositary receipt adr glaxo interim wellcome ad represent glaxo wellcome ordinary share fourth interim smithkline beecham ad represent smithkline total dividend smithkline beecham share beecham ordinary share glaxosmithkline ad represent twoglaxosmithkline ordinary share accordingly holder total equivalent dividend gsk share glaxowellcome adrs holders smithkline beecham adrsreceived record date fourth interim dividend nd december glaxo wellcome ad glaxosmithkline ad relation smithkline beecham share th december smithkline beechamads glaxosmithkline adss relation smithkline beecham adss fourth interim dividend pay th april shareholders adr glaxosmithkline share commence trading london stock holders smithkline beecham record date exchange glaxosmithkline adss commenced trading new york stock exchange th december dividend adss guide holder adr table set taxation dividendspaid ad dollar year general guide shareholder glaxosmithkline receive dividend adjust uk tax credit withholding tax advice merger direct effect tax whereapplicable translate dollar applicable position uk resident shareholder resident shareholder exchange rate information contain scheme document issuedtoshareholder thjuly general information th april claim refund tax credit dividend concern uk tax effect share ownership set uk tax authority negligible benefit outin taxation information shareholder shareholder shareholder areinany doubt taxation position consult glaxo wellcome smithkline beecham theirown professional adviser year shareholder return glaxosmithkline dividend glaxosmithkline share price share price gsk gw sb ftse glaxosmithkline dividend policy set merger document issue shareholders st january high year glaxosmithkline initially pay dividend line glaxo low year wellcome dividend penny glaxo wellcome share th december equivalent penny glaxosmithkline share st december subsequently assume earning continue grow glaxosmithkline increasedecrease year maintain annual dividend penny share whilstbuilde dividend cover ratio distributable follow announcement merger glaxo profitsand dividend industry average close wellcomeand smithkline beecham january share tosmithkline beecham recent payout ratio cent pricesof separate company track closely toglaxowellcome high payout ratio period st january th december day merger complete glaxosmithkline pay dividend quarterly expect theglaxowellcome share price smithkline beecham share glaxosmithkline normally follow pattern establish price increase cent year smithkline beecham level dividend stdecember ftse index decline cent quarter high dividend fourth quarter expect positive benefit merger strong dividend calendar operatingperformance company year help quarter glaxo wellcome smithkline beecham achieve improved share price performance relative uk stock market addition result announcement th april investor sentiment shift away technology sector exdividend date nd defensive sector pharmaceutical record date th payable th july share glaxosmithkline start trade th december th december th march share price second quarter decrease cent compare decline result announcement th july ftse index sixper cent exdividend date st august record date rd august market capitalisation payable th october market capitalisation glaxosmithkline st december billion date glaxosmithkline large quarter company market capitalisation ftse index result announcement rd october year share price performance exdividend date st october record date nd november gw share price sb share price ftse index payable rd january fourth quarter result announcement th february dec figures st december st december years st december th december glaxo wellcome share price increase increase percent smithkline beecham share price increase increase percent year st december st december ftse index increase increase percent glaxosmithkline taxation information shareholder summary principal tax consequence holder stamp duty ordinary share ordinary share adr citizen resident uk stamp duty case stamp duty reserve tax united kingdom united states set sdrt subject certain exemption payable complete analysis possible tax consequence purchase purchase ordinary share rate cent ownership security holder security purchase price minimum charge advise consult tax adviser respect tax stampduty liability arise consequence purchase ownership ordinary share ordinary share adr include specifically shareholder consequence state local tax law united states taxation dividend statement united kingdom united gross dividend receive include amount state tax law practice set base law respect associate tax credit uk withholding tax treat practice force date report foreign source dividend income tax purpose eligible dividend receive deduction allow holder ordinary share adr generally treat corporation dividend ordinary share adr payable owner underlie share purpose current usdollar dividend ordinary share payable pound united statesunite kingdom double taxation convention relate sterling dividend pay pound sterling include income gain income tax convention estate gift taxis income dollar calculate reference estate gift tax convention purpose exchange rate day dividend receive holder internal revenue code amend code uk taxis withhold dividend distribution eligible credit october uk government announce holder federal income tax liability subject agree renegotiate new income tax convention replace generally applicable limitation holder tax position exist convention discussion start january willdetermine effective use credit continue possible state change ukwithholde taxis tax liability arise taxation dividend capital gain result th april rate tax credit reduce renegotiation likely date come effect ninth act abolish consequently claim refund new convention oftax credit dividend pay date follow analysis deal dividend pay th april ofnegligible benefit shareholder advance corporation tax act abolish dividend pay date taxation capital gain generally holder subject uk capital gain tax uk shareholders butwill subject tax capital gain realise sale orother disposal ordinary share ordinary share adr taxation dividend th april rate tax credit reduce estate gift taxis ninth result compensate reduction rate tax estate gift tax convention shareholder ondividend income increase tax bear uk generally subject uk inheritance tax resident individual shareholder tax credit longerrepayable shareholder tax liability stamp duty theassociate tax credit uk stamp duty case sdrt subject certain exemption payable issue transfer ordinary share taxation capital gain adr custodian depository rate cent uk shareholder liable uk tax gain theirprice issue consideration provide disposalof ordinary share ordinary share adr iftransferre sale value transfer alsobe entitle indexation relief taper relief sale consideration indexation relief calculate market value share stmarch cost subsequent purchase sdrt payable transfer adr uk date purchase indexation relief individual stamp duty payable transfer adr provide shareholder cease th april taper relief available instrument transfer execute remain times toindividual shareholder hold deem hold outside uk stamp duty transfer adr sharesfor year sell payable rate cent consideration transfer sale underlie ordinary share result inheritance tax liability uk stamp duty case sdrt rate individual shareholder liable inheritance tax cent transfer ordinary share ordinary share adr broadly tax minimum charge stamp duty liability arise charge value shareholder estate reduce result transfer way gift disposal market value exceptional gift disposal subject uk inheritance tax estate gift tax estate gift tax convention generally provide tax pay united states credit tax payable united kingdomglaxosmithkline shareholder information ordinary share annual general meeting company share list london stock exchange queen elizabeth ii conference centre st broad sanctuary westminster registrar london swp ee company share register administer lloyds tsb registrar provide follow service agm company principal forum communication private shareholder addition formal resolution glaxosmithkline investment plan meet presentation chief executive plan enable shareholder reinvest quarterly dividend andor officer performance business future monthly investment company ordinary share development opportunity question board special dealing arrangement chairman board committee question glaxosmithkline individual saving account matter relate committee glaxosmithkline individual saving account isa tax investor hold share company nominee service efficient way invest inthecompany ordinary share arrange nominee service appoint proxy glaxosmithkline corporate sponsor nominee inrespect shareholding order attend vote corporate sponsor nominee provide facility meeting adr holder wish attend meeting obtain shareholder hold share need share certificate aproxy bank new york enable shareholder detail hold main share register attend meeting vote business transact remain confidential adrholder instruct bank new york ordinary share represent adr vote wwwshareviewcouk complete return voting card provide bank shareview portfolio service provide shareholder ofnew york accordance instruction give information investment company shareholder register service wwwshareviewcouk financial reporting share deal facility financial reporting calendar natwest stockbroker limit offer sharedealing service announcement st quarter result th april behalf company shareholder wish buy sell announcement nd quarter result th july thecompany share publication halfyear reportreview august share price information announcement rd quarter result rd october share price information available company website preliminary announcement annual result th february wwwgskcom information available ceefax teletext publication annual reportreview march andfrom ft cityline call call charge p minute time result announcement result announcement issue london stock american depositary share exchangelse available lse news service company share list new york stock exchange time shortly issue medium inthe form american depositary share adss available company web site file usa evidence american depositary receipt adr security exchange commission sec new york whichrepresent ordinary share stock exchange adr programme administrator financial report adr programme administer bank new york company publish annual report investor provide follow service need detail report annual review interim report review publish halfyear global buydirect global buydirect direct ad purchasesale dividend financial report post shareholder date reinvestment plan adr holders publication available date company web site shareholder provide review elect smithkline beecham plc float rate unsecured loan stock receive report copy print form recent previous financial loan stock list exchange holder report available uk company registrar choose redeem smithkline beecham plc par theusa companys customer response centre ie loan stock hold business day march june september december holder wish redeem publication loan stock complete notice environmental health safety review available loan stock certificate return registrar secretariat company head office toarrive day relevant redemption date glaxosmithkline share capital nature trading market dollar ad ordinary share company list london fiscal period th december high low stock exchange th december ordinary share december list new york stock exchange inthe form november american depositary share adss date october september follow table set period indicate high quarter end st december low middle market quotation pence ordinary share quarter end th september london stock exchange derive daily official list quarter end th june high low report sale price dollar quarter end st march adss new york stock exchange derive new quarter end st december york stock exchange composite tape quarter end th september information relate share ad price glaxo quarter end th june wellcome smithkline beecham prior date merger quarter end st march give glaxosmithkline penny ordinary share fiscal period th december high low quarter end st march smithkline beecham pence ordinary share february fiscal period th december high low january december th st december november october dollar ad september fiscal period th december high low quarter end st december quarter end st march quarter end th september february quarter end th june january quarter end st march th st december quarter end st december quarter end th september th march quarter end th june quarter end st march glaxo wellcome penny ordinary share fiscal period th december high low december november october dollar ad september fiscal period th december high low quarter end st december quarter end th september december quarter end th june november quarter end st march october quarter end st december september quarter end th september quarter end st december quarter end th june quarter end th september quarter end st march quarter end th june quarter end st march quarter end st december quarter end th september quarter end th june quarter end st march prior th april smithkline beecham ordinary share capital consist b share high low price table relate share th april ordinary share thereaftershare capital glaxosmithkline analysis shareholding number total ordinary analysis shareholding st december account account total share hold ordinary share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit total bank new york hold hold bny nominees limited represent company adr programme ad represent ordinary share p nominal value th march number holder record ordinary share usa holdings ordinary share thenumberof register holder adr holding adr certain ordinary share adrs hold broker nominee number holder record register holder usa representative number beneficial holder orofthe residence beneficial holder control company far know company directly indirectly own control corporation government thecompany know arrangement operation result change control company substantial shareholding th march company receive notification follow interest cent ordinary share bnynominee limited hold ordinary share represent cent ordinary share hold behalf holder american depositary receipt far know company person owner cent ordinary share company prior merger glaxo wellcome smithkline beecham th december shareholder interest cent share capital glaxo wellcome smithkline beecham exclude bank new york depositary forthe adrs company case glaxo wellcome th february company receive notification wellcome trust limited interest cent case smithkline beecham th february company receive notification follow interest mercury asset management group limit cent prudential portfolio manager limit cent barclay global investor uk limit cent hill samuel offshore trust limited trustee sb employee share ownership trust cent director officer interest director officer company define thecompanie act share option company give remuneration report exchange control limitation affect securityholder currently uk law decree regulation restrict import export capital affect remittance dividend orother payment holder company ordinary share nonresident uk limitation relate nonresident uk english law company memorandum article association right tobe holder tovote respect company ordinaryshare glaxosmithkline cross reference form f table provide cross reference information include annual report requirement form f item item identity director senior management adviser na financial information offer statistic expect timetable na consolidated statement financial information financial statement item key information legal proceeding select financial datum b significant change risk factor note post balance sheet event information company offer list history development company share price history b business overview c market product competition additional information regulation b memorandum articles association marketing distribution c material contract manufacture supply exchange control research development e taxation intellectual property h document display information technology quantitative qualitative disclosure market risk environment health safety treasury policy global community partnership note financial instrument relate disclosure access medicine description security equity security na c organisational structure default dividend arrearage delinquencie na property plant equipment note segment information material modification right security holder note tangible fix asset use proceed na operate financial review prospect reserve operating result reserve financial statement na financial statement accounting principle director statement responsibility b liquidity capital resource report auditor c research development patent license etc consolidated statement profit loss trend information consolidate statement total recognise gain loss director senior management employee consolidated statement cash flow director senior management consolidated balance sheet b compensation reconciliation movement equity shareholder fund remuneration report company balance sheet c board practice note financial statement corporate governance exhibit na employee glaxosmithkline people note employee cost financial record e share ownership glaxosmithkline people note employee share scheme major shareholder relate party transaction major shareholder b relate party transaction cross reference form f glaxosmithkline cautionary factor affect future result relate party transaction cautionary statement private security glaxosmithkline cent interest quest diagnostic litigation reform act inc activity quest company core group annual report account period report business interest hold investment file securities exchange commission commission include annual report form f material contract year end st december form f contain board glaxo wellcome plc smithkline beecham plc write information release oral statement announce th january term agreement public future behalf group contain forthe propose merger company merger forwardlooke statement forwardlooke statement wasimplemente way scheme arrangement thegroup current expectation forecast future event thdecember date glaxosmithkline plc aninvestor identify statement fact acquire thewhole issue share capital glaxo donot relate strictly historical current fact use word wellcome plc andsmithkline beecham plc anticipate estimate expect intend project plan believe word term similar meaning th january glaxosmithkline complete acquisition connection discussion future operate financial block drug company inc manufacturer toothpaste performance particular include statement relate oral healthcare consumer product million future action prospective product product approval future million performance result current anticipate product sale effort expense outcome contingency legal document display proceeding financial result document refer annual report available group forwardlooke statement inspection register office company form f report file commission public statement group make turn incorrect affected inappropriate inaccurate assumption group use basis forwardlooke statement know unknown risk uncertaintie factor mention discussion group business form f important determine future result consequently forwardlooke statement view guarantee actual future result vary materially group undertake obligation publicly update forwardlooke statement result new information future event investor note cautionary discussion risk uncertaintie relevant group business set risk factor discussion provide permit private security litigation reform act glaxosmithkline glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation advance corporation tax act advance payment uk tax dividend pay direct equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline adopt london stock exchange address principle aspect corporate governance company glaxosmithkline plc creditor account payable currency swap exchange currency couple subsequent reexchange currency agree exchange rate date debtor account receivable define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derive value price rate underlie item dilute earning ordinary share diluted income ordinary share dividend cover profit attributable shareholdersnet income divide dividend payable shareholder earning ordinary share basic income ordinary share employee share ownership trust trust establish group satisfy share base employee incentive plan equity shareholder fund aggregation share reserve own shareholder equivalent shareholder equity finance lease capital lease free cash flow cash resource available payment dividend shareholder acquisition freehold ownership absolute right perpetuity gearing ratio net debt percentage shareholder fund minority interest group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement bymake offset commitment intangible fix asset asset physical substance brand licence patent knowhow marketing right purchase outside party interest cover number time profit interest exceed net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit loss account reserve retain earning profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement total recognise gain loss statement comprehensive income stock inventory subsidiary undertaking company glaxosmithkline hold majority shareholding andor exercise control tangible fix asset property plant equipment turnover revenueglaxosmithkline index directtoconsumer advertising g access medicine director gear ratio accountability control senior management global communication accounting policy board executive global community partnership accounting standard glaxo wellcome global supply initiative acquisition disposal interest glossary term adr programme administrator interest contract go concern basis american depositary share remuneration goodwill animal research report governmental investigation annual general meeting responsibility group company antitrust service contract antibacterial share option h antiviral share ownership guideline healthcare service associate company smithkline beecham hedging audit committee diversity history development company auditor divest business hiv aids appointment divest product audit report impairment fix asset fee dividend incorporation glaxosmithkline plc information technology b e intangible asset balance sheet early drug discovery intellectual property block drug inc earningsearning share interest cover board executive interest rate risk management board committee ebusiness internal control business performance employee investment cost investor information business segment disable diversity j c numbers joint ventures capital employ performance reward associates capital expenditure share scheme cardiovascular training development l cash flow employee share ownership trust lease cautionary factor affect environment health safety legal proceeding future result equity risk management liquid investment centralnervoussystemcnsdisorder european monetary union loan overdraft centre excellence drug discovery exchange control lymphatic filariasis chairman chief executive exchange rate officer statement external supplier charitable donation malaria chlorofluorocarbon cfc f manufacture supply combine code fair value manufacture restructuring commitment finance committee market capitalisation commit facility financial asset liability market distribution community programme financial highlight maturity counterparty risk competition financial instrument memorandum article consumer healthcare relate disclosure association contact detail cover financial period merger contaminate land financial position resource accounting contingent liability financial record accounting alignment control company year record adjustment corporate executive team quarterly trend general corporate governance financial reporting calendar term cross reference form f financial statement metabolic gastrointestinal financial summary financial trend ratio n derivative financial instrument fix asset investment net debt dermatological foreign exchange risk management net interest payable description business forwardlooke statement new product development dialogue shareholder new product supply nonexecutive director noon buying rate nutritional healthcare glaxosmithkline index oncology emesis sale operate financial review consumer healthcare prospect pharmaceutical oral care operating incomeexpense sb clinical laboratory outlook segment information overthecounter otc medicine select financial datum senior management compensation p interests patent share capital payment policy share premium account pension postretirement share price benefit share purchase pipeline share statistic post balance sheet event shareholder information presentation financial statement shareholder return price control shareholder fund principal financial statement shareholding analysis product statement total approval submission recognise gain loss consumer healthcare strategic master plan deliver market development pipeline discontinuation taxation liability taxation information shareholder new product development tax rate new product supply trade mark pharmaceutical treasury operation treasury policy profit loss account tuberculosis property plant equipment provision liability charge u uk segment r gaap reconciliation accounting reconciliation movement principle equity shareholder fund consolidate balance sheet registrar consolidated income statement regulation comprehensive income remuneration nomination change shareholders equity committee consolidate statement cash flow remuneration report earning sharead report director material difference research development uk gaap accounting policy postretirement benefit animal research purchase accounting consumer healthcare result usaccounte principle disease develop world segment information expenditure select financial datum pharmaceutical taxation pipeline convenience translation principal respiratory financial statement return capital employ revenue accounting policy v risk factor vaccine risk oversight compliance council rocc w world economy world market wwwgskcom